WO2001068848A2 - Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides - Google Patents

Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides Download PDF

Info

Publication number
WO2001068848A2
WO2001068848A2 PCT/US2001/006520 US0106520W WO0168848A2 WO 2001068848 A2 WO2001068848 A2 WO 2001068848A2 US 0106520 W US0106520 W US 0106520W WO 0168848 A2 WO0168848 A2 WO 0168848A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
acid sequence
sequence
shows
amino acid
Prior art date
Application number
PCT/US2001/006520
Other languages
English (en)
Other versions
WO2001068848A3 (fr
Inventor
Kevin P. Baker
Jian Chen
Luc Desnoyers
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
James Pan
Victoria Smith
Colin K. Watanabe
William I. Wood
Zemin Zhang
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/005601 external-priority patent/WO2000056889A2/fr
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/fr
Priority claimed from PCT/US2000/006884 external-priority patent/WO2001005972A1/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/013705 external-priority patent/WO2000073445A2/fr
Priority claimed from PCT/US2000/014042 external-priority patent/WO2000077037A2/fr
Priority claimed from PCT/US2000/014941 external-priority patent/WO2000073348A2/fr
Priority claimed from PCT/US2000/015264 external-priority patent/WO2000073452A2/fr
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/fr
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/fr
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/fr
Priority to AU6802801A priority Critical patent/AU6802801A/xx
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/fr
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/fr
Priority to EP01945919A priority patent/EP1259614A2/fr
Priority to AU2001268028A priority patent/AU2001268028A1/en
Priority to CA002401448A priority patent/CA2401448A1/fr
Priority to JP2001567332A priority patent/JP2004508805A/ja
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Priority to US09/816,744 priority patent/US6579520B2/en
Priority to US09/866,028 priority patent/US6642360B2/en
Priority to AU6531101A priority patent/AU6531101A/xx
Priority to JP2002501551A priority patent/JP2004510409A/ja
Priority to CA002591814A priority patent/CA2591814A1/fr
Priority to EP01939834A priority patent/EP1286749A1/fr
Priority to EP05024025A priority patent/EP1666597A3/fr
Priority to CA002591583A priority patent/CA2591583A1/fr
Priority to CA002410162A priority patent/CA2410162A1/fr
Priority to EP05024032A priority patent/EP1659177A3/fr
Priority to EP05024023A priority patent/EP1683864A3/fr
Priority to EP05024030A priority patent/EP1666491A1/fr
Priority to CA002591656A priority patent/CA2591656A1/fr
Priority to CA002594659A priority patent/CA2594659A1/fr
Priority to CA002591929A priority patent/CA2591929A1/fr
Priority to EP05024033A priority patent/EP1666493A1/fr
Priority to EP05024031A priority patent/EP1666492A1/fr
Priority to EP05024037A priority patent/EP1700867A3/fr
Priority to EP05024035A priority patent/EP1666594A3/fr
Priority to CA002591630A priority patent/CA2591630A1/fr
Priority to EP05024034A priority patent/EP1666497A3/fr
Priority to CA002591590A priority patent/CA2591590A1/fr
Priority to EP05024028A priority patent/EP1686174A1/fr
Priority to PCT/US2001/017800 priority patent/WO2001093983A1/fr
Priority to EP05024027A priority patent/EP1666596A1/fr
Priority to CA002585822A priority patent/CA2585822A1/fr
Priority to EP05024038A priority patent/EP1702928A3/fr
Priority to CA002591930A priority patent/CA2591930A1/fr
Priority to AU2001265311A priority patent/AU2001265311A1/en
Priority to CA002591841A priority patent/CA2591841A1/fr
Priority to EP04005726A priority patent/EP1489095A1/fr
Priority to US09/874,503 priority patent/US20020177188A1/en
Priority to AU2001278852A priority patent/AU2001278852A1/en
Priority to EP14166919.2A priority patent/EP2792747A1/fr
Priority to DK08019420.2T priority patent/DK2042597T3/da
Priority to EP09004417A priority patent/EP2077276A1/fr
Priority to CA2709771A priority patent/CA2709771A1/fr
Priority to CA002648048A priority patent/CA2648048A1/fr
Priority to EP10182597A priority patent/EP2275549A1/fr
Priority to EP09004418A priority patent/EP2075253A1/fr
Priority to CA002412211A priority patent/CA2412211A1/fr
Priority to CA002648046A priority patent/CA2648046A1/fr
Priority to PCT/US2001/019692 priority patent/WO2002000690A2/fr
Priority to EP01957073A priority patent/EP1309620A2/fr
Priority to EP09004415A priority patent/EP2168980A1/fr
Priority to CA002648051A priority patent/CA2648051A1/fr
Priority to JP2002505812A priority patent/JP2004506413A/ja
Priority to EP08019420.2A priority patent/EP2042597B1/fr
Priority to PCT/US2001/020118 priority patent/WO2002016429A2/fr
Priority to EP04011258A priority patent/EP1445318A2/fr
Priority to US09/888,257 priority patent/US20030060612A1/en
Priority to AU2001270118A priority patent/AU2001270118A1/en
Priority to EP01948667A priority patent/EP1311674A2/fr
Priority to EP04011151A priority patent/EP1445317A3/fr
Priority to MXPA03001645A priority patent/MXPA03001645A/es
Priority to JP2002521524A priority patent/JP2004520806A/ja
Priority to KR10-2003-7002685A priority patent/KR20030029847A/ko
Priority to CA002420140A priority patent/CA2420140A1/fr
Priority to CA002416456A priority patent/CA2416456A1/fr
Priority to AU2001273150A priority patent/AU2001273150A1/en
Priority to JP2002514192A priority patent/JP2004514420A/ja
Priority to PCT/US2001/021066 priority patent/WO2002008288A2/fr
Priority to AU7315001A priority patent/AU7315001A/xx
Priority to CA002416538A priority patent/CA2416538A1/fr
Priority to AU2001271973A priority patent/AU2001271973A1/en
Priority to EP01951036A priority patent/EP1309685A2/fr
Priority to JP2002514188A priority patent/JP2004516013A/ja
Priority to PCT/US2001/021735 priority patent/WO2002008284A2/fr
Priority to US09/908,827 priority patent/US20030054442A1/en
Priority to US09/918,585 priority patent/US20030060406A1/en
Priority to PCT/US2001/025464 priority patent/WO2002016581A2/fr
Priority to AU2001284906A priority patent/AU2001284906A1/en
Priority to CA002420176A priority patent/CA2420176A1/fr
Priority to KR10-2003-7002671A priority patent/KR20040014392A/ko
Priority to JP2002522254A priority patent/JP2004520808A/ja
Priority to EP01964006A priority patent/EP1311662A2/fr
Priority to MXPA03001644A priority patent/MXPA03001644A/es
Priority to US09/929,769 priority patent/US6914130B2/en
Priority to US09/931,836 priority patent/US7435793B2/en
Priority to CA002420193A priority patent/CA2420193A1/fr
Priority to JP2002522275A priority patent/JP2004520810A/ja
Priority to AU8678501A priority patent/AU8678501A/xx
Priority to AU2001286785A priority patent/AU2001286785B2/en
Priority to PCT/US2001/026626 priority patent/WO2002016602A2/fr
Priority to MXPA03001643A priority patent/MXPA03001643A/es
Priority to KR1020037002672A priority patent/KR100607611B1/ko
Priority to US09/938,418 priority patent/US20020161199A1/en
Priority to EP01966255A priority patent/EP1311668A2/fr
Priority to US09/941,992 priority patent/US20030082546A1/en
Priority to PCT/US2001/027099 priority patent/WO2002024888A2/fr
Priority to EP07022176A priority patent/EP1944317A3/fr
Priority to JP2002529483A priority patent/JP4451059B2/ja
Priority to EP01985272A priority patent/EP1341814A2/fr
Priority to AU2002216610A priority patent/AU2002216610A1/en
Priority to CA002421056A priority patent/CA2421056A1/fr
Priority to CA002632702A priority patent/CA2632702A1/fr
Priority to US09/943,780 priority patent/US20030096742A1/en
Priority to US09/943,851 priority patent/US20020150976A1/en
Priority to US09/944,396 priority patent/US20020132981A1/en
Priority to US09/944,413 priority patent/US20020156004A1/en
Priority to US09/944,432 priority patent/US20020142419A1/en
Priority to US09/944,449 priority patent/US20020102647A1/en
Priority to US09/944,403 priority patent/US20020165143A1/en
Priority to US09/943,762 priority patent/US20020142958A1/en
Priority to US09/944,457 priority patent/US6734288B2/en
Priority to US09/943,664 priority patent/US20040091972A1/en
Priority to US09/944,884 priority patent/US7018837B2/en
Priority to US09/944,862 priority patent/US20020115145A1/en
Priority to US09/944,852 priority patent/US20030083479A1/en
Priority to US09/944,896 priority patent/US7189566B2/en
Priority to US09/944,907 priority patent/US20020198147A1/en
Priority to US09/944,944 priority patent/US6929947B2/en
Priority to US09/945,584 priority patent/US6908993B2/en
Priority to US09/945,587 priority patent/US6936254B2/en
Priority to US09/944,654 priority patent/US20020142959A1/en
Priority to US09/944,929 priority patent/US7550573B2/en
Priority to US09/945,015 priority patent/US20020132768A1/en
Priority to US09/946,374 priority patent/US20030073129A1/en
Priority to AU1661002A priority patent/AU1661002A/xx
Publication of WO2001068848A2 publication Critical patent/WO2001068848A2/fr
Priority to US09/964,994 priority patent/US6740520B2/en
Priority to US09/978,191 priority patent/US20030050239A1/en
Priority to US09/978,188 priority patent/US20030139328A1/en
Priority to US09/978,189 priority patent/US6972325B2/en
Priority to US09/978,299 priority patent/US20030199435A1/en
Priority to US09/978,194 priority patent/US20030195333A1/en
Priority to US09/978,193 priority patent/US20030073624A1/en
Priority to US09/978,192 priority patent/US20020177553A1/en
Priority to US09/978,295 priority patent/US20020156006A1/en
Priority to US09/978,298 priority patent/US20030134785A1/en
Priority to US09/978,423 priority patent/US20030069178A1/en
Priority to US09/978,564 priority patent/US7195760B2/en
Priority to US09/978,697 priority patent/US20020169284A1/en
Priority to US09/978,757 priority patent/US20030083248A1/en
Priority to US09/978,403 priority patent/US20030050240A1/en
Priority to US09/978,375 priority patent/US7196165B2/en
Priority to US09/978,802 priority patent/US20030199674A1/en
Priority to US09/978,681 priority patent/US20030195148A1/en
Priority to US09/978,585 priority patent/US20030049633A1/en
Priority to US09/978,643 priority patent/US20030104998A1/en
Priority to US09/978,824 priority patent/US20050124789A9/en
Priority to US09/978,665 priority patent/US7294700B2/en
Priority to US09/981,915 priority patent/US20030054986A1/en
Priority to US09/981,915 priority patent/US7285623B2/en
Priority to US09/978,544 priority patent/US20030199436A1/en
Priority to US09/978,824 priority patent/US20030055216A1/en
Priority to US10/210,028 priority patent/US20030203446A1/en
Priority to US10/152,388 priority patent/US20040223964A1/en
Priority to US10/165,247 priority patent/US7112657B2/en
Priority to US10/145,089 priority patent/US7208575B2/en
Priority to US10/164,749 priority patent/US20040029218A1/en
Priority to US10/166,709 priority patent/US20030104536A1/en
Priority to US10/162,521 priority patent/US7067628B2/en
Priority to US10/165,036 priority patent/US20050227342A1/en
Priority to US10/164,829 priority patent/US20030194780A1/en
Priority to US10/160,502 priority patent/US7220835B2/en
Priority to US10/143,029 priority patent/US7105640B2/en
Priority to US10/145,124 priority patent/US20030190701A1/en
Priority to US10/164,728 priority patent/US20030186368A1/en
Priority to US10/165,067 priority patent/US7279553B2/en
Priority to US10/145,017 priority patent/US20030186365A1/en
Priority to US10/164,929 priority patent/US20030194781A1/en
Priority to US10/013,922 priority patent/US20030195345A1/en
Priority to US09/999,834 priority patent/US20030064407A1/en
Priority to US09/999,833 priority patent/US6916648B2/en
Priority to US10/017,085 priority patent/US6974696B2/en
Priority to US10/002,967 priority patent/US20030148373A1/en
Priority to US10/017,086 priority patent/US7122375B2/en
Priority to US09/999,830 priority patent/US20030077700A1/en
Priority to US09/999,832 priority patent/US20020192706A1/en
Priority to US10/017,084 priority patent/US20030203402A1/en
Priority to US10/020,445 priority patent/US20030198994A1/en
Priority to US10/017,083 priority patent/US20030148376A1/en
Priority to US09/999,829 priority patent/US20030195344A1/en
Priority to US09/999,832 priority patent/US7132283B2/en
Priority to US10/017,081 priority patent/US20030049684A1/en
Priority to US10/013,926 priority patent/US7074593B2/en
Priority to US10/013,925 priority patent/US7037710B2/en
Priority to US10/013,927 priority patent/US7189529B2/en
Priority to US10/013,921 priority patent/US20030068648A1/en
Priority to US10/013,923 priority patent/US7169912B2/en
Priority to US10/013,917 priority patent/US7029874B2/en
Priority to US10/013,918 priority patent/US20030211091A1/en
Priority to US10/013,920 priority patent/US20040006219A1/en
Priority to US10/013,928 priority patent/US20030215905A1/en
Priority to US10/013,929 priority patent/US7019124B2/en
Priority to US10/016,177 priority patent/US20030073131A1/en
Priority to US10/000,157 priority patent/US20020182673A1/en
Priority to US09/990,444 priority patent/US6930170B2/en
Priority to US09/993,583 priority patent/US7074897B2/en
Priority to US09/990,438 priority patent/US20030027754A1/en
Priority to US09/993,469 priority patent/US20030068623A1/en
Priority to US09/990,443 priority patent/US20030054987A1/en
Priority to US09/991,854 priority patent/US20030059780A1/en
Priority to US09/993,667 priority patent/US20030022187A1/en
Priority to US09/992,598 priority patent/US6956108B2/en
Priority to US09/990,726 priority patent/US20030054359A1/en
Priority to US09/991,163 priority patent/US20020132253A1/en
Priority to US09/991,073 priority patent/US20020127576A1/en
Priority to US09/993,748 priority patent/US20030069403A1/en
Priority to US09/990,436 priority patent/US20020198148A1/en
Priority to US09/990,711 priority patent/US20030032023A1/en
Priority to US09/992,521 priority patent/US20030083461A1/en
Priority to US09/990,442 priority patent/US20020132252A1/en
Priority to US09/990,427 priority patent/US20030073809A1/en
Priority to US09/990,562 priority patent/US20030027985A1/en
Priority to US09/993,687 priority patent/US20020198149A1/en
Priority to US09/990,456 priority patent/US20020137890A1/en
Priority to US09/990,440 priority patent/US20030060407A1/en
Priority to US09/997,653 priority patent/US7034122B2/en
Priority to US09/998,156 priority patent/US20030044806A1/en
Priority to US09/997,601 priority patent/US20030054404A1/en
Priority to US09/997,333 priority patent/US6953836B2/en
Priority to US09/998,041 priority patent/US7309775B2/en
Priority to US09/997,384 priority patent/US7119177B2/en
Priority to US09/997,585 priority patent/US20030119055A1/en
Priority to US09/997,601 priority patent/US7189814B2/en
Priority to US09/997,585 priority patent/US7166282B2/en
Priority to US09/997,666 priority patent/US7244816B2/en
Priority to US09/997,857 priority patent/US20030064375A1/en
Priority to US09/997,573 priority patent/US20030049682A1/en
Priority to US09/997,529 priority patent/US7309761B2/en
Priority to US09/997,514 priority patent/US7019116B2/en
Priority to US09/997,428 priority patent/US20030027162A1/en
Priority to US09/997,641 priority patent/US20030224358A1/en
Priority to US09/998,041 priority patent/US20030119001A1/en
Priority to US09/997,349 priority patent/US7034106B2/en
Priority to US09/997,683 priority patent/US20030059783A1/en
Priority to US09/997,529 priority patent/US20030134284A1/en
Priority to US09/997,666 priority patent/US20030027163A1/en
Priority to US09/997,440 priority patent/US20030059833A1/en
Priority to US09/997,542 priority patent/US20030068647A1/en
Priority to US09/997,384 priority patent/US20030087305A1/en
Priority to US09/997,614 priority patent/US20030124531A1/en
Priority to US09/997,628 priority patent/US20030059782A1/en
Priority to US09/997,641 priority patent/US7112656B2/en
Priority to US10/002,796 priority patent/US20030032057A1/en
Priority to US09/997,559 priority patent/US20030054403A1/en
Priority to US09/991,150 priority patent/US20030194760A1/en
Priority to US09/991,172 priority patent/US20030050457A1/en
Priority to US09/990,441 priority patent/US7041804B2/en
Priority to US09/991,181 priority patent/US6913919B2/en
Priority to US09/990,437 priority patent/US20030045463A1/en
Priority to US09/991,157 priority patent/US7101687B2/en
Priority to US09/989,723 priority patent/US20020072092A1/en
Priority to US09/989,722 priority patent/US20020072067A1/en
Priority to US09/989,721 priority patent/US20020142961A1/en
Priority to US09/989,328 priority patent/US7056736B2/en
Priority to US09/989,862 priority patent/US20030130182A1/en
Priority to US09/989,726 priority patent/US7018811B2/en
Priority to US09/989,735 priority patent/US6972185B2/en
Priority to US09/989,734 priority patent/US7491529B2/en
Priority to US09/989,729 priority patent/US20030059831A1/en
Priority to US09/989,732 priority patent/US7037679B2/en
Priority to US09/989,727 priority patent/US20020072497A1/en
Priority to US09/989,279 priority patent/US7083978B2/en
Priority to US09/989,730 priority patent/US7157247B2/en
Priority to US09/989,724 priority patent/US7060812B2/en
Priority to US09/989,731 priority patent/US20020103125A1/en
Priority to US09/989,728 priority patent/US7029873B2/en
Priority to US09/989,725 priority patent/US20030139329A1/en
Priority to US09/989,293 priority patent/US7034136B2/en
Priority to US10/001,054 priority patent/US20020192209A1/en
Priority to US10/006,063 priority patent/US20030114652A1/en
Priority to US10/006,117 priority patent/US7071304B2/en
Priority to US10/006,130 priority patent/US7098312B2/en
Priority to US10/006,485 priority patent/US7026448B2/en
Priority to US10/006,768 priority patent/US6936697B2/en
Priority to US10/006,856 priority patent/US7538086B2/en
Priority to US10/006,041 priority patent/US6951921B2/en
Priority to US10/006,116 priority patent/US20030082626A1/en
Priority to US10/006,172 priority patent/US7081514B2/en
Priority to US10/006,818 priority patent/US20030054406A1/en
Priority to US10/007,236 priority patent/US7034123B2/en
Priority to US10/006,867 priority patent/US7160985B2/en
Priority to US10/006,746 priority patent/US7026449B2/en
Priority to US10/007,194 priority patent/US7041805B2/en
Priority to JP2002570731A priority patent/JP4424646B2/ja
Priority to US10/012,754 priority patent/US20030187191A1/en
Priority to AT01986152T priority patent/ATE374819T1/de
Priority to US10/015,967 priority patent/US20030065154A1/en
Priority to US10/012,137 priority patent/US20030187189A1/en
Priority to US10/015,967 priority patent/US7291712B2/en
Priority to CA002439594A priority patent/CA2439594A1/fr
Priority to US10/012,149 priority patent/US7038019B2/en
Priority to AU2002236618A priority patent/AU2002236618B2/en
Priority to US10/011,692 priority patent/US20030109672A1/en
Priority to US10/011,671 priority patent/US20030096954A1/en
Priority to KR10-2003-7011325A priority patent/KR20040055731A/ko
Priority to US10/012,754 priority patent/US7375184B2/en
Priority to EP01986152A priority patent/EP1366161B1/fr
Priority to US10/011,795 priority patent/US7012131B2/en
Priority to DE60130804T priority patent/DE60130804T2/de
Priority to US10/011,833 priority patent/US6951920B2/en
Priority to US10/012,231 priority patent/US6924355B2/en
Priority to PT01986152T priority patent/PT1366161E/pt
Priority to US10/012,755 priority patent/US20030096955A1/en
Priority to US10/012,101 priority patent/US20030187239A1/en
Priority to PCT/US2001/048060 priority patent/WO2002070706A2/fr
Priority to US10/012,237 priority patent/US20030191281A1/en
Priority to US10/012,753 priority patent/US7488796B2/en
Priority to ES01986152T priority patent/ES2295224T3/es
Priority to US10/012,121 priority patent/US7022817B2/en
Priority to EP07016434A priority patent/EP1873245A1/fr
Priority to US10/012,752 priority patent/US7026455B2/en
Priority to DK01986152T priority patent/DK1366161T3/da
Priority to US10/012,064 priority patent/US6953841B2/en
Priority to US10/013,910 priority patent/US7057018B2/en
Priority to US10/013,911 priority patent/US20030187193A1/en
Priority to US10/013,907 priority patent/US20030064925A1/en
Priority to US10/013,915 priority patent/US20030204053A1/en
Priority to US10/013,906 priority patent/US20030191282A1/en
Priority to US10/013,430 priority patent/US20030092883A1/en
Priority to US10/013,913 priority patent/US20030083462A1/en
Priority to US10/013,909 priority patent/US20030186318A1/en
Priority to US10/015,822 priority patent/US20030130491A1/en
Priority to US10/015,519 priority patent/US7033785B2/en
Priority to US10/015,869 priority patent/US20030073130A1/en
Priority to US10/015,653 priority patent/US20030187195A1/en
Priority to US10/015,499 priority patent/US20030065142A1/en
Priority to US10/015,869 priority patent/US7189530B2/en
Priority to US10/015,393 priority patent/US6951737B2/en
Priority to US10/015,671 priority patent/US6946263B2/en
Priority to US10/015,389 priority patent/US6936436B2/en
Priority to US10/015,480 priority patent/US7074912B2/en
Priority to US10/015,386 priority patent/US7022498B2/en
Priority to US10/015,715 priority patent/US7033786B2/en
Priority to US10/015,388 priority patent/US20030191299A1/en
Priority to US10/015,387 priority patent/US20030135034A1/en
Priority to US10/015,390 priority patent/US20030216562A1/en
Priority to US10/015,391 priority patent/US20030120053A1/en
Priority to US10/015,385 priority patent/US20030195347A1/en
Priority to US10/017,610 priority patent/US20030113795A1/en
Priority to US10/017,306 priority patent/US20030170718A1/en
Priority to US10/020,063 priority patent/US20030119097A1/en
Priority to US10/017,867 priority patent/US20030180792A1/en
Priority to US10/017,527 priority patent/US20030082628A1/en
Priority to US10/017,407 priority patent/US20030125535A1/en
Priority to US10/036,342 priority patent/US7193045B2/en
Priority to US10/035,958 priority patent/US7241862B2/en
Priority to US10/036,041 priority patent/US20020192751A1/en
Priority to US10/035,977 priority patent/US20030134327A1/en
Priority to US10/036,150 priority patent/US7256039B2/en
Priority to US10/036,160 priority patent/US7125959B2/en
Priority to US10/036,063 priority patent/US20030092063A1/en
Priority to US10/035,719 priority patent/US20030036114A1/en
Priority to US10/035,855 priority patent/US7105639B2/en
Priority to US10/036,214 priority patent/US20030032061A1/en
Priority to US10/052,586 priority patent/US20020127584A1/en
Priority to US09/978,187 priority patent/US20030096744A1/en
Priority to US10/066,203 priority patent/US20030180796A1/en
Priority to US10/066,500 priority patent/US20020177165A1/en
Priority to US10/066,494 priority patent/US20030032063A1/en
Priority to US10/066,211 priority patent/US20030044844A1/en
Priority to US10/066,269 priority patent/US20030040014A1/en
Priority to US10/066,193 priority patent/US20030044902A1/en
Priority to US10/066,198 priority patent/US20030170721A1/en
Priority to US10/066,273 priority patent/US7317092B2/en
Priority to US10/081,056 priority patent/US20040043927A1/en
Priority to US10/119,480 priority patent/US20040087769A1/en
Priority to US10/121,045 priority patent/US20030073210A1/en
Priority to US10/121,040 priority patent/US20030082759A1/en
Priority to US10/121,042 priority patent/US20030096386A1/en
Priority to US10/121,047 priority patent/US20030077778A1/en
Priority to US10/121,041 priority patent/US20030077776A1/en
Priority to US10/121,051 priority patent/US20030092147A1/en
Priority to US10/121,044 priority patent/US20030190717A1/en
Priority to US10/121,046 priority patent/US20030194791A1/en
Priority to US10/121,059 priority patent/US20030190721A1/en
Priority to US10/121,058 priority patent/US20030190720A1/en
Priority to US10/121,049 priority patent/US20030022239A1/en
Priority to US10/121,052 priority patent/US20030199052A1/en
Priority to US10/121,060 priority patent/US20030190722A1/en
Priority to US10/121,050 priority patent/US20030054516A1/en
Priority to US10/121,054 priority patent/US20030199054A1/en
Priority to US10/121,061 priority patent/US20030082761A1/en
Priority to US10/121,055 priority patent/US20030190718A1/en
Priority to US10/121,048 priority patent/US20030199051A1/en
Priority to US10/121,053 priority patent/US20030199053A1/en
Priority to US10/121,056 priority patent/US20030082760A1/en
Priority to US10/121,063 priority patent/US20030199055A1/en
Priority to US10/121,057 priority patent/US20030190719A1/en
Priority to US10/121,062 priority patent/US20030077779A1/en
Priority to US10/121,043 priority patent/US7220831B2/en
Priority to US10/123,213 priority patent/US20030199057A1/en
Priority to US10/123,322 priority patent/US20030199059A1/en
Priority to US10/123,262 priority patent/US20030049816A1/en
Priority to US10/123,154 priority patent/US20030190724A1/en
Priority to US10/123,155 priority patent/US20030068794A1/en
Priority to US10/123,771 priority patent/US20030199060A1/en
Priority to US10/123,292 priority patent/US20030073211A1/en
Priority to US10/123,157 priority patent/US20030190725A1/en
Priority to US10/123,156 priority patent/US20030194792A1/en
Priority to US10/123,215 priority patent/US7291329B2/en
Priority to US10/123,109 priority patent/US20030190723A1/en
Priority to US10/123,108 priority patent/US7635478B2/en
Priority to US10/123,214 priority patent/US7343721B2/en
Priority to US10/123,236 priority patent/US20030068795A1/en
Priority to US10/123,291 priority patent/US20030199058A1/en
Priority to US10/123,213 priority patent/US7193048B2/en
Priority to US10/123,212 priority patent/US7276577B2/en
Priority to US10/123,261 priority patent/US20030068796A1/en
Priority to US10/123,235 priority patent/US20030082762A1/en
Priority to US10/123,905 priority patent/US7285625B2/en
Priority to US10/123,903 priority patent/US20030073212A1/en
Priority to US10/123,911 priority patent/US7408032B2/en
Priority to US10/123,904 priority patent/US20030022328A1/en
Priority to US10/123,902 priority patent/US20030077781A1/en
Priority to US10/123,907 priority patent/US7084258B2/en
Priority to US10/123,913 priority patent/US20030203462A1/en
Priority to US10/123,905 priority patent/US20030087344A1/en
Priority to US10/123,912 priority patent/US20030100087A1/en
Priority to US10/123,909 priority patent/US7193049B2/en
Priority to US10/123,910 priority patent/US7329404B2/en
Priority to US10/123,908 priority patent/US7335728B2/en
Priority to US10/123,906 priority patent/US20030190726A1/en
Priority to US10/124,817 priority patent/US20030077786A1/en
Priority to US10/124,813 priority patent/US7312307B2/en
Priority to US10/124,823 priority patent/US20030199062A1/en
Priority to US10/124,814 priority patent/US7105335B2/en
Priority to US10/124,820 priority patent/US20030190729A1/en
Priority to US10/124,819 priority patent/US7285626B2/en
Priority to US10/124,818 priority patent/US20030082763A1/en
Priority to US10/124,822 priority patent/US7109305B2/en
Priority to US10/125,795 priority patent/US7304131B2/en
Priority to US10/124,816 priority patent/US20030190728A1/en
Priority to US10/124,824 priority patent/US20030077659A1/en
Priority to US10/125,704 priority patent/US7357926B2/en
Priority to US10/124,821 priority patent/US20030199023A1/en
Priority to US10/125,166 priority patent/US20030039648A1/en
Priority to US10/125,805 priority patent/US20030194794A1/en
Priority to US10/125,924 priority patent/US7342097B2/en
Priority to US10/125,922 priority patent/US7309762B2/en
Priority to US10/125,932 priority patent/US7317079B2/en
Priority to US10/125,931 priority patent/US20030199063A1/en
Priority to US10/125,927 priority patent/US20030190731A1/en
Priority to US10/127,831 priority patent/US20030082689A1/en
Priority to US10/127,966 priority patent/US20030003507A1/en
Priority to US10/128,689 priority patent/US20030087365A1/en
Priority to US10/131,825 priority patent/US7282566B2/en
Priority to US10/131,823 priority patent/US7304132B2/en
Priority to US10/131,817 priority patent/US7291701B2/en
Priority to US10/063,520 priority patent/US20030187196A1/en
Priority to US10/063,517 priority patent/US7232889B2/en
Priority to US10/063,510 priority patent/US7109292B2/en
Priority to US10/063,518 priority patent/US7465785B2/en
Priority to US10/063,521 priority patent/US20030190669A1/en
Priority to US10/063,519 priority patent/US20030009013A1/en
Priority to US10/063,528 priority patent/US20030181666A1/en
Priority to US10/063,567 priority patent/US20030069394A1/en
Priority to US10/063,532 priority patent/US7202336B2/en
Priority to US10/063,545 priority patent/US7256261B2/en
Priority to US10/063,545 priority patent/US20020183505A1/en
Priority to US10/063,568 priority patent/US20030181668A1/en
Priority to US10/063,562 priority patent/US20030181697A1/en
Priority to US10/063,538 priority patent/US7253255B2/en
Priority to US10/063,536 priority patent/US7259238B2/en
Priority to US10/063,554 priority patent/US7223841B2/en
Priority to US10/063,555 priority patent/US20030065143A1/en
Priority to US10/063,553 priority patent/US7235630B2/en
Priority to US10/063,564 priority patent/US20030180794A1/en
Priority to US10/063,548 priority patent/US20030187228A1/en
Priority to US10/063,566 priority patent/US20030073821A1/en
Priority to US10/063,526 priority patent/US20030171550A1/en
Priority to US10/063,549 priority patent/US7253256B2/en
Priority to US10/063,551 priority patent/US7214777B2/en
Priority to US10/063,553 priority patent/US20030045684A1/en
Priority to US10/063,540 priority patent/US20030181667A1/en
Priority to US10/063,534 priority patent/US7193060B2/en
Priority to US10/063,561 priority patent/US7271247B2/en
Priority to US10/063,523 priority patent/US7220830B2/en
Priority to US10/063,525 priority patent/US20030036634A1/en
Priority to US10/063,547 priority patent/US7294690B2/en
Priority to US10/063,551 priority patent/US20020183494A1/en
Priority to US10/063,527 priority patent/US20030181637A1/en
Priority to US10/063,524 priority patent/US7205391B2/en
Priority to US10/063,546 priority patent/US7435798B2/en
Priority to US10/063,524 priority patent/US20030027992A1/en
Priority to US10/063,565 priority patent/US20030180904A1/en
Priority to US10/063,569 priority patent/US20030018168A1/en
Priority to US10/063,544 priority patent/US20030027212A1/en
Priority to US10/063,548 priority patent/US7232892B2/en
Priority to US10/063,540 priority patent/US7193061B2/en
Priority to US10/063,547 priority patent/US20020182638A1/en
Priority to US10/063,536 priority patent/US20030181696A1/en
Priority to US10/063,537 priority patent/US7276586B2/en
Priority to US10/063,523 priority patent/US20030181636A1/en
Priority to US10/063,560 priority patent/US7232882B2/en
Priority to US10/063,569 priority patent/US7378491B2/en
Priority to US10/063,563 priority patent/US20030060602A1/en
Priority to US10/063,541 priority patent/US20030060601A1/en
Priority to US10/063,530 priority patent/US7193059B2/en
Priority to US10/063,570 priority patent/US7507404B2/en
Priority to US10/063,615 priority patent/US7405269B2/en
Priority to US10/137,868 priority patent/US20030082764A1/en
Priority to US10/063,596 priority patent/US7285624B2/en
Priority to US10/063,593 priority patent/US7189805B2/en
Priority to US10/063,602 priority patent/US7230082B2/en
Priority to US10/063,577 priority patent/US7423130B2/en
Priority to US10/063,614 priority patent/US7393931B2/en
Priority to US10/063,592 priority patent/US7220841B2/en
Priority to US10/137,865 priority patent/US20030032155A1/en
Priority to US10/063,578 priority patent/US7417125B2/en
Priority to US10/063,612 priority patent/US7399828B2/en
Priority to US10/063,611 priority patent/US20030181677A1/en
Priority to US10/063,581 priority patent/US7189803B2/en
Priority to US10/063,606 priority patent/US20030181675A1/en
Priority to US10/063,592 priority patent/US20030181672A1/en
Priority to US10/137,867 priority patent/US20030207349A1/en
Priority to US10/063,597 priority patent/US7227000B2/en
Priority to US10/063,587 priority patent/US7244428B2/en
Priority to US10/063,611 priority patent/US7378501B2/en
Priority to US10/063,610 priority patent/US20030180907A1/en
Priority to US10/063,582 priority patent/US7205389B2/en
Priority to US10/063,591 priority patent/US7196174B2/en
Priority to US10/063,579 priority patent/US20030181638A1/en
Priority to US10/063,591 priority patent/US20030180906A1/en
Priority to US10/063,617 priority patent/US7423119B2/en
Priority to US10/063,600 priority patent/US7230076B2/en
Priority to US10/063,618 priority patent/US7468424B2/en
Priority to US10/063,583 priority patent/US7189804B2/en
Priority to US10/063,607 priority patent/US7345145B2/en
Priority to US10/063,588 priority patent/US20030130483A1/en
Priority to US10/063,616 priority patent/US7358339B2/en
Priority to US10/063,610 priority patent/US7371814B2/en
Priority to US10/063,598 priority patent/US7223838B2/en
Priority to US10/063,609 priority patent/US7402661B2/en
Priority to US10/063,589 priority patent/US20030181641A1/en
Priority to US10/063,604 priority patent/US7390876B2/en
Priority to US10/140,023 priority patent/US20030207416A1/en
Priority to US10/140,470 priority patent/US20030022331A1/en
Priority to US10/140,024 priority patent/US20040058424A1/en
Priority to US10/139,980 priority patent/US7247710B2/en
Priority to US10/139,963 priority patent/US7288625B2/en
Priority to US10/140,020 priority patent/US20030207415A1/en
Priority to US10/140,474 priority patent/US20030032156A1/en
Priority to US10/140,865 priority patent/US20030207420A1/en
Priority to US10/063,660 priority patent/US7189822B2/en
Priority to US10/140,809 priority patent/US20030207418A1/en
Priority to US10/140,860 priority patent/US7307151B2/en
Priority to US10/063,651 priority patent/US7193057B2/en
Priority to US10/063,659 priority patent/US7186801B2/en
Priority to US10/063,670 priority patent/US20030180839A1/en
Priority to US10/140,921 priority patent/US7317080B2/en
Priority to US10/063,653 priority patent/US7238787B2/en
Priority to US10/063,662 priority patent/US20030180795A1/en
Priority to US10/063,666 priority patent/US7411037B2/en
Priority to US10/063,671 priority patent/US20030180840A1/en
Priority to US10/063,647 priority patent/US7193046B2/en
Priority to US10/063,652 priority patent/US7230077B2/en
Priority to US10/063,639 priority patent/US7081520B2/en
Priority to US10/063,646 priority patent/US7189821B2/en
Priority to US10/063,661 priority patent/US7193047B2/en
Priority to US10/140,925 priority patent/US20030073215A1/en
Priority to US10/063,677 priority patent/US20030187242A1/en
Priority to US10/063,654 priority patent/US7202337B2/en
Priority to US10/063,657 priority patent/US7193063B2/en
Priority to US10/063,673 priority patent/US20030180908A1/en
Priority to US10/063,676 priority patent/US20030180843A1/en
Priority to US10/063,646 priority patent/US20030181681A1/en
Priority to US10/063,643 priority patent/US20030181680A1/en
Priority to US10/140,864 priority patent/US20030207419A1/en
Priority to US10/063,647 priority patent/US20030187197A1/en
Priority to US10/063,638 priority patent/US7101970B2/en
Priority to US10/063,648 priority patent/US7193062B2/en
Priority to US10/063,664 priority patent/US7256262B2/en
Priority to US10/063,672 priority patent/US20030181700A1/en
Priority to US10/063,644 priority patent/US7196167B2/en
Priority to US10/140,805 priority patent/US20030207417A1/en
Priority to US10/063,668 priority patent/US20030191290A1/en
Priority to US10/063,642 priority patent/US20030181650A1/en
Priority to US10/063,669 priority patent/US20030180838A1/en
Priority to US10/063,644 priority patent/US20030181651A1/en
Priority to US10/063,649 priority patent/US20030181652A1/en
Priority to US10/063,675 priority patent/US20030180842A1/en
Priority to US10/140,928 priority patent/US20030068798A1/en
Priority to US10/063,640 priority patent/US7354997B2/en
Priority to US10/140,808 priority patent/US7425621B2/en
Priority to US10/063,665 priority patent/US7427664B2/en
Priority to US10/063,674 priority patent/US20030180841A1/en
Priority to US10/063,650 priority patent/US7217787B2/en
Priority to US10/141,756 priority patent/US7488586B2/en
Priority to US10/063,694 priority patent/US20030180848A1/en
Priority to US10/063,735 priority patent/US20030138882A1/en
Priority to US10/063,731 priority patent/US20030180921A1/en
Priority to US10/063,705 priority patent/US7220850B2/en
Priority to US10/063,688 priority patent/US20030186408A1/en
Priority to US10/063,727 priority patent/US20030180857A1/en
Priority to US10/063,736 priority patent/US20030180860A1/en
Priority to US10/063,682 priority patent/US20030181701A1/en
Priority to US10/063,744 priority patent/US20030180863A1/en
Priority to US10/063,718 priority patent/US20030190698A1/en
Priority to US10/063,722 priority patent/US20030180918A1/en
Priority to US10/063,692 priority patent/US20030180846A1/en
Priority to US10/063,712 priority patent/US20030180912A1/en
Priority to US10/063,689 priority patent/US20030180845A1/en
Priority to US10/063,730 priority patent/US20030180858A1/en
Priority to US10/063,684 priority patent/US20030186407A1/en
Priority to US10/063,717 priority patent/US20030180916A1/en
Priority to US10/063,709 priority patent/US7189564B2/en
Priority to US10/063,726 priority patent/US20030180919A1/en
Priority to US10/141,760 priority patent/US7342104B2/en
Priority to US10/063,724 priority patent/US20030180856A1/en
Priority to US10/063,703 priority patent/US7189563B2/en
Priority to US10/063,713 priority patent/US20030180855A1/en
Priority to US10/141,755 priority patent/US7297764B2/en
Priority to US10/063,715 priority patent/US20030180914A1/en
Priority to US10/063,698 priority patent/US20030180849A1/en
Priority to US10/063,714 priority patent/US20030180913A1/en
Priority to US10/063,711 priority patent/US20030180911A1/en
Priority to US10/063,728 priority patent/US20030180920A1/en
Priority to US10/063,734 priority patent/US20030180859A1/en
Priority to US10/063,732 priority patent/US20030180922A1/en
Priority to US10/063,710 priority patent/US20030180910A1/en
Priority to US10/063,699 priority patent/US20030180850A1/en
Priority to US10/063,702 priority patent/US7193074B2/en
Priority to US10/141,754 priority patent/US7361732B2/en
Priority to US10/063,721 priority patent/US20030181702A1/en
Priority to US10/063,716 priority patent/US20030180915A1/en
Priority to US10/063,685 priority patent/US20030180909A1/en
Priority to US10/063,693 priority patent/US20030180847A1/en
Priority to US10/063,723 priority patent/US20030181703A1/en
Priority to US10/063,720 priority patent/US20030180917A1/en
Priority to US10/141,701 priority patent/US20030207421A1/en
Priority to US10/063,686 priority patent/US20030180844A1/en
Priority to US10/063,707 priority patent/US20030180853A1/en
Priority to US10/143,114 priority patent/US20030036180A1/en
Priority to US10/063,741 priority patent/US7118887B2/en
Priority to US10/063,745 priority patent/US20040058411A1/en
Priority to US10/142,425 priority patent/US20030207424A1/en
Priority to US10/142,430 priority patent/US7309766B2/en
Priority to US10/143,113 priority patent/US7329730B2/en
Priority to US10/142,417 priority patent/US7304133B2/en
Priority to US10/063,742 priority patent/US7189532B2/en
Priority to US10/063,743 priority patent/US20030180862A1/en
Priority to US10/142,431 priority patent/US7285629B2/en
Priority to US10/142,419 priority patent/US7153941B2/en
Priority to US10/143,032 priority patent/US7408033B2/en
Priority to US10/142,423 priority patent/US20030049817A1/en
Priority to US10/146,730 priority patent/US20030207427A1/en
Priority to US10/146,792 priority patent/US20030207428A1/en
Priority to US10/147,528 priority patent/US20030219885A1/en
Priority to US10/147,492 priority patent/US20030082765A1/en
Priority to US10/147,519 priority patent/US20030077791A1/en
Priority to US10/147,536 priority patent/US20040077064A1/en
Priority to US10/152,395 priority patent/US7189534B2/en
Priority to US10/153,934 priority patent/US20030129695A1/en
Priority to US10/156,843 priority patent/US20030207805A1/en
Priority to US10/157,786 priority patent/US20030208055A1/en
Priority to US10/157,782 priority patent/US20030077792A1/en
Priority to US10/160,498 priority patent/US20030073216A1/en
Priority to US10/158,791 priority patent/US20030207429A1/en
Priority to US10/158,782 priority patent/US20030082766A1/en
Priority to US10/173,700 priority patent/US20030027262A1/en
Priority to US10/173,704 priority patent/US20030170795A1/en
Priority to US10/173,690 priority patent/US20030166105A1/en
Priority to US10/173,692 priority patent/US20030166188A1/en
Priority to US10/173,695 priority patent/US20030032101A1/en
Priority to US10/173,703 priority patent/US20030170794A1/en
Priority to US10/173,696 priority patent/US20030082767A1/en
Priority to US10/173,699 priority patent/US20030166109A1/en
Priority to US10/173,707 priority patent/US20030166110A1/en
Priority to US10/173,694 priority patent/US20030166107A1/en
Priority to US10/173,701 priority patent/US20030104538A1/en
Priority to US10/173,698 priority patent/US20030166108A1/en
Priority to US10/173,705 priority patent/US20030032103A1/en
Priority to US10/173,693 priority patent/US20030073169A1/en
Priority to US10/173,706 priority patent/US20030022293A1/en
Priority to US10/173,691 priority patent/US20030166106A1/en
Priority to US10/173,689 priority patent/US20030166104A1/en
Priority to US10/173,697 priority patent/US20030032102A1/en
Priority to US10/173,702 priority patent/US20030170793A1/en
Priority to US10/174,569 priority patent/US20030166111A1/en
Priority to US10/174,581 priority patent/US7153939B2/en
Priority to US10/174,590 priority patent/US20030008352A1/en
Priority to US10/174,570 priority patent/US20030211572A1/en
Priority to US10/174,574 priority patent/US20030170796A1/en
Priority to US10/174,572 priority patent/US20030027263A1/en
Priority to US10/174,575 priority patent/US20030096351A1/en
Priority to US10/174,589 priority patent/US20030166114A1/en
Priority to US10/174,591 priority patent/US20030166115A1/en
Priority to US10/174,588 priority patent/US20030027266A1/en
Priority to US10/174,578 priority patent/US20030073170A1/en
Priority to US10/174,579 priority patent/US20030027264A1/en
Priority to US10/174,585 priority patent/US20030032105A1/en
Priority to US10/174,571 priority patent/US20030068679A1/en
Priority to US10/174,583 priority patent/US7211645B2/en
Priority to US10/174,587 priority patent/US20030166113A1/en
Priority to US10/174,582 priority patent/US20030027265A1/en
Priority to US10/174,586 priority patent/US20030032106A1/en
Priority to US10/174,576 priority patent/US7125962B2/en
Priority to US10/175,753 priority patent/US20030077732A1/en
Priority to US10/175,735 priority patent/US20030082715A1/en
Priority to US10/175,752 priority patent/US20030022295A1/en
Priority to US10/175,738 priority patent/US20030022294A1/en
Priority to US10/175,736 priority patent/US20030166117A1/en
Priority to US10/175,746 priority patent/US20030027270A1/en
Priority to US10/175,748 priority patent/US20030166121A1/en
Priority to US10/175,745 priority patent/US20030166120A1/en
Priority to US10/175,747 priority patent/US20030032107A1/en
Priority to US10/175,751 priority patent/US20030166122A1/en
Priority to US10/175,742 priority patent/US20030166118A1/en
Priority to US10/175,743 priority patent/US20030027269A1/en
Priority to US10/175,750 priority patent/US20030073172A1/en
Priority to US10/175,744 priority patent/US20030166119A1/en
Priority to US10/175,754 priority patent/US20030166123A1/en
Priority to US10/175,739 priority patent/US20030027267A1/en
Priority to US10/175,749 priority patent/US20050196832A1/en
Priority to US10/175,741 priority patent/US20030073171A1/en
Priority to US10/176,485 priority patent/US20030032109A1/en
Priority to US10/176,988 priority patent/US20030170802A1/en
Priority to US10/176,913 priority patent/US20030022298A1/en
Priority to US10/176,483 priority patent/US20030017541A1/en
Priority to US10/176,754 priority patent/US7709602B2/en
Priority to US10/176,759 priority patent/US20030166128A1/en
Priority to US10/176,914 priority patent/US20030017543A1/en
Priority to US10/176,493 priority patent/US20030032111A1/en
Priority to US10/176,749 priority patent/US20030017542A1/en
Priority to US10/176,753 priority patent/US20030044917A1/en
Priority to US10/176,484 priority patent/US20030059876A9/en
Priority to US10/176,479 priority patent/US20030040054A1/en
Priority to US10/176,482 priority patent/US20030022296A1/en
Priority to US10/176,746 priority patent/US20030068680A1/en
Priority to US10/176,920 priority patent/US20030166129A1/en
Priority to US10/176,919 priority patent/US20030032114A1/en
Priority to US10/176,757 priority patent/US7317082B2/en
Priority to US10/176,917 priority patent/US20030044918A1/en
Priority to US10/176,993 priority patent/US20030027280A1/en
Priority to US10/176,989 priority patent/US20030170803A1/en
Priority to US10/176,747 priority patent/US20030027273A1/en
Priority to US10/176,981 priority patent/US20030170800A1/en
Priority to US10/176,921 priority patent/US20030027276A1/en
Priority to US10/176,918 priority patent/US7495083B2/en
Priority to US10/176,911 priority patent/US20030032113A1/en
Priority to US10/176,491 priority patent/US20030087373A1/en
Priority to US10/176,487 priority patent/US20030032110A1/en
Priority to US10/176,490 priority patent/US20030170798A1/en
Priority to US10/176,760 priority patent/US7339033B2/en
Priority to US10/176,486 priority patent/US7354999B2/en
Priority to US10/176,987 priority patent/US20030027278A1/en
Priority to US10/176,751 priority patent/US20030036117A1/en
Priority to US10/176,924 priority patent/US20030166131A1/en
Priority to US10/176,986 priority patent/US20030073173A1/en
Priority to US10/176,925 priority patent/US20030032115A1/en
Priority to US10/176,922 priority patent/US20030166130A1/en
Priority to US10/176,923 priority patent/US20030068681A1/en
Priority to US10/176,488 priority patent/US20030027271A1/en
Priority to US10/176,481 priority patent/US20030032108A1/en
Priority to US10/176,991 priority patent/US20030027324A1/en
Priority to US10/176,489 priority patent/US20030166125A1/en
Priority to US10/176,992 priority patent/US20030027279A1/en
Priority to US10/176,755 priority patent/US20030166127A1/en
Priority to US10/176,748 priority patent/US20030040055A1/en
Priority to US10/176,752 priority patent/US20030170799A1/en
Priority to US10/176,916 priority patent/US20030040056A1/en
Priority to US10/176,985 priority patent/US20030027277A1/en
Priority to US10/176,983 priority patent/US20030170801A1/en
Priority to US10/176,480 priority patent/US20030166124A1/en
Priority to US10/176,915 priority patent/US20030017544A1/en
Priority to US10/176,756 priority patent/US20030032112A1/en
Priority to US10/176,979 priority patent/US20030087374A1/en
Priority to US10/176,492 priority patent/US20030027272A1/en
Priority to US10/176,750 priority patent/US20030027274A1/en
Priority to US10/176,982 priority patent/US20030044919A1/en
Priority to US10/176,758 priority patent/US20030008353A1/en
Priority to US10/176,978 priority patent/US20030032116A1/en
Priority to US10/176,984 priority patent/US20030166132A1/en
Priority to US10/179,521 priority patent/US20030170806A1/en
Priority to US10/179,509 priority patent/US20030207392A1/en
Priority to US10/179,519 priority patent/US7339024B2/en
Priority to US10/179,507 priority patent/US20030040057A1/en
Priority to US10/179,514 priority patent/US20030044922A1/en
Priority to US10/179,516 priority patent/US20030040058A1/en
Priority to US10/179,508 priority patent/US20030166133A1/en
Priority to US10/179,506 priority patent/US20030044920A1/en
Priority to US10/179,513 priority patent/US20030044921A1/en
Priority to US10/179,520 priority patent/US20030096353A1/en
Priority to US10/179,511 priority patent/US20030104539A1/en
Priority to US10/179,518 priority patent/US20030104540A1/en
Priority to US10/179,522 priority patent/US20030044923A1/en
Priority to US10/179,523 priority patent/US20030215909A1/en
Priority to US10/179,517 priority patent/US20030170805A1/en
Priority to US10/179,526 priority patent/US20030100061A1/en
Priority to US10/179,512 priority patent/US20030166134A1/en
Priority to US10/179,510 priority patent/US20030032117A1/en
Priority to US10/179,515 priority patent/US20030166135A1/en
Priority to US10/179,525 priority patent/US20030040060A1/en
Priority to US10/180,555 priority patent/US20030032123A1/en
Priority to US10/180,559 priority patent/US20030032124A1/en
Priority to US10/180,550 priority patent/US20030064440A1/en
Priority to US10/180,557 priority patent/US20030022301A1/en
Priority to US10/180,560 priority patent/US20030044925A1/en
Priority to US10/180,554 priority patent/US20050202526A1/en
Priority to US10/180,540 priority patent/US20030040061A1/en
Priority to US10/180,545 priority patent/US20030040062A1/en
Priority to US10/180,549 priority patent/US20030032122A1/en
Priority to US10/180,541 priority patent/US20030036120A1/en
Priority to US10/180,544 priority patent/US20030032119A1/en
Priority to US10/180,556 priority patent/US7355000B2/en
Priority to US10/180,551 priority patent/US20030036123A1/en
Priority to US10/180,543 priority patent/US20030032118A1/en
Priority to US10/180,542 priority patent/US20030036121A1/en
Priority to US10/180,553 priority patent/US7365156B2/en
Priority to US10/180,547 priority patent/US20030032121A1/en
Priority to US10/180,546 priority patent/US20030032120A1/en
Priority to US10/180,548 priority patent/US7696319B2/en
Priority to US10/180,552 priority patent/US7348415B2/en
Priority to US10/183,010 priority patent/US20030032126A1/en
Priority to US10/183,013 priority patent/US7309769B2/en
Priority to US10/183,008 priority patent/US20030040064A1/en
Priority to US10/183,019 priority patent/US7425605B2/en
Priority to US10/183,011 priority patent/US20030068682A1/en
Priority to US10/183,018 priority patent/US20030104541A1/en
Priority to US10/183,003 priority patent/US20030082716A1/en
Priority to US10/183,014 priority patent/US20030064441A1/en
Priority to US10/183,009 priority patent/US7339034B2/en
Priority to US10/183,015 priority patent/US20030044926A1/en
Priority to US10/181,000 priority patent/US7319137B2/en
Priority to US10/183,012 priority patent/US7718770B2/en
Priority to US10/183,001 priority patent/US7084255B2/en
Priority to US10/180,998 priority patent/US7087421B2/en
Priority to US10/183,017 priority patent/US20030040065A1/en
Priority to US10/180,999 priority patent/US7297767B2/en
Priority to US10/183,016 priority patent/US20030082717A1/en
Priority to US10/183,006 priority patent/US7297776B2/en
Priority to US10/183,002 priority patent/US20030054454A1/en
Priority to US10/183,005 priority patent/US7317093B2/en
Priority to US10/184,613 priority patent/US20030119105A1/en
Priority to US10/184,612 priority patent/US20030036127A1/en
Priority to US10/184,633 priority patent/US20030068683A1/en
Priority to US10/184,615 priority patent/US20030044927A1/en
Priority to US10/184,654 priority patent/US7378486B2/en
Priority to US10/184,630 priority patent/US20030036133A1/en
Priority to US10/184,628 priority patent/US7309770B2/en
Priority to US10/184,651 priority patent/US7291704B2/en
Priority to US10/184,638 priority patent/US20030054456A1/en
Priority to US10/184,642 priority patent/US7332573B2/en
Priority to US10/184,618 priority patent/US7393917B2/en
Priority to US10/184,639 priority patent/US7291703B2/en
Priority to US10/184,631 priority patent/US20030036134A1/en
Priority to US10/184,627 priority patent/US20030040070A1/en
Priority to US10/184,641 priority patent/US20030073174A1/en
Priority to US10/184,652 priority patent/US20030032134A1/en
Priority to US10/184,616 priority patent/US20030036128A1/en
Priority to US10/184,619 priority patent/US20030049738A1/en
Priority to US10/184,640 priority patent/US7271250B2/en
Priority to US10/184,627 priority patent/US7282569B2/en
Priority to US10/184,614 priority patent/US20030032128A1/en
Priority to US10/184,630 priority patent/US7304143B2/en
Priority to US10/184,632 priority patent/US20030036135A1/en
Priority to US10/184,647 priority patent/US20030032133A1/en
Priority to US10/184,623 priority patent/US20030032129A1/en
Priority to US10/184,643 priority patent/US20030044929A1/en
Priority to US10/184,644 priority patent/US20030044930A1/en
Priority to US10/184,625 priority patent/US20030040068A1/en
Priority to US10/184,646 priority patent/US20030032132A1/en
Priority to US10/184,637 priority patent/US20030032131A1/en
Priority to US10/184,658 priority patent/US20030027281A1/en
Priority to US10/184,636 priority patent/US20030036136A1/en
Priority to US10/184,656 priority patent/US20030044931A1/en
Priority to US10/184,645 priority patent/US7291718B2/en
Priority to US10/184,620 priority patent/US20030044928A1/en
Priority to US10/184,635 priority patent/US20030032130A1/en
Priority to US10/184,629 priority patent/US20030036132A1/en
Priority to US10/184,617 priority patent/US20030036129A1/en
Priority to US10/184,626 priority patent/US20030040069A1/en
Priority to US10/184,621 priority patent/US20030054455A1/en
Priority to US10/184,624 priority patent/US20030104542A1/en
Priority to US10/184,650 priority patent/US20030036138A1/en
Priority to US10/184,655 priority patent/US20030040073A1/en
Priority to US10/184,634 priority patent/US20030068684A1/en
Priority to US10/184,657 priority patent/US20030104543A1/en
Priority to US10/184,622 priority patent/US20030036130A1/en
Priority to US10/187,750 priority patent/US20030049740A1/en
Priority to US10/187,592 priority patent/US7314913B2/en
Priority to US10/187,747 priority patent/US7291707B2/en
Priority to US10/187,884 priority patent/US20030036155A1/en
Priority to US10/187,888 priority patent/US20030073175A1/en
Priority to US10/187,597 priority patent/US20030036141A1/en
Priority to US10/187,755 priority patent/US7312309B2/en
Priority to US10/187,601 priority patent/US7291705B2/en
Priority to US10/187,588 priority patent/US7351795B2/en
Priority to US10/187,748 priority patent/US20030068687A1/en
Priority to US10/187,591 priority patent/US7709603B2/en
Priority to US10/187,887 priority patent/US7285645B2/en
Priority to US10/187,740 priority patent/US20030064443A1/en
Priority to US10/187,599 priority patent/US7355013B2/en
Priority to US10/187,594 priority patent/US7294335B2/en
Priority to US10/187,598 priority patent/US20030036142A1/en
Priority to US10/187,739 priority patent/US7291706B2/en
Priority to US10/187,595 priority patent/US7563867B2/en
Priority to US10/187,752 priority patent/US20030054457A1/en
Priority to US10/187,886 priority patent/US7291708B2/en
Priority to US10/187,738 priority patent/US20030064442A1/en
Priority to US10/188,766 priority patent/US7351804B2/en
Priority to US10/187,753 priority patent/US20030036152A1/en
Priority to US10/188,774 priority patent/US20030040074A1/en
Priority to US10/187,749 priority patent/US20030153036A1/en
Priority to US10/187,603 priority patent/US20030036146A1/en
Priority to US10/187,743 priority patent/US20030036148A1/en
Priority to US10/188,773 priority patent/US20030036159A1/en
Priority to US10/187,602 priority patent/US20030036145A1/en
Priority to US10/187,746 priority patent/US20030036149A1/en
Priority to US10/187,596 priority patent/US20030032136A1/en
Priority to US10/188,780 priority patent/US7268217B2/en
Priority to US10/187,885 priority patent/US20030032138A1/en
Priority to US10/187,757 priority patent/US7276578B2/en
Priority to US10/187,754 priority patent/US20030036153A1/en
Priority to US10/188,771 priority patent/US20030068689A1/en
Priority to US10/188,770 priority patent/US7358340B2/en
Priority to US10/187,745 priority patent/US7250490B2/en
Priority to US10/188,769 priority patent/US20030036157A1/en
Priority to US10/188,767 priority patent/US7312310B2/en
Priority to US10/187,741 priority patent/US20030036147A1/en
Priority to US10/187,600 priority patent/US20030036143A1/en
Priority to US10/187,751 priority patent/US20030036151A1/en
Priority to US10/188,775 priority patent/US20030040075A1/en
Priority to US10/187,747 priority patent/US20030036150A1/en
Priority to US10/187,742 priority patent/US20030068686A1/en
Priority to US10/187,883 priority patent/US20030064444A1/en
Priority to US10/188,781 priority patent/US20030036160A1/en
Priority to US10/192,008 priority patent/US20030068693A1/en
Priority to US10/192,016 priority patent/US20030068697A1/en
Priority to US10/192,006 priority patent/US20030068692A1/en
Priority to US10/192,010 priority patent/US20030044932A1/en
Priority to US10/192,009 priority patent/US20030068694A1/en
Priority to US10/192,011 priority patent/US20030207395A1/en
Priority to US10/192,014 priority patent/US7312315B2/en
Priority to US10/192,012 priority patent/US7304134B2/en
Priority to US10/192,007 priority patent/US7317083B2/en
Priority to US10/192,015 priority patent/US20030049742A1/en
Priority to US10/194,488 priority patent/US20030068704A1/en
Priority to US10/194,457 priority patent/US20030153037A1/en
Priority to US10/194,486 priority patent/US20030207396A1/en
Priority to US10/194,463 priority patent/US20030064447A1/en
Priority to US10/194,485 priority patent/US7449549B2/en
Priority to US10/194,459 priority patent/US7307144B2/en
Priority to US10/194,425 priority patent/US20030049744A1/en
Priority to US10/194,395 priority patent/US7326773B2/en
Priority to US10/194,394 priority patent/US7390886B2/en
Priority to US10/194,460 priority patent/US20030064446A1/en
Priority to US10/194,458 priority patent/US20030068702A1/en
Priority to US10/194,363 priority patent/US20030064445A1/en
Priority to US10/194,362 priority patent/US20030068698A1/en
Priority to US10/194,364 priority patent/US7314918B2/en
Priority to US10/194,456 priority patent/US20030059879A1/en
Priority to US10/194,461 priority patent/US20030054459A1/en
Priority to US10/194,361 priority patent/US20030036161A1/en
Priority to US10/194,487 priority patent/US7427667B2/en
Priority to US10/194,359 priority patent/US8063186B2/en
Priority to US10/194,365 priority patent/US7381791B2/en
Priority to US10/194,424 priority patent/US7335730B2/en
Priority to US10/194,462 priority patent/US7388073B2/en
Priority to US10/194,484 priority patent/US20030064448A1/en
Priority to US10/194,423 priority patent/US7339025B2/en
Priority to US10/194,360 priority patent/US20030073176A1/en
Priority to US10/195,899 priority patent/US20030049747A1/en
Priority to US10/195,901 priority patent/US20030036165A1/en
Priority to US10/195,892 priority patent/US7385033B2/en
Priority to US10/195,900 priority patent/US7351789B2/en
Priority to US10/195,883 priority patent/US20060073544A1/en
Priority to US10/195,887 priority patent/US7375179B2/en
Priority to US10/195,886 priority patent/US20030068705A1/en
Priority to US10/195,898 priority patent/US20030071834A1/en
Priority to US10/195,893 priority patent/US20030206188A1/en
Priority to US10/195,897 priority patent/US20030036164A1/en
Priority to US10/195,888 priority patent/US20060073545A1/en
Priority to US10/195,902 priority patent/US20030038826A1/en
Priority to US10/195,890 priority patent/US7309776B2/en
Priority to US10/195,896 priority patent/US20030063112A1/en
Priority to US10/195,884 priority patent/US20030064449A1/en
Priority to US10/195,889 priority patent/US7534856B2/en
Priority to US10/195,891 priority patent/US7304135B2/en
Priority to US10/195,885 priority patent/US7399824B2/en
Priority to US10/195,894 priority patent/US20030043176A1/en
Priority to US10/195,895 priority patent/US7378487B2/en
Priority to US10/196,750 priority patent/US7288628B2/en
Priority to US10/196,760 priority patent/US7408034B2/en
Priority to US10/196,752 priority patent/US20030068708A1/en
Priority to US10/196,756 priority patent/US7304145B2/en
Priority to US10/196,757 priority patent/US7375196B2/en
Priority to US10/196,745 priority patent/US7423120B2/en
Priority to US10/196,759 priority patent/US20030071835A1/en
Priority to US10/196,753 priority patent/US7371815B2/en
Priority to US10/196,746 priority patent/US7345147B2/en
Priority to US10/196,747 priority patent/US20030162250A1/en
Priority to US10/196,761 priority patent/US20030068710A1/en
Priority to US10/196,754 priority patent/US7282561B2/en
Priority to US10/196,743 priority patent/US20030038827A1/en
Priority to US10/196,758 priority patent/US20030059880A1/en
Priority to US10/196,749 priority patent/US7312316B2/en
Priority to US10/196,751 priority patent/US7309771B2/en
Priority to US10/196,744 priority patent/US7465786B2/en
Priority to US10/196,755 priority patent/US20030064451A1/en
Priority to US10/196,748 priority patent/US20030049748A1/en
Priority to US10/196,762 priority patent/US20030040078A1/en
Priority to US10/197,698 priority patent/US20030068714A1/en
Priority to US10/197,709 priority patent/US20040023321A1/en
Priority to US10/197,705 priority patent/US20030049752A1/en
Priority to US10/197,692 priority patent/US20030068711A1/en
Priority to US10/197,697 priority patent/US20030054463A1/en
Priority to US10/197,708 priority patent/US20030049753A1/en
Priority to US10/197,694 priority patent/US20030054462A1/en
Priority to US10/197,706 priority patent/US20030104548A1/en
Priority to US10/197,700 priority patent/US20030049751A1/en
Priority to US10/197,695 priority patent/US20030040079A1/en
Priority to US10/197,704 priority patent/US20030064452A1/en
Priority to US10/197,691 priority patent/US20030092121A1/en
Priority to US10/197,696 priority patent/US20030068713A1/en
Priority to US10/197,701 priority patent/US20030104547A1/en
Priority to US10/197,693 priority patent/US20030068712A1/en
Priority to US10/197,703 priority patent/US20030068715A1/en
Priority to US10/197,699 priority patent/US20030049750A1/en
Priority to US10/197,710 priority patent/US20030064453A1/en
Priority to US10/197,707 priority patent/US20030054464A1/en
Priority to US10/197,711 priority patent/US20030068716A1/en
Priority to US10/199,458 priority patent/US20030054467A1/en
Priority to US10/198,760 priority patent/US20030113842A1/en
Priority to US10/199,315 priority patent/US20030068725A1/en
Priority to US10/198,758 priority patent/US20030064454A1/en
Priority to US10/200,617 priority patent/US20030059884A1/en
Priority to US10/199,456 priority patent/US20030064459A1/en
Priority to US10/197,942 priority patent/US20030175882A1/en
Priority to US10/199,301 priority patent/US20030068722A1/en
Priority to US10/198,759 priority patent/US20030207398A1/en
Priority to US10/198,764 priority patent/US20030049754A1/en
Priority to US10/199,666 priority patent/US20030049765A1/en
Priority to US10/199,673 priority patent/US20030068732A1/en
Priority to US10/198,761 priority patent/US20030068718A1/en
Priority to US10/198,769 priority patent/US20030049757A1/en
Priority to US10/199,307 priority patent/US20030068723A1/en
Priority to US10/198,766 priority patent/US20030064455A1/en
Priority to US10/199,313 priority patent/US20030064458A1/en
Priority to US10/199,665 priority patent/US20030049764A1/en
Priority to US10/199,672 priority patent/US20030148442A1/en
Priority to US10/198,765 priority patent/US20030049755A1/en
Priority to US10/199,461 priority patent/US20030068730A1/en
Priority to US10/199,667 priority patent/US20030068731A1/en
Priority to US10/199,463 priority patent/US20030215910A1/en
Priority to US10/198,763 priority patent/US20030068720A1/en
Priority to US10/199,309 priority patent/US20030064457A1/en
Priority to US10/199,460 priority patent/US20030068729A1/en
Priority to US10/199,303 priority patent/US20030054465A1/en
Priority to US10/199,670 priority patent/US20040033560A1/en
Priority to US10/199,306 priority patent/US20030049759A1/en
Priority to US10/198,771 priority patent/US20030092122A1/en
Priority to US10/199,314 priority patent/US20030049762A1/en
Priority to US10/199,302 priority patent/US20030073179A1/en
Priority to US10/198,767 priority patent/US20030068721A1/en
Priority to US10/198,762 priority patent/US20030068719A1/en
Priority to US10/198,757 priority patent/US20030068717A1/en
Priority to US10/198,770 priority patent/US20030059882A1/en
Priority to US10/199,308 priority patent/US20030059883A1/en
Priority to US10/199,318 priority patent/US20030054466A1/en
Priority to US10/199,311 priority patent/US20030049761A1/en
Priority to US10/199,459 priority patent/US20030068728A1/en
Priority to US10/199,462 priority patent/US20030054468A1/en
Priority to US10/199,310 priority patent/US20030049760A1/en
Priority to US10/199,304 priority patent/US20030064456A1/en
Priority to US10/199,669 priority patent/US20030049766A1/en
Priority to US10/199,316 priority patent/US20030068726A1/en
Priority to US10/199,312 priority patent/US20030068724A1/en
Priority to US10/199,305 priority patent/US20030049758A1/en
Priority to US10/199,457 priority patent/US20030068727A1/en
Priority to US10/199,464 priority patent/US20030032140A1/en
Priority to US10/199,317 priority patent/US20030049763A1/en
Priority to US10/198,768 priority patent/US20030049756A1/en
Priority to US10/201,527 priority patent/US20030054471A1/en
Priority to US10/201,533 priority patent/US20030068737A1/en
Priority to US10/201,329 priority patent/US20030064460A1/en
Priority to US10/201,328 priority patent/US20030054470A1/en
Priority to US10/201,323 priority patent/US20030073180A1/en
Priority to US10/201,528 priority patent/US20030054472A1/en
Priority to US10/201,324 priority patent/US20030054469A1/en
Priority to US10/201,326 priority patent/US20030068735A1/en
Priority to US10/201,530 priority patent/US20030054474A1/en
Priority to US10/201,322 priority patent/US20030068734A1/en
Priority to US10/201,321 priority patent/US20030068733A1/en
Priority to US10/201,529 priority patent/US20030054473A1/en
Priority to US10/201,771 priority patent/US20030068740A1/en
Priority to US10/201,534 priority patent/US20030049767A1/en
Priority to US10/201,327 priority patent/US20030077736A1/en
Priority to US10/201,770 priority patent/US20030049768A1/en
Priority to US10/201,325 priority patent/US20030096357A1/en
Priority to US10/201,532 priority patent/US20030068736A1/en
Priority to US10/202,472 priority patent/US20030054478A1/en
Priority to US10/202,412 priority patent/US20030064461A1/en
Priority to US10/202,471 priority patent/US20030215911A1/en
Priority to US10/201,858 priority patent/US20040038337A1/en
Priority to US10/201,535 priority patent/US20030068738A1/en
Priority to US10/202,408 priority patent/US20030054475A1/en
Priority to US10/201,769 priority patent/US7087737B2/en
Priority to US10/201,857 priority patent/US20030104549A1/en
Priority to US10/202,473 priority patent/US20030068743A1/en
Priority to US10/202,469 priority patent/US20030049771A1/en
Priority to US10/201,853 priority patent/US20040053358A1/en
Priority to US10/202,413 priority patent/US20030104550A1/en
Priority to US10/201,856 priority patent/US20030049770A1/en
Priority to US10/202,475 priority patent/US20030180881A1/en
Priority to US10/202,410 priority patent/US20030068742A1/en
Priority to US10/202,474 priority patent/US20030068744A1/en
Priority to US10/202,409 priority patent/US20030054476A1/en
Priority to US10/202,470 priority patent/US20030049772A1/en
Priority to US10/202,411 priority patent/US20030054477A1/en
Priority to US10/201,855 priority patent/US20030049769A1/en
Priority to US10/202,476 priority patent/US20030049773A1/en
Priority to US10/201,854 priority patent/US20030068741A1/en
Priority to US10/201,772 priority patent/US20030113843A1/en
Priority to US10/202,941 priority patent/US20030096358A1/en
Priority to US10/205,503 priority patent/US20030068745A1/en
Priority to US10/202,934 priority patent/US20030049774A1/en
Priority to US10/205,510 priority patent/US20030073181A1/en
Priority to US10/202,936 priority patent/US20030049776A1/en
Priority to US10/205,504 priority patent/US20030049778A1/en
Priority to US10/202,940 priority patent/US20030104552A1/en
Priority to US10/202,938 priority patent/US20030104551A1/en
Priority to US10/205,507 priority patent/US20030054480A1/en
Priority to US10/205,502 priority patent/US20030054479A1/en
Priority to US10/205,511 priority patent/US20030054481A1/en
Priority to US10/205,509 priority patent/US20030049779A1/en
Priority to US10/205,508 priority patent/US20030104554A1/en
Priority to US10/205,506 priority patent/US20030207399A1/en
Priority to US10/202,935 priority patent/US20030049775A1/en
Priority to US10/202,939 priority patent/US20030049777A1/en
Priority to US10/205,512 priority patent/US20030068746A1/en
Priority to US10/205,908 priority patent/US20030045700A1/en
Priority to US10/205,896 priority patent/US20030068749A1/en
Priority to US10/205,904 priority patent/US20030073813A1/en
Priority to US10/206,914 priority patent/US20030068758A1/en
Priority to US10/206,907 priority patent/US20030119110A1/en
Priority to US10/205,893 priority patent/US20030059885A1/en
Priority to US10/206,926 priority patent/US20030068763A1/en
Priority to US10/206,911 priority patent/US20030068755A1/en
Priority to US10/205,903 priority patent/US20030068752A1/en
Priority to US10/205,895 priority patent/US20030049780A1/en
Priority to US10/205,905 priority patent/US20030104555A1/en
Priority to US10/205,891 priority patent/US20030073182A1/en
Priority to US10/205,894 priority patent/US20030068748A1/en
Priority to US10/206,927 priority patent/US20030068764A1/en
Priority to US10/205,909 priority patent/US20030049783A1/en
Priority to US10/206,913 priority patent/US20030068757A1/en
Priority to US10/205,897 priority patent/US20030059886A1/en
Priority to US10/206,928 priority patent/US20030064465A1/en
Priority to US10/205,902 priority patent/US20030054482A1/en
Priority to US10/205,892 priority patent/US20030068747A1/en
Priority to US10/206,920 priority patent/US20030068759A1/en
Priority to US10/205,898 priority patent/US20030068750A1/en
Priority to US10/206,912 priority patent/US20030068756A1/en
Priority to US10/206,915 priority patent/US20040029221A1/en
Priority to US10/206,917 priority patent/US20030073183A1/en
Priority to US10/205,899 priority patent/US20030049781A1/en
Priority to US10/206,909 priority patent/US20030068753A1/en
Priority to US10/206,918 priority patent/US20030104556A1/en
Priority to US10/205,900 priority patent/US20030049782A1/en
Priority to US10/206,921 priority patent/US20030068760A1/en
Priority to US10/206,925 priority patent/US20030068762A1/en
Priority to US10/206,923 priority patent/US20030068761A1/en
Priority to US10/206,916 priority patent/US20040091959A1/en
Priority to US10/205,890 priority patent/US20040048334A1/en
Priority to US10/206,910 priority patent/US20030068754A1/en
Priority to US10/205,907 priority patent/US20030054483A1/en
Priority to US10/205,901 priority patent/US20030068751A1/en
Priority to US10/206,919 priority patent/US20030064462A1/en
Priority to US10/206,924 priority patent/US20030064464A1/en
Priority to US10/205,910 priority patent/US20030096359A1/en
Priority to US10/206,922 priority patent/US20030064463A1/en
Priority to US10/208,024 priority patent/US20040048335A1/en
Priority to US10/207,923 priority patent/US20030073184A1/en
Priority to US10/207,920 priority patent/US20030068769A1/en
Priority to US10/208,022 priority patent/US20030068772A1/en
Priority to US10/208,028 priority patent/US20030073186A1/en
Priority to US10/208,030 priority patent/US20030068776A1/en
Priority to US10/207,919 priority patent/US20030068768A1/en
Priority to US10/208,029 priority patent/US20030068775A1/en
Priority to US10/208,025 priority patent/US20030104557A1/en
Priority to US10/208,023 priority patent/US20030068773A1/en
Priority to US10/208,026 priority patent/US20030068774A1/en
Priority to US10/207,918 priority patent/US20030068767A1/en
Priority to US10/207,922 priority patent/US20030064468A1/en
Priority to US10/207,914 priority patent/US20030064466A1/en
Priority to US10/207,924 priority patent/US20030073185A1/en
Priority to US10/207,925 priority patent/US20030068770A1/en
Priority to US10/208,027 priority patent/US20030064469A1/en
Priority to US10/208,021 priority patent/US20030068771A1/en
Priority to US10/207,915 priority patent/US20030215912A1/en
Priority to US10/207,921 priority patent/US20030064467A1/en
Priority to US10/207,916 priority patent/US7189838B2/en
Priority to US10/207,917 priority patent/US20030068766A1/en
Priority to US10/226,739 priority patent/US7390879B2/en
Priority to US10/232,225 priority patent/US20030096969A1/en
Priority to US10/232,232 priority patent/US20030069407A1/en
Publication of WO2001068848A3 publication Critical patent/WO2001068848A3/fr
Priority to US10/244,990 priority patent/US20030113852A1/en
Priority to US10/293,654 priority patent/US7235633B2/en
Priority to ZA2003/01204A priority patent/ZA200301204B/en
Priority to US10/410,927 priority patent/US20030180255A1/en
Priority to US10/429,667 priority patent/US20030207401A1/en
Priority to US10/458,573 priority patent/US7718397B2/en
Priority to US10/458,442 priority patent/US20030203451A1/en
Priority to US10/617,573 priority patent/US7771719B1/en
Priority to US10/700,992 priority patent/US20040086970A1/en
Priority to US10/735,014 priority patent/US7442772B2/en
Priority to US10/758,377 priority patent/US20040126807A1/en
Priority to US10/795,503 priority patent/US20060210991A1/en
Priority to US10/795,482 priority patent/US20060019307A1/en
Priority to US10/886,040 priority patent/US20070003545A9/en
Priority to US10/805,667 priority patent/US20050037458A1/en
Priority to US10/916,250 priority patent/US7368250B2/en
Priority to US10/943,353 priority patent/US20050059115A1/en
Priority to US11/021,330 priority patent/US20050159588A1/en
Priority to US11/021,329 priority patent/US20050159591A1/en
Priority to US11/025,607 priority patent/US20050181478A1/en
Priority to US11/026,279 priority patent/US20050176041A1/en
Priority to US11/030,464 priority patent/US20050214819A1/en
Priority to US11/036,582 priority patent/US20050164266A1/en
Priority to US11/038,549 priority patent/US20060246461A1/en
Priority to US11/038,328 priority patent/US20050202475A1/en
Priority to US11/039,623 priority patent/US20060068404A1/en
Priority to US11/040,638 priority patent/US20050244852A1/en
Priority to US11/042,889 priority patent/US20050272058A1/en
Priority to US11/042,449 priority patent/US20050221352A1/en
Priority to US11/046,650 priority patent/US7547507B2/en
Priority to US11/067,573 priority patent/US20050260622A1/en
Priority to US11/078,280 priority patent/US20050250136A1/en
Priority to US11/084,458 priority patent/US20050260632A1/en
Priority to US11/084,792 priority patent/US20060051777A1/en
Priority to US11/090,729 priority patent/US20060068413A1/en
Priority to US11/100,159 priority patent/US7425613B2/en
Priority to US11/122,524 priority patent/US20060003355A1/en
Priority to US11/124,327 priority patent/US20050266461A1/en
Priority to US11/149,801 priority patent/US20060040289A1/en
Priority to US11/150,463 priority patent/US20060051783A1/en
Priority to US11/150,758 priority patent/US20060051784A1/en
Priority to US11/150,881 priority patent/US20060084084A1/en
Priority to US11/151,868 priority patent/US20060051785A1/en
Priority to US11/172,714 priority patent/US20060019287A1/en
Priority to US11/189,442 priority patent/US20060246465A1/en
Priority to US11/190,075 priority patent/US20060088854A1/en
Priority to US11/194,054 priority patent/US20060194219A1/en
Priority to US11/199,816 priority patent/US20060068423A1/en
Priority to US11/216,875 priority patent/US20060029966A1/en
Priority to US11/240,891 priority patent/US20060246540A1/en
Priority to US11/258,349 priority patent/US7470774B2/en
Priority to US11/258,348 priority patent/US7462692B2/en
Priority to US11/296,155 priority patent/US20060127983A1/en
Priority to JP2005363921A priority patent/JP2006104212A/ja
Priority to US11/323,117 priority patent/US20070092941A1/en
Priority to US11/341,175 priority patent/US7468427B2/en
Priority to JP2006024604A priority patent/JP2006223304A/ja
Priority to US11/369,228 priority patent/US20060188914A1/en
Priority to US11/367,172 priority patent/US20060257897A1/en
Priority to US11/407,991 priority patent/US20060183169A1/en
Priority to US11/457,750 priority patent/US20070031901A1/en
Priority to JP2006252159A priority patent/JP2007077155A/ja
Priority to US11/535,718 priority patent/US7691978B2/en
Priority to US11/528,596 priority patent/US20070025962A1/en
Priority to JP2006266069A priority patent/JP2007049999A/ja
Priority to US11/529,324 priority patent/US8273703B2/en
Priority to US11/697,201 priority patent/US20070178539A1/en
Priority to US11/786,466 priority patent/US20080182275A1/en
Priority to US11/796,725 priority patent/US20090197301A1/en
Priority to US11/802,794 priority patent/US20090291097A1/en
Priority to US11/907,316 priority patent/US20090117114A1/en
Priority to US11/907,754 priority patent/US20090087429A1/en
Priority to US11/949,633 priority patent/US20080160021A1/en
Priority to US12/031,612 priority patent/US7514538B2/en
Priority to US12/079,178 priority patent/US20090170158A1/en
Priority to US12/214,762 priority patent/US20090035261A1/en
Priority to JP2008194678A priority patent/JP2009039117A/ja
Priority to JP2008194721A priority patent/JP2009039118A/ja
Priority to JP2008194764A priority patent/JP2009039119A/ja
Priority to US12/319,421 priority patent/US7786272B2/en
Priority to US12/393,224 priority patent/US20090227776A1/en
Priority to US12/412,796 priority patent/US8338132B2/en
Priority to US12/549,497 priority patent/US8034342B2/en
Priority to JP2009209981A priority patent/JP2010046065A/ja
Priority to US12/702,086 priority patent/US8097700B2/en
Priority to US12/825,263 priority patent/US20110064728A1/en
Priority to JP2011173336A priority patent/JP6033531B2/ja
Priority to US13/270,006 priority patent/US20120064073A1/en
Priority to US13/269,984 priority patent/US20120058909A1/en
Priority to US13/593,362 priority patent/US20130064827A1/en
Priority to JP2014187275A priority patent/JP2015037408A/ja
Priority to US14/489,167 priority patent/US20150141283A1/en
Priority to US14/581,971 priority patent/US20150266953A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates generally to the identification and isolation of novel DNA and to the recombinant production of novel polypeptides.
  • Extracellular proteins play important roles in, among other things, the formation, differentiation and maintenance of multicellular organisms.
  • secreted polypeptides or signaling molecules normally pass through the cellular secretory pathway to reach their site of action in the extracellular environment.
  • Secreted proteins have various industrial applications, including as pharmaceuticals, diagnostics, biosensors and bioreactors.
  • Most protein drugs available at present, such as thrombolytic agents, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secretory proteins.
  • Their receptors, which are membrane proteins, also have potential as therapeutic or diagnostic agents.
  • Efforts are being undertaken by both industry and proficient to identify new, native secreted proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., Proc. Natl. Acad. Sci. 93:7108-7113 (1996); U.S. Patent No. 5,536,637)].
  • Membrane-bound proteins and receptors can play important roles in, among other things, the formation, differentiation and maintenance of multicellular organisms.
  • the fate of many individual cells, e.g. , proliferation, migration, differentiation, or interaction with other cells is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones) which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins.
  • Such membrane-bound proteins and cell receptors include, but are not limited to, cytokine receptors, receptor kinases, receptor phosphatases, receptors involved in cell-cell interactions, and cellular adhesin molecules like selectins and integrins. For instance, transduction of signals that regulate cell growth .and differentiation is regulated in part by phosphorylation of various cellular proteins . Protein tyrosine kinases , enzymes that catalyze that process, can also act as growth factor receptors. Examples include fibroblast growth factor receptor and nerve growth factor receptor.
  • Membrane-bound proteins and receptor molecules have various industrial applications, including as pharmaceutical and diagnostic agents.
  • Receptor immunoadhesins for instance, can be employed as therapeutic agents to block receptor-ligand interactions.
  • the membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.
  • Efforts are being undertaken by both industry .and ME to identify new, native receptor or membrane-bound proteins . Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel receptor or membrane-bound proteins.
  • the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PRO polypeptide.
  • the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83 % nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88 % nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93 % nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95 % nucleic acid sequence identity, alternatively at least about
  • the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83 % nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88 % nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93 % nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95 % nucleic acid sequence identity, alternatively at least about
  • the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83 % nucleic acid sequence identity, alternatively at least about 84 % nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity,
  • Another aspect the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain(s) of such polypeptide are disclosed herein. Therefore, soluble extracellular domains of the herein described PRO polypeptides are contemplated.
  • Another embodiment is directed to fragments of a PRO polypeptide coding sequence, or the complement thereof, that may find use as, for example, hybridization probes, for encoding fragments of a PRO polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-PRO antibody or as antisense oligonucleotide probes.
  • nucleic acid fragments are usually at least about 10 nucleotides in length, alternatively at least about 15 nucleotides in length, alternatively at least about 20 nucleotides in length, alternatively at least about 30 nucleotides in length, alternatively at least about 40 nucleotides in length, alternatively at least about 50 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 70 nucleotides in length, alternatively at least about 80 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 100 nucleotides in length, alternatively at least about 110 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 130 nucleotides in length, alternatively at least about 140 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 160 nucleotides in length, alternatively at least about 170 nucleo
  • novel fragments of a PRO polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PRO polypeptide-encoding nucleotide sequence with other known nucleotide sequences using any of a number of well known sequence alignment programs and determining which PRO polypeptide-encoding nucleotide sequence fragment(s) are novel. All of such PRO polypeptide-encoding nucleotide sequences are contemplated herein. Also contemplated are the PRO polypeptide fragments encoded by these nucleotide molecule fragments, preferably those PRO polypeptide fragments that comprise a binding site for an anti-PRO antibody.
  • the invention provides isolated PRO polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention concerns an isolated PRO polypeptide, comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99%
  • the invention concerns an isolated PRO polypeptide comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91 % amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about at least about
  • the invention provides an isolated PRO polypeptide without the N-terminal signal sequence and/or the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described.
  • Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.
  • Another aspect the invention provides an isolated PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated.
  • Processes . for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PRO polypeptide as defined herein.
  • the agonist or antagomst is an anti-PRO antibody or a small molecule.
  • the invention concerns a method of identifying agonists or antagonists to a PRO polypeptide which comprise contacting the PRO polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO polypeptide.
  • the PRO polypeptide is a native PRO polypeptide.
  • the invention concerns a composition of matter comprising a PRO polypeptide, or an agonist or antagonist of a PRO polypeptide as herein described, or an anti-PRO antibody, in combination with a carrier.
  • the carrier is a pharmaceutically acceptable carrier.
  • Another embodiment of the present invention is directed to the use of a PRO polypeptide, or an agonist or antagonist thereof as hereinbefore described, or an anti-PRO antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the PRO polypeptide, an agonist or antagonist thereof or an anti-PRO antibody.
  • the invention provides vectors comprising DNA encoding any of the herein described polypeptides.
  • Host cell comprising any such vector are also provided.
  • the host cells may be CHO cells, E. coli, or yeast.
  • a process for producing any of the herein described polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.
  • the invention provides chimeric molecules comprising any of the herein described polypeptides fused to a heterologous polypeptide or amino acid sequence.
  • Example of such chimeric molecules comprise any of the herein described polypeptides fused to an epitope tag sequence or a Fc region of an immunoglobulin.
  • the invention provides an antibody which binds, preferably specifically, to any of the above or below described polypeptides.
  • the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody.
  • the invention provides oligonucleotide probes which may be useful for isolating genomic and cDNA nucleotide sequences, measuring or detecting expression of an associated gene or as antisense probes, wherein those probes may be derived from any of the above or below described nucleotide sequences. Preferred probe lengths are described above.
  • the present invention is directed to methods of using the PRO polypeptides of the present invention for a variety of uses based upon the functional biological assay data presented in the Examples below.
  • Figure 1 shows a nucleotide sequence (SEQ ID NO:l) of a native sequence PR0276 cDNA, wherein SEQ ID NO:l is a clone designated herein as "DNA16435-1208".
  • Figure 2 shows the amino acid sequence (SEQ ID NO:2) derived from the coding sequence of SEQ ID NO:2
  • Figure 3 shows a nucleotide sequence (SEQ ID NO:3) of a native sequence PR0284 cDNA, wherein SEQ ID NO:3 is a clone designated herein as "DNA23318-1211".
  • Figure 4 shows the amino acid sequence (SEQ ID NO:4) derived from the coding sequence of SEQ ID NO: 3 shown in Figure 3.
  • Figure 5 shows a nucleotide sequence (SEQ ID NO:5) of a native sequence PRO 193 cDNA, wherein SEQ ID NO:5 is a clone designated herein as "DNA23322-1393".
  • Figure 6 shows the amino acid sequence (SEQ ID NO: 6) derived from the coding sequence of SEQ ID NO: 5 shown in Figure 5.
  • Figure 7 shows a nucleotide sequence (SEQ ID NO:7) of a native sequence PRO190 cDNA, wherein
  • SEQ ID NO:7 is a clone designated herein as "DNA23334-1392".
  • Figure 8 shows the amino acid sequence (SEQ ID NO: 8) derived from the coding sequence of SEQ ID NO: 7 shown in Figure 7.
  • Figure 9 shows a nucleotide sequence (SEQ ID NO:9) of a native sequence PRO180 cDNA, wherein SEQ ID NO:9 is a clone designated herein as "DNA26843-1389" .
  • Figure 10 shows the amino acid sequence (SEQ ID NO: 10) derived from the coding sequence of SEQ ID NQ:9 shown in Figure 9.
  • Figure 11 shows a nucleotide sequence (SEQ ID NO: 11) of a native sequence PR0194 cDNA, wherein SEQ ID NO: 11 is a clone designated herein as "DNA26844-1394".
  • Figure 12 shows the amino acid sequence (SEQ ID NO: 12) derived from the coding sequence of SEQ ID NO: 11 shown in Figure 11.
  • Figure 13 shows a nucleotide sequence (SEQ ID NO: 13) of a native sequence PR0218 cDNA, wherein SEQ ID NO: 13 is a clone designated herein as "DNA30867-1335".
  • Figure 14 shows the amino acid sequence (SEQ ID NO: 14) derived from the coding sequence of SEQ ID NO: 13 shown in Figure 13.
  • Figure 15 shows a nucleotide sequence (SEQ ID NO: 15) of a native sequence PRO260 cDNA, wherein SEQ ID NO:15 is a clone designated herein as "DNA33470-1175".
  • Figure 16 shows the amino acid sequence (SEQ ID NO: 16) derived from the coding sequence of SEQ
  • Figure 17 shows a nucleotide sequence (SEQ ID NO: 17) of a native sequence PR0233 cDNA, wherein SEQ ID NO: 17 is a clone designated herein as "DNA34436-1238".
  • Figure 18 shows the amino acid sequence (SEQ ID NO: 18) derived from the coding sequence of SEQ ID NO: 17 shown in Figure 17.
  • Figure 19 shows a nucleotide sequence (SEQ ID NO: 19) of a native sequence PR0234 cDNA, wherein SEQ ID NO: 19 is a clone designated herein as "DNA35557-1137".
  • Figure 20 shows the amino acid sequence (SEQ ID NO:20) derived from the coding sequence of SEQ ID NO: 19 shown in Figure 19.
  • Figure 21 shows a nucleotide sequence (SEQ ID NO:21) of a native sequence PR0236 cDNA, wherein
  • SEQ ID NO:21 is a clone designated herein as "DNA35599-1168".
  • Figure 22 shows the amino acid sequence (SEQ ID NO:22) derived from the coding sequence of SEQ ID NO:21 shown in Figure 21.
  • Figure 23 shows a nucleotide sequence (SEQ ID NO:23) of a native sequence PR0244 cDNA, wherein SEQ ID NO:23 is a clone designated herein as "DNA35668-1171 " .
  • Figure 24 shows the amino acid sequence (SEQ ID NO: 24) derived from the coding sequence of SEQ ID NO:23 shown in Figure 23.
  • Figure 25 shows a nucleotide sequence (SEQ ID NO:25) of a native sequence PR0262 cDNA, wherein SEQ ID N0:25 is a clone designated herein as "DNA36992-1168".
  • Figure 26 shows the amino acid sequence (SEQ ID NO:26) derived from the coding sequence of SEQ
  • Figure 27 shows a nucleotide sequence (SEQ ID NO:27) of a native sequence PR0271 cDNA, wherein SEQ ID NO:27 is a clone designated herein as "DNA39423-1182".
  • Figure 28 shows the amino acid sequence (SEQ ID NO:28) derived from the coding sequence of SEQ ID NO:27 shown in Figure 27.
  • Figure 29 shows a nucleotide sequence (SEQ ID NO:29) of a native sequence PR0268 cDNA, wherein SEQ ID N0:29 is a clone designated herein as "DNA39427-1179".
  • Figure 30 shows the amino acid sequence (SEQ ID NO:30) derived from the coding sequence of SEQ ID NO:29 shown in Figure 29.
  • Figure 31 shows a nucleotide sequence (SEQ ID NO: 31) of a native sequence PRO270 cDNA, wherein SEQ ID NO:31 is a clone designated herein as "DNA39510-1181".
  • Figure 32 shows the amino acid sequence (SEQ ID NO: 32) derived from the coding sequence of SEQ ID NO:31 shown in Figure 31.
  • Figure 33 shows a nucleotide sequence (SEQ ID NO:33) of a native sequence PR0355 cDNA, wherein SEQ ID NO:33 is a clone designated herein as "DNA39518-1247".
  • Figure 34 shows the amino acid sequence (SEQ ID NO: 34) derived from the coding sequence of SEQ ID NO:33 shown in Figure 33.
  • Figure 35 shows a nucleotide sequence (SEQ ID NO:35) of a native sequence PR0298 cDNA, wherein
  • SEQ ID NO:35 is a clone designated herein as "DNA39975-1210".
  • Figure 36 shows the amino acid sequence (SEQ ID NO:36) derived from the coding sequence of SEQ ID NO:35 shown in Figure 35.
  • Figure 37 shows a nucleotide sequence (SEQ ID NO: 37) of a native sequence PR0299 cDNA, wherein SEQ ID NO:37 is a clone designated herein as "DNA39976-1215" .
  • Figure 38 shows the amino acid sequence (SEQ ID NO:38) derived from the coding sequence of SEQ ID NO: 37 shown in Figure 37.
  • Figure 39 shows a nucleotide sequence (SEQ ID NO:39) of a native sequence PR0296 cDNA, wherein SEQ ID NO:39 is a clone designated herein as "DNA39979-1213".
  • Figure 40 shows the amino acid sequence (SEQ ID NO: 40) derived from the coding sequence of SEQ
  • Figure 41 shows a nucleotide sequence (SEQ ID NO:41) of a native sequence PR0329 cDNA, wherein SEQ ID NO:41 is a clone designated herein as "DNA40594-1233".
  • Figure 42 shows the amino acid sequence (SEQ ID NO: 42) derived from the coding sequence of SEQ ID NO:41 shown in Figure 41.
  • Figure 43 shows a nucleotide sequence (SEQ ID NO:43) of a native sequence PRO330 cDNA, wherein SEQ ID NO:43 is a clone designated herein as "DNA40603-1232".
  • Figure 44 shows the amino acid sequence (SEQ ID NO: 44) derived from the coding sequence of SEQ ID NO: 43 shown in Figure 43.
  • Figure 45 shows a nucleotide sequence (SEQ ID NO:45) of a native sequence PR0294 cDNA, wherein
  • SEQ ID NO:45 is a clone designated herein as "DNA40604-1187".
  • Figure 46 shows the amino acid sequence (SEQ ID NO: 46) derived from the coding sequence of SEQ ID NO: 45 shown in Figure 45.
  • Figure 47 shows a nucleotide sequence (SEQ ID NO:47) of a native sequence PRO300 cDNA, wherein SEQ ID NO:47 is a clone designated herein as "DNA40625-1189".
  • Figure 48 shows the amino acid sequence (SEQ ID NO: 48) derived from the coding sequence of SEQ ID NO:47 shown in Figure 47.
  • Figure 49 shows a nucleotide sequence (SEQ ID NO:49) of a native sequence PRO307 cDNA, wherein SEQ ID NO:49 is a clone designated herein as "DNA41225-1217".
  • Figure 50 shows the amino acid sequence (SEQ ID NO: 50) derived from the coding sequence of SEQ ID NO:49 shown in Figure 49.
  • Figure 51 shows a nucleotide sequence (SEQ ID NO:51) of a native sequence PR0334 cDNA, wherein SEQ ID NO:51 is a clone designated herein as "DNA41379-1236" .
  • Figure 52 shows the amino acid sequence (SEQ ID NO: 52) derived from the coding sequence of SEQ ID NO:51 shown in Figure 51.
  • Figure 53 shows a nucleotide sequence (SEQ ID NO:53) of a native sequence PR0352 cDNA, wherein SEQ ID NO:53 is a clone designated herein as "DNA41386-1316".
  • Figure 54 shows the amino acid sequence (SEQ ID NO: 54) derived from the coding sequence of SEQ
  • Figure 55 shows a nucleotide sequence (SEQ ID NO:55) of a native sequence PRO710 cDNA, wherein SEQ ID NO:55 is a clone designated herein as "DNA44161-1434".
  • Figure 56 shows the amino acid sequence (SEQ ID NO: 56) derived from the coding sequence of SEQ ID NO:55 shown in Figure 55.
  • Figure 57 shows a nucleotide sequence (SEQ ID NO:57) of a native sequence PR0873 cDNA, wherein SEQ ID NO:57 is a clone designated herein as "DNA44179-1362".
  • Figure 58 shows the amino acid sequence (SEQ ID NO:58) derived from the coding sequence of SEQ ID NO:57 shown in Figure 57.
  • Figure 59 shows a nucleotide sequence (SEQ ID NO: 59) of a native sequence PR0354 cDNA, wherein
  • SEQ ID NO:59 is a clone designated herein as "DNA44192-1246".
  • Figure 60 shows the amino acid sequence (SEQ ID NO: 60) derived from the coding sequence of SEQ ID NO:59 shown in Figure 59.
  • Figure 61 shows a nucleotide sequence (SEQ ID NO:61) of a native sequence PR01151 cDNA, wherein SEQ ID NO:61 is a clone designated herein as "DNA44694-1500" .
  • Figure 62 shows the amino acid sequence (SEQ ID NO: 62) derived from the coding sequence of SEQ ID NO:61 shown in Figure 61.
  • Figure 63 shows a nucleotide sequence (SEQ ID NO:63) of a native sequence PR0382 cDNA, wherein SEQ ID NO:63 is a clone designated herein as "DNA45234-1277".
  • Figure 64 shows the amino acid sequence (SEQ ID NO: 64) derived from the coding sequence of SEQ
  • Figure 65 shows a nucleotide sequence (SEQ ID NO : 65) of a native sequence PRO 1864 cDNA, wherein SEQ ID NO:65 is a clone designated herein as "DNA45409-2511".
  • Figure 66 shows the amino acid sequence (SEQ ID NO: 66) derived from the coding sequence of SEQ ID NO:65 shown in Figure 65.
  • Figure 67 shows a nucleotide sequence (SEQ ID NO:67) of a native sequence PR0386 cDNA, wherein SEQ ID NO:67 is a clone designated herein as "DNA45415-1318".
  • Figure 68 shows the amino acid sequence (SEQ ID NO: 68) derived from the coding sequence of SEQ ID NO: 67 shown in Figure 67.
  • Figure 69 shows a nucleotide sequence (SEQ ID NO: 69) of a native sequence PR0541 cDNA, wherein SEQ ID NO:69 is a clone designated herein as "DNA45417-1432".
  • Figure 70 shows the amino acid sequence (SEQ ID NO: 70) derived from the coding sequence of SEQ ID NO: 69 shown in Figure 69.
  • Figure 71 shows a nucleotide sequence (SEQ ID NO:71) of a native sequence PR0852 cDNA, wherein SEQ ID NO:71 is a clone designated herein as "DNA45493-1349".
  • Figure 72 shows the amino acid sequence (SEQ ID NO: 72) derived from the coding sequence of SEQ ID NO:71 shown in Figure 71.
  • Figure 73 shows a nucleotide sequence (SEQ ID NO:73) of a native sequence PRO700 cDNA, wherein
  • SEQ ID NO:73 is a clone designated herein as "DNA46776-1284".
  • Figure 74 shows the amino acid sequence (SEQ ID NO:74) derived from the coding sequence of SEQ ID NO:73 shown in Figure 73.
  • Figures 75A-75B show a nucleotide sequence (SEQ ID NO:75) of a native sequence PRO708 cDNA, wherein SEQ ID NO:75 is a clone designated herein as "DNA48296-1292" .
  • Figure 76 shows the amino acid sequence (SEQ ID NO: 76) derived from the coding sequence of SEQ ID NO:75 shown in Figures 75A-75B.
  • Figure 77 shows a nucleotide sequence (SEQ ID NO:77) of a native sequence PRO707 cDNA, wherein SEQ ID NO:77 is a clone designated herein as "DNA48306-1291".
  • Figure 78 shows the amino acid sequence (SEQ ID NO: 78) derived from the coding sequence of SEQ
  • Figure 79 shows a nucleotide sequence (SEQ ID NO:79) of a native sequence PR0864 cDNA, wherein SEQ ID NO:79 is a clone designated herein as "DNA48328-1355" .
  • Figure 80 shows the amino acid sequence (SEQ ID NO: 80) derived from the coding sequence of SEQ ID NO:79 shown in Figure 79.
  • Figure 81 shows a nucleotide sequence (SEQ ID NO:81) of a native sequence PRO706 cDNA, wherein SEQ ID NO:81 is a clone designated herein as "DNA48329-1290".
  • Figure 82 shows the amino acid sequence (SEQ ID NO: 82) derived from the coding sequence of SEQ ID NO:81 shown in Figure 81.
  • Figure 83 shows a nucleotide sequence (SEQ ID NO:83) of a native sequence PR0732 cDNA, wherein
  • SEQ ID NO:83 is a clone designated herein as "DNA48334-1435".
  • Figure 84 shows the amino acid sequence (SEQ ID NO: 84) derived from the coding sequence of SEQ ID NO:83 shown in Figure 83.
  • Figure 85 shows a nucleotide sequence (SEQ ID NO:85) of a native sequence PR0537 cDNA, wherein SEQ ID NO:85 is a clone designated herein as "DNA49141-1431".
  • Figure 86 shows the amino acid sequence (SEQ ID NO: 86) derived from the coding sequence of SEQ ID NO:85 shown in Figure 85.
  • Figure 87 shows a nucleotide sequence (SEQ ID NO:87) of a native sequence PR0545 cDNA, wherein SEQ ID NO:87 is a clone designated herein as "DNA49624-1279".
  • Figure 88 shows the amino acid sequence (SEQ ID NO: 88) derived from the coding sequence of SEQ ID NO:87 shown in Figure 87.
  • Figure 89 shows a nucleotide sequence (SEQ ID NO:89) of a native sequence PR0718 cDNA, wherein SEQ ID NO:89 is a clone designated herein as "DNA49647-1398".
  • Figure 90 shows the amino acid sequence (SEQ ID NO: 90) derived from the coding sequence of SEQ ID NO:89 shown in Figure 89.
  • Figure 91 shows a nucleotide sequence (SEQ ID NO:91) of a native sequence PR0872 cDNA, wherein SEQ ID NO:91 is a clone designated herein as "DNA49819-1439".
  • Figure 92 shows the amino acid sequence (SEQ ID NO:92) derived from the coding sequence of SEQ
  • Figure 93 shows a nucleotide sequence (SEQ ID NO:93) of a native sequence PRO704 cDNA, wherein SEQ ID NO:93 is a clone designated herein as "DNA50911-1288".
  • Figure 94 shows the amino acid sequence (SEQ ID NO: 94) derived from the coding sequence of SEQ ID NO: 93 shown in Figure 93.
  • Figure 95 shows a nucleotide sequence (SEQ ID NO:95) of a native sequence PRO705 cDNA, wherein SEQ ID NO:95 is a clone designated herein as "DNA50914-1289".
  • Figure 96 shows the amino acid sequence (SEQ ID NO: 96) derived from the coding sequence of SEQ ID NO:95 shown in Figure 95.
  • Figure 97 shows a nucleotide sequence (SEQ ID NO:97) of a native sequence PR0871 cDNA, wherein
  • SEQ ID NO:97 is a clone designated herein as "DNA50919-1361".
  • Figure 98 shows the amino acid sequence (SEQ ID NO: 98) derived from the coding sequence of SEQ ID NO:97 shown in Figure 97.
  • Figure 99 shows a nucleotide sequence (SEQ ID NO: 99) of a native sequence PRO702 cDNA, wherein SEQ ID NO:99 is a clone designated herein as "DNA50980-1286".
  • Figure 100 shows the amino acid sequence (SEQ ID NO: 100) derived from the coding sequence of SEQ ID NO: 99 shown in Figure 99.
  • Figure 101 shows anucleotide sequence (SEQ ID NO: 101) of a native sequence PR0944 cDNA, wherein SEQ ID NO: 101 is a clone designated herein as "DNA52185-1370".
  • Figure 102 shows the amino acid sequence (SEQ ID NO: 102) derived from the coding sequence of SEQ
  • Figure 103 shows anucleotide sequence (SEQ ID NO: 103) of a native sequence PR0739 cDNA, wherein SEQ ID NO: 103 is a clone designated herein as "DNA52756".
  • Figure 104 shows the amino acid sequence (SEQ ID NO: 104) derived from the coding sequence of SEQ ID NO: 103 shown in Figure 103.
  • Figure 105 shows anucleotide sequence (SEQ ID NO: 105) of a native sequence PR0941 cDNA, wherein SEQ ID NO: 105 is a clone designated herein as "DNA53906-1368".
  • Figure 106 shows the amino acid sequence (SEQ ID NO: 106) derived from the coding sequence of SEQ ID NO: 105 shown in Figure 105.
  • Figure 107 shows a nucleotide sequence (SEQ ID NO: 107) of a native sequence PRO1082 cDNA, wherein SEQ ID NO: 107 is a clone designated herein as "DNA53912-1457".
  • Figure 108 shows the amino acid sequence (SEQ ID NO: 108) derived from the coding sequence of SEQ ID NO: 107 shown in Figure 107.
  • Figure 109 shows a nucleotide sequence (SEQ ID NO:109) of a native sequence PR01133 cDNA, wherein SEQ ID NO: 109 is a clone designated herein as "DNA53913-1490".
  • Figure 110 shows the amino acid sequence (SEQ ID NO: 110) derived from the coding sequence of SEQ ID NO: 109 shown in Figure 109.
  • Figure 111 shows a nucleotide sequence (SEQ ID NO: 111) of a native sequence PR0983 cDNA, wherein
  • SEQ ID NO:lll is a clone designated herein as "DNA53977-1371".
  • Figure 112 shows the amino acid sequence (SEQ ID NO: 112) derived from (he coding sequence of SEQ ID NO:lll shown in Figure 111.
  • Figure 113 shows a nucleotide sequence (SEQ ID NO: 113) of a native sequence PR0784 cDNA, wherein SEQ ID NO:113 is a clone designated herein as "DNA53978-1443".
  • Figure 114 shows the amino acid sequence (SEQ ID NO: 114) derived from the coding sequence of SEQ ID NO:113 shown in Figure 113.
  • Figure 115 shows a nucleotide sequence (SEQ ID NO: 115) of a native sequence PR0783 cDNA, wherein SEQ ID NO: 115 is a clone designated herein as "DNA53996-1442".
  • Figure 116 shows the amino acid sequence (SEQ ID NO : 116) derived from the coding sequence of SEQ
  • Figure 117 shows a nucleotide sequence (SEQ ID NO: 117) of a native sequence PRO940 cDNA, wherein SEQ ID NO: 117 is a clone designated herein as "DNA54002-1367".
  • Figure 118 shows the amino acid sequence (SEQ ID NO : 118) derived from the coding sequence of SEQ ID NO: 117 shown in Figure 117.
  • Figure 119 shows a nucleotide sequence (SEQ ID NO: 119) of a native sequence PR0768 cDNA, wherein SEQ ID NO:119 is a clone designated herein as "DNA55737-1345".
  • Figure 120 shows the amino acid sequence (SEQ ID NO: 120) derived from the coding sequence of SEQ ID NO: 119 shown in Figure 119.
  • Figure 121 shows a nucleotide sequence (SEQ ID NO: 121) of a native sequence PRO1079 cDNA, wherein SEQ ID NO: 121 is a clone designated herein as "DNA56050-1455".
  • Figure 122 shows the amino acid sequence (SEQ ID NO: 122) derived from the coding sequence of SEQ ID NO: 121 shown in Figure 121.
  • Figure 123 shows a nucleotide sequence (SEQ ID NO: 123) of a native sequence PRO1078 cDNA, wherein SEQ ID NO:123 is a clone designated herein as "DNA56052-1454".
  • Figure 124 shows the amino acid sequence (SEQ ID NO: 124) derived from the coding sequence of SEQ ID NO : 123 shown in Figure 123.
  • Figure 125 shows a nucleotide sequence (SEQ ID NO: 125) of a native sequence PRO1018 cDNA, wherein SEQ ID NO: 125 is a clone designated herein as "DNA56107-1415".
  • Figure 126 shows the amino acid sequence (SEQ ID NO: 126) derived from the coding sequence of SEQ ID NO: 125 shown in Figure 125.
  • Figure 127 shows anucleotide sequence (SEQ ID NO: 127) of a native sequence PR0793 cDNA, wherein SEQ ID NO:127 is a clone designated herein as "DNA56110-1437".
  • Figure 128 shows the amino acid sequence (SEQ ID NO : 128) derived from the coding sequence of SEQ ID NO: 127 shown in Figure 127.
  • Figure 129 shows a nucleotide sequence (SEQ ID NO: 129) of a native sequence PR01773 cDNA, wherein SEQ ID NO: 129 is a clone designated herein as "DNA56406-1704".
  • Figure 130 shows the amino acid sequence (SEQ ID NO: 130) derived from the coding sequence of SEQ
  • Figure 131 shows a nucleotide sequence (SEQ ID NO: 131) of a native sequence PRO1014 cDNA, wherein SEQ ID NO: 131 is a clone designated herein as "DNA56409-1377".
  • Figure 132 shows the amino acid sequence (SEQ ID NO: 132) derived from the coding sequence of SEQ ID NO: 131 shown in Figure 131.
  • Figure 133 shows a nucleotide sequence (SEQ ID NO: 133) of a native sequence PRO1013 cDNA, wherein SEQ ID NO: 133 is a clone designated herein as "DNA56410-1414".
  • Figure 134 shows the amino acid sequence (SEQ ID NO: 134) derived from the coding sequence of SEQ ID NO: 133 shown in Figure 133.
  • Figure 135 shows a nucleotide sequence (SEQ ID NO : 135) of a native sequence PR0937 cDNA, wherein
  • SEQ ID NO: 135 is a clone designated herein as "DNA56436-1448".
  • Figure 136 shows the amino acid sequence (SEQ ID NO: 136) derived from the coding sequence of SEQ ID NO: 135 shown in Figure 135.
  • Figure 137 shows a nucleotide sequence (SEQ ID NO: 137) of a native sequence PR01477 cDNA, wherein SEQ ID NO: 137 is a clone designated herein as "DNA56529-1647" .
  • Figure 138 shows the amino acid sequence (SEQ ID NO: 138) derived from the coding sequence of SEQ ID NO: 137 shown in Figure 137.
  • Figure 139 shows anucleotide sequence (SEQ ID NO: 139) of a native sequence PR0842 cDNA, wherein SEQ ID N0:139 is a clone designated herein as "DNA56855-1447".
  • Figure 140 shows the amino acid sequence (SEQ ID NO: 140) derived from the coding sequence of SEQ
  • Figure 141 shows anucleotide sequence (SEQ ID NO: 141) of a native sequence PR0839 cDNA, wherein SEQ ID NO:141 is a clone designated herein as "DNA56859-1445".
  • Figure 142 shows the amino acid sequence (SEQ ID NO: 142) derived from the coding sequence of SEQ ID NO: 141 shown in Figure 141.
  • Figure 143 shows a nucleotide sequence (SEQ ID NO: 143) of a native sequence PRO1180 cDNA, wherein SEQ ID NO: 143 is a clone designated herein as "DNA56860-1510".
  • Figure 144 shows the amino acid sequence (SEQ ID NO: 144) derived from the coding sequence of SEQ ID NO: 143 shown in Figure 143.
  • Figure 145 shows a nucleotide sequence (SEQ ID NO: 145) of a native sequence PR01134 cDNA, wherein SEQ ID NO:145 is a clone designated herein as "DNA56865-1491".
  • Figure 146 shows the amino acid sequence (SEQ ID NO: 146) derived from the coding sequence of SEQ ID NO: 145 shown in Figure 145.
  • Figure 147 shows a nucleotide sequence (SEQ ID NO:147) of a native sequence PR01115 cDNA, wherein SEQ ID NO: 147 is a clone designated herein as "DNA56868-1478".
  • Figure 148 shows the amino acid sequence (SEQ ID NO: 148) derived from the coding sequence of SEQ ID NO: 147 shown in Figure 147.
  • Figure 149 shows a nucleotide sequence (SEQ ID NO: 149) of a native sequence PRO 1277 cDNA, wherein SEQ ID NO:149 is a clone designated herein as "DNA56869-1545".
  • Figure 150 shows the amino acid sequence (SEQ ID NO: 150) derived from the coding sequence of SEQ ID NO: 149 shown in Figure 149.
  • Figure 151 shows a nucleotide sequence (SEQ ID NO: 151) of a native sequence PR01135 cDNA, wherein SEQ ID NO:151 is a clone designated herein as "DNA56870-1492".
  • Figure 152 shows the amino acid sequence (SEQ ID NO: 152) derived from the coding sequence of SEQ ID NO:151 shown in Figure 151.
  • Figure 153 shows anucleotide sequence (SEQ ID NO:153) of anative sequence PR0827cDNA, wherein SEQ ID NO: 153 is a clone designated herein as "DNA57039-1402".
  • Figure 154 shows the amino acid sequence (SEQ ID NO: 154) derived from the coding sequence of SEQ
  • Figure 155 shows a nucleotide sequence (SEQ ID NO: 155) of a native sequence PRO1057 cDNA, wherein SEQ ID NO: 155 is a clone designated herein as "DNA57253-1382".
  • Figure 156 shows the amino acid sequence (SEQ ID NO: 156) derived from the coding sequence of SEQ ID NO: 155 shown in Figure 155.
  • Figure 157 shows a nucleotide sequence (SEQ ID NO: 157) of a native sequence PR01113 cDNA, wherein SEQ ID NO: 157 is a clone designated herein as "DNA57254-1477".
  • Figure 158 shows the amino acid sequence (SEQ ID NO: 158) derived from the coding sequence of SEQ ID NO: 157 shown in Figure 157.
  • Figure 159 shows a nucleotide sequence (SEQ ID NO: 159) of a native sequence PRO 1006 cDNA, wherein SEQ ID NO: 159 is a clone designated herein as "DNA57699-1412".
  • Figure 160 shows the amino acid sequence (SEQ ID NO: 160) derived from the coding sequence of SEQ ID NO: 159 shown in Figure 159.
  • Figure 161 shows a nucleotide sequence (SEQ ID NO: 161) of a native sequence PRO1074 cDNA, wherein SEQ ID NO: 161 is a clone designated herein as "DNA57704-1452" .
  • Figure 162 shows the amino acid sequence (SEQ ID NO: 162) derived from the coding sequence of SEQ ID NO:161 shown in Figure 161.
  • Figure 163 shows a nucleotide sequence (SEQ ID NO: 163) of a native sequence PRO1073 cDNA, wherein SEQ ID NO: 163 is a clone designated herein as "DNA57710-1451".
  • Figure 164 shows the amino acid sequence (SEQ ID NO: 164) derived from the coding sequence of SEQ ID NO: 163 shown in Figure 163.
  • Figure 165 shows a nucleotide sequence (SEQ ID NO: 165) of a native sequence PR01136 cDNA, wherein SEQ ID NO:165 is a clone designated herein as "DNA57827-1493".
  • Figure 166 shows the amino acid sequence (SEQ ID NO : 166) derived from the coding sequence of SEQ ID NO: 165 shown in Figure 165.
  • Figure 167 shows a nucleotide sequence (SEQ ID NO: 167) of a native sequence PRO1004 cDNA, wherein SEQ ID NO: 167 is a clone designated herein as "DNA57844-1410".
  • Figure 168 shows the amino acid sequence (SEQ ID NO: 168) derived from the coding sequence of SEQ
  • Figure 169 shows a nucleotide sequence (SEQ ID NO: 169) of a native sequence PR01344 cDNA, wherein SEQ ID NO:169 is a clone designated herein as "DNA58723-1588".
  • Figure 170 shows the amino acid sequence (SEQ ID NO: 170) derived from the coding sequence of SEQ ID NO: 169 shown in Figure 169.
  • Figure 171 shows a nucleotide sequence (SEQ ID NO:171) of a native sequence PRO1110 cDNA, wherein SEQ ID NO: 171 is a clone designated herein as "DNA58727-1474".
  • Figure 172 shows the amino acid sequence (SEQ ID NO: 172) derived from the coding sequence of SEQ ID NO: 171 shown in Figure 171.
  • Figure 173 shows a nucleotide sequence (SEQ ID NO: 173) of a native sequence PR01378 cDNA, wherein SEQ ID NO: 173 is a clone designated herein as "DNA58730-1607".
  • Figure 174 shows the amino acid sequence (SEQ ID NO: 174) derived from the coding sequence of SEQ ID NO: 173 shown in Figure 173.
  • Figure 175 shows a nucleotide sequence (SEQ ID NO: 175) of a native sequence PRO 1481 cDNA, wherein SEQ ID NO: 175 is a clone designated herein as "DNA58732-1650" .
  • Figure 176 shows the amino acid sequence (SEQ ID NO: 176) derived from the coding sequence of SEQ ID NO: 175 shown in Figure 175.
  • Figure 177 shows a nucleotide sequence (SEQ ID NO: 177) of a native sequence PRO1109 cDNA, wherein SEQ ID NO: 177 is a clone designated herein as "DNA58737-1473".
  • Figure 178 shows the amino acid sequence (SEQ ID NO: 178) derived from the coding sequence of SEQ
  • Figure 179 shows a nucleotide sequence (SEQ ID NO: 179) of a native sequence PRO 1383 cDNA, wherein SEQ ID NO: 179 is a clone designated herein as "DNA58743-1609".
  • Figure 180 shows the amino acid sequence (SEQ ID NO: 180) derived from the coding sequence of SEQ ID NO: 179 shown in Figure 179.
  • Figure 181 shows a nucleotide sequence (SEQ ID NO: 181) of a native sequence PRO1072 cDNA, wherein SEQ ID NO:181 is a clone designated herein as "DNA58747-1384".
  • Figure 182 shows the amino acid sequence (SEQ ID NO: 182) derived from the coding sequence of SEQ ID NO: 181 shown in Figure 181.
  • Figure 183 shows a nucleotide sequence (SEQ ID NO: 183) of a native sequence PR01189 cDNA, wherein SEQ ID NO: 183 is a clone designated herein as "DNA58828-1519".
  • Figure 184 shows the amino acid sequence (SEQ ID NO: 184) derived from the coding sequence of SEQ ID NO: 183 shown in Figure 183.
  • Figure 185 shows a nucleotide sequence (SEQ ID NO: 185) of a native sequence PRO 1003 cDNA, wherein SEQ ID NO: 185 is a clone designated herein as "DNA58846-1409".
  • Figure 186 shows the amino acid sequence (SEQ ID NO: 186) derived from the coding sequence of SEQ ID NO: 185 shown in Figure 185.
  • Figure 187 shows a nucleotide sequence (SEQ ID NO:187) of a native sequence PRO1108 cDNA, wherein SEQ ID NO: 187 is a clone designated herein as "DNA58848-1472".
  • Figure 188 shows the amino acid sequence (SEQ ID NO: 188) derived from the coding sequence of SEQ ID NO: 187 shown in Figure 187.
  • Figure 189 shows a nucleotide sequence (SEQ ID NO:189) of a native sequence PROH37 cDNA, wherein SEQ ID NO: 189 is a clone designated herein as "DNA58849-1494" .
  • Figure 190 shows the amino acid sequence (SEQ ID NO: 190) derived from the coding sequence of SEQ ID NO: 189 shown in Figure 189.
  • Figure 191 shows a nucleotide sequence (SEQ ID NO:191) of a native sequence PROH38 cDNA, wherein SEQ ID NO: 191 is a clone designated herein as "DNA58850-1495".
  • Figure 192 shows the amino acid sequence (SEQ ID NO: 192) derived from the coding sequence of SEQ
  • Figure 193 shows a nucleotide sequence (SEQ ID NO: 193) of a native sequence PR01415 cDNA, wherein SEQ ID NO: 193 is a clone designated herein as "DNA58852-1637".
  • Figure 194 shows the amino acid sequence (SEQ ID NO: 194) derived from the coding sequence of SEQ ID NO: 193 shown in Figure 193.
  • Figure 195 shows a nucleotide sequence (SEQ ID NO: 195) of a native sequence PRO1054 cDNA, wherein SEQ ID NO:195 is a clone designated herein as "DNA58853-1423".
  • Figure 196 shows the amino acid sequence (SEQ ID NO: 196) derived from the coding sequence of SEQ ID NO: 195 shown in Figure 195.
  • Figure 197 shows a nucleotide sequence (SEQ ID NO: 197) of a native sequence PR0994 cDNA, wherein
  • SEQ ID N0:197 is a clone designated herein as "DNA58855-1422".
  • Figure 198 shows the amino acid sequence (SEQ ID NO: 198) derived from the coding sequence of SEQ ID NO: 197 shown in Figure 197.
  • Figure 199 shows a nucleotide sequence (SEQ ID NO: 199) of a native sequence PRO 1069 cDNA, wherein SEQ ID NO: 199 is a clone designated herein as "DNA59211-1450" .
  • Figure 200 shows the amino acid sequence (SEQ ID NO: 200) derived from the coding sequence of SEQ ID NO: 199 shown in Figure 199.
  • Figure 201 shows a nucleotide sequence (SEQ ID NO:201) of a native sequence PR01411 cDNA, wherein SEQ ID NO:201 is a clone designated herein as "DNA59212-1627".
  • Figure 202 shows the amino acid sequence (SEQ ID NO: 202) derived from the coding sequence of SEQ ID NO:201 shown in Figure 201.
  • Figure 203 shows a nucleotide sequence (SEQ ID NO:203) of a native sequence PR01129 cDNA, wherein SEQ ID NO:203 is a clone designated herein as "DNA59213-1487".
  • Figure 204 shows the amino acid sequence (SEQ ID NO: 204) derived from the coding sequence of SEQ ID NO:203 shown in Figure 203.
  • Figure 205 shows a nucleotide sequence (SEQ ID NO:205) of a native sequence PR01359 cDNA, wherein SEQ ID NO:205 is a clone designated herein as "DNA59219-1613".
  • Figure 206 shows the amino acid sequence (SEQ ID NO: 206) derived from the coding sequence of SEQ
  • Figure 207 shows a nucleotide sequence (SEQ ID NO:207) of a native sequence PR01139 cDNA, wherein SEQ ID NO:207 is a clone designated herein as "DNA59497-1496".
  • Figure 208 shows the amino acid sequence (SEQ ID NO: 208) derived from the coding sequence of SEQ ID NO:207 shown in Figure 207.
  • Figure 209 shows a nucleotide sequence (SEQ ID NO:209) of a native sequence PRO1065 cDNA, wherein SEQ ID NO:209 is a clone designated herein as "DNA59602-1436".
  • Figure 210 shows the amino acid sequence (SEQ ID NO:210) derived from the coding sequence of SEQ ID NO:209 shown in Figure 209.
  • Figure 211 shows a nucleotide sequence (SEQ ID NO:211) of a native sequence PRO1028 cDNA, wherein SEQ ID NO:211 is a clone designated herein as "DNA59603-1419".
  • Figure 212 shows the amino acid sequence (SEQ ID NO:212) derived from the coding sequence of SEQ ID NO:211 shown in Figure 211.
  • Figure 213 shows a nucleotide sequence (SEQ ID NO:213) of a native sequence PRO1027 cDNA, wherein SEQ ID NO:213 is a clone designated herein as "DNA59605-1418" .
  • Figure 214 shows the amino acid sequence (SEQ ID NO:214) derived from the coding sequence of SEQ ID NO:213 shown in Figure 213.
  • Figure 215 shows a nucleotide sequence (SEQ ID NO:215) of a native sequence PRO1140 cDNA, wherein SEQ ID NO:215 is a clone designated herein as "DNA59607-1497".
  • Figure 216 shows the amino acid sequence (SEQ ID NO:216) derived from the coding sequence of SEQ
  • Figure 217 shows a nucleotide sequence (SEQ ID NO:217) of a native sequence PR01291 cDNA, wherein SEQ ID NO:217 is a clone designated herein as "DNA59610-1556".
  • Figure 218 shows the amino acid sequence (SEQ ID NO:218) derived from the coding sequence of SEQ ID NO:217 shown in Figure 217.
  • Figure 219 shows a nucleotide sequence (SEQ ID NO:219) of a native sequence PRO1105 cDNA, wherein SEQ ID NO:219 is a clone designated herein as "DNA59612-1466".
  • Figure 220 shows the amino acid sequence (SEQ ID NO:220) derived from the coding sequence of SEQ ID NO:219 shown in Figure 219.
  • Figure 221 shows a nucleotide sequence (SEQ ID NO:221) of a native sequence PRO1026 cDNA, wherein SEQ ID NO:221 is a clone designated herein as "DNA59613-1417".
  • Figure 222 shows the amino acid sequence (SEQ ID NO: 222) derived from the coding sequence of SEQ ID NO :221 shown in Figure 221.
  • Figure 223 shows a nucleotide sequence (SEQ ID NO:223) of a native sequence PRO1104 cDNA, wherein SEQ ID NO:223 is a clone designated herein as "DNA59616-1465".
  • Figure 224 shows the amino acid sequence (SEQ ID NO: 224) derived from the coding sequence of SEQ ID NO:223 shown in Figure 223.
  • Figure 225 shows a nucleotide sequence (SEQ ID NO:225) of a native sequence PRO1100 cDNA, wherein SEQ ID NO:225 is a clone designated herein as "DNA59619-1464".
  • Figure 226 shows the amino acid sequence (SEQ ID NO:226) derived from the coding sequence of SEQ ID NO:225 shown in Figure 225.
  • Figure 227 shows a nucleotide sequence (SEQ ID NO:227) of a native sequence PROH41 cDNA, wherein SEQ ID NO:227 is a clone designated herein as "DNA59625-1498".
  • Figure 228 shows the amino acid sequence (SEQ ID NO: 228) derived from the coding sequence of SEQ ID NO:227 shown in Figure 227.
  • Figure 229 shows a nucleotide sequence (SEQ ID NO:229) of a native sequence PR01772 cDNA, wherein SEQ ID N0:229 is a clone designated herein as "DNA59817-1703".
  • Figure 230 shows the amino acid sequence (SEQ ID NO:230) derived from the coding sequence of SEQ
  • Figure 231 shows a nucleotide sequence (SEQ ID NO:231) of a native sequence PRO1064 cDNA, wherein SEQ ID NO:231 is a clone designated herein as "DNA59827-1426".
  • Figure 232 shows the amino acid sequence (SEQ ID NO:232) derived from the coding sequence of SEQ ID NO:231 shown in Figure 231.
  • Figure 233 shows a nucleotide sequence (SEQ ID NO:233) of a native sequence PR01379 cDNA, wherein SEQ ID NO:233 is a clone designated herein as "DNA59828-1608".
  • Figure 234 shows the amino acid sequence (SEQ ID NO: 234) derived from the coding sequence of SEQ ID NO:233 shown in Figure 233.
  • Figure 235 shows a nucleotide sequence (SEQ ID NO:235) of a native sequence PR03573 cDNA, wherein SEQ ID NO:235 is a clone designated herein as "DNA59837-2545".
  • Figure 236 shows the amino acid sequence (SEQ ID NO:236) derived from the coding sequence of SEQ ID NO:235 shown in Figure 235.
  • Figure 237 shows a nucleotide sequence (SEQ ID NO:237) of a native sequence PR03566 cDNA, wherein SEQ ID NO:237 is a clone designated herein as "DNA59844-2542" .
  • Figure 238 shows the amino acid sequence (SEQ ID NO:238) derived from the coding sequence of SEQ ID NO:237 shown in Figure 237.
  • Figure 239 shows a nucleotide sequence (SEQ ID NO:239) of a native sequence PR01156 cDNA, wherein SEQ ID NO:239 is a clone designated herein as "DNA59853-1505 " .
  • Figure 240 shows the amino acid sequence (SEQ ID NO: 240) derived from the coding sequence of SEQ ID NO:239 shown in Figure 239.
  • Figure 241 shows a nucleotide sequence (SEQ ID NO:241) of a native sequence PRO1098 cDNA, wherein SEQ ID NO:241 is a clone designated herein as "DNA59854-1459".
  • Figure 242 shows the amino acid sequence (SEQ ID NO:242) derived from the coding sequence of SEQ ID NO.-241 shown in Figure 241.
  • Figure 243 shows a nucleotide sequence (SEQ ID NO:243) of a native sequence PROH28 cDNA, wherein SEQ ID NO:243 is a clone designated herein as "DNA59855-1485".
  • Figure 244 shows the amino acid sequence (SEQ ID NO:244) derived from the coding sequence of SEQ
  • Figure 245 shows a nucleotide sequence (SEQ ID NO:245) of a native sequence PR01248 cDNA, wherein SEQ ID NO:245 is a clone designated herein as "DNA60278-1530".
  • Figure 246 shows the amino acid sequence (SEQ ID NO:246) derived from the coding sequence of SEQ ID NO:245 shown in Figure 245.
  • Figure 247 shows a nucleotide sequence (SEQ ID NO:247) of a native sequence PR01127 cDNA, wherein SEQ ID NO:247 is a clone designated herein as "DNA60283-1484".
  • Figure 248 shows the amino acid sequence (SEQ ID NO:248) derived from the coding sequence of SEQ ID NO:247 shown in Figure 247.
  • Figure 249 shows a nucleotide sequence (SEQ ID NO:249) of a native sequence PR01316 cDNA, wherein SEQ ID NO:249 is a clone designated herein as "DNA60608-1577".
  • Figure 250 shows the amino acid sequence (SEQ ID NO:250) derived from the coding sequence of SEQ ID NO:249 shown in Figure 249.
  • Figure 251 shows a nucleotide sequence (SEQ ID NO:251) of a native sequence PROH97 cDNA, wherein SEQ ID NO:251 is a clone designated herein as "DNA60611-1524".
  • Figure 252 shows the amino acid sequence (SEQ ID NO:252) derived from the coding sequence of SEQ ID NO-.251 shown in Figure 251.
  • Figure 253 shows a nucleotide sequence (SEQ ID NO:253) of a native sequence PRO 1125 cDNA, wherein SEQ ID NO:253 is a clone designated herein as "DNA60619-1482".
  • Figure 254 shows the amino acid sequence (SEQ ID NO:254) derived from the coding sequence of SEQ
  • Figure 255 shows a nucleotide sequence (SEQ ID NO:255) of a native sequence PR01158 cDNA, wherein SEQ ID NO:255 is a clone designated herein as "DNA60625-1507".
  • Figure 256 shows the amino acid sequence (SEQ ID NO:256) derived from the coding sequence of SEQ ID NO:255 shown in Figure 255.
  • Figure 257 shows a nucleotide sequence (SEQ ID NO:257) of a native sequence PR01124 cDNA, wherein SEQ ID NO:257 is a clone designated herein as "DNA60629-1481".
  • Figure 258 shows the amino acid sequence (SEQ ID NO:258) derived from the coding sequence of SEQ ID NO:257 shown in Figure 257.
  • Figure 259 shows a nucleotide sequence (SEQ ID NO:259) of a native sequence PRO1380 cDNA, wherein SEQ ID NO:259 is a clone designated herein as "DNA60740-1615".
  • Figure 260 shows the amino acid sequence (SEQ ID NO: 260) derived from the coding sequence of SEQ ID NO:259 shown in Figure 259.
  • Figure 261 shows a nucleotide sequence (SEQ ID NO:261) of a native sequence PR01377 cDNA, wherein SEQ ID NO:261 is a clone designated herein as "DNA61608-1606".
  • Figure 262 shows the amino acid sequence (SEQ ID NO: 262) derived from the coding sequence of SEQ ID NO-.261 shown in Figure 261.
  • Figure 263 shows a nucleotide sequence (SEQ ID NO-.263) of a native sequence PR01287 cDNA, wherein SEQ ID N0:263 is a clone designated herein as "DNA61755-1554".
  • Figure 264 shows the amino acid sequence (SEQ ID NO: 264) derived from the coding sequence of SEQ ID NO.-263 shown in Figure 263.
  • Figure 265 shows a nucleotide sequence (SEQ ID NO:265) of a native sequence PR01249 cDNA, wherein SEQ ID NO:265 is a clone designated herein as "DNA62809-1531 " .
  • Figure 266 shows the amino acid sequence (SEQ ID NO:266) derived from the coding sequence of SEQ ID NO:265 shown in Figure 265.
  • Figure 267 shows a nucleotide sequence (SEQ ID NO -.267) of a native sequence PRO 1335 cDN , wherein SEQ ID NO:267 is a clone designated herein as "DNA62812-1594".
  • Figure 268 shows the amino acid sequence (SEQ ID NO:268) derived from the coding sequence of SEQ
  • Figure 269 shows a nucleotide sequence (SEQ ID NO:269) of a native sequence PR03572 cDNA, wherein SEQ ID N0:269 is a clone designated herein as "DNA62813-2544".
  • Figure 270 shows the amino acid sequence (SEQ ID NO: 270) derived from the coding sequence of SEQ ID NO:269 shown in Figure 269.
  • Figure 271 shows a nucleotide sequence (SEQ ID NO:271) of a native sequence PR01599 cDNA, wherein SEQ ID NO:271 is a clone designated herein as "DNA62845-1684".
  • Figure 272 shows the amino acid sequence (SEQ ID NO:272) derived from the coding sequence of SEQ ID NO:271 shown in Figure 271.
  • Figure 273 shows a nucleotide sequence (SEQ ID NO:273) of a native sequence PR01374 cDNA, wherein SEQ ID NO:273 is a clone designated herein as "DNA64849-1604".
  • Figure 274 shows the amino acid sequence (SEQ ID NO: 274) derived from the coding sequence of SEQ ID NO:273 shown in Figure 273.
  • Figure 275 shows a nucleotide sequence (SEQ ID NO:275) of a native sequence PR01345 cDNA, wherein SEQ ID NO:275 is a clone designated herein as "DNA64852-1589".
  • Figure 276 shows the amino acid sequence (SEQ ID NO:276) derived from the coding sequence of SEQ ID NO:275 shown in Figure 275.
  • Figure 277 shows a nucleotide sequence (SEQ ID NO:277) of a native sequence PR01311 cDNA, wherein SEQ ID NO:277 is a clone designated herein as "DNA64863-1573".
  • Figure 278 shows the amino acid sequence (SEQ ID NO:278) derived from the coding sequence of SEQ ID NO:277 shown in Figure 277.
  • Figure 279 shows a nucleotide sequence (SEQ ID NO:279) of a native sequence PR01357 cDNA, wherein SEQ ID NO:279 is a clone designated herein as "DNA64881-1602".
  • Figure 280 shows the amino acid sequence (SEQ ID NO: 280) derived from the coding sequence of SEQ ID NO:279 shown in Figure 279.
  • Figure 281 shows a nucleotide sequence (SEQ ID NO:281) of a native sequence PR01557 cDNA, wherein SEQ ID NO:281 is a clone designated herein as "DNA64902-1667".
  • Figure 282 shows the amino acid sequence (SEQ ID NO:282) derived from the coding sequence of SEQ
  • Figure 283 shows a nucleotide sequence (SEQ ID NO:283) of a native sequence PRO1305 cDNA, wherein SEQ ID NO:283 is a clone designated herein as "DNA64952-1568".
  • Figure 284 shows the .amino acid sequence (SEQ ID NO: 284) derived from the coding sequence of SEQ ID NO:283 shown in Figure 283.
  • Figure 285 shows a nucleotide sequence (SEQ ID NO: 285) of a native sequence PRO 1302 cDNA, wherein SEQ ID NO:285 is a clone designated herein as "DNA65403-1565".
  • Figure 286 shows the amino acid sequence (SEQ ID NO:286) derived from the coding sequence of SEQ ID NO:285 shown in Figure 285.
  • Figure 287 shows a nucleotide sequence (SEQ ID NO:287) of a native sequence PR01266 cDNA, wherein SEQ ID NO:287 is a clone designated herein as "DNA65413-1534".
  • Figure 288 shows the amino acid sequence (SEQ ID NO:288) derived from the coding sequence of SEQ ID NO:287 shown in Figure 287.
  • Figures 289A-289B show a nucleotide sequence (SEQ ID NO:289) of a native sequence PR01336 cDNA, wherein SEQ ID NO:289 is a clone designated herein as "DNA65423-1595" .
  • Figure 290 shows the amino acid sequence (SEQ ID NO:290) derived from the coding sequence of SEQ ID NO:289 shown in Figures 289A-289B.
  • Figure 291 shows a nucleotide sequence (SEQ ID NO:291) of a native sequence PR01278 cDNA, wherein SEQ ID NO:291 is a clone designated herein as "DNA66304-1546".
  • Figure 292 shows the amino acid sequence (SEQ ID NO:292) derived from the coding sequence of SEQ
  • Figure 293 shows a nucleotide sequence (SEQ ID NO:293) of a native sequence PRO 1270 cDNA, wherein SEQ ID NO:293 is a clone designated herein as "DNA66308-1537".
  • Figure 294 shows the amino acid sequence (SEQ ID NO:294) derived from the coding sequence of SEQ ID NO :293 shown in Figure 293.
  • Figure 295 shows a nucleotide sequence (SEQ ID NO:295) of a native sequence PR01298 cDNA, wherein SEQ ID NO:295 is a clone designated herein as "DNA66511-1563".
  • Figure 296 shows the amino acid sequence (SEQ ID NO:296) derived from the coding sequence of SEQ ID NO:295 shown in Figure 295.
  • Figure 297 shows a nucleotide sequence (SEQ ID NO:297) of a native sequence PRO1301 cDNA, wherein SEQ ID NO:297 is a clone designated herein as "DNA66512-1564".
  • Figure 298 shows the amino acid sequence (SEQ ID NO:298) derived from the coding sequence of SEQ ID NO:297 shown in Figure 297.
  • Figure 299 shows a nucleotide sequence (SEQ ID NO:299) of a native sequence PR01268 cDNA, wherein SEQ ID NO:299 is a clone designated herein as "DNA66519-1535".
  • Figure 300 shows the amino acid sequence (SEQ ID NO: 300) derived from the coding sequence of SEQ ID NO:299 shown in Figure 299.
  • Figure 301 shows a nucleotide sequence (SEQ ID NO:301) of a native sequence PR01327 cDNA, wherein SEQ ID NO:301 is a clone designated herein as "DNA66521-1583".
  • Figure 302 shows the amino acid sequence (SEQ ID NO:302) derived from the coding sequence of SEQ ID NO:301 shown in Figure 301.
  • Figure 303 shows a nucleotide sequence (SEQ ID NO:303) of a native sequence PR01328 cDNA, wherein SEQ ID NO:303 is a clone designated herein as "DNA66658-1584".
  • Figure 304 shows the amino acid sequence (SEQ ID NO: 304) derived from the coding sequence of SEQ ID NO:303 shown in Figure 303.
  • Figure 305 shows a nucleotide sequence (SEQ ID NO:305) of a native sequence PR01329 cDNA, wherein SEQ ID NO:305 is a clone designated herein as "DNA66660-1585".
  • Figure 306 shows the amino acid sequence (SEQ ID NO: 306) derived from the coding sequence of SEQ
  • Figure 307 shows a nucleotide sequence (SEQ ID NO:307) of a native sequence PR01339 cDNA, wherein SEQ ID NO:307 is a clone designated herein as "DNA66669-1597".
  • Figure 308 shows the amino acid sequence (SEQ ID NO:308) derived from the coding sequence of SEQ ID NO:307 shown in Figure 307.
  • Figure 309 shows a nucleotide sequence (SEQ ID NO:309) of a native sequence PR01342 cDNA, wherein SEQ ID NO:309 is a clone designated herein as "DNA66674-1599".
  • Figure 310 shows the amino acid sequence (SEQ ID NO:310) derived from the coding sequence of SEQ ID NO:309 shown in Figure 309.
  • Figures 311A-311B show a nucleotide sequence (SEQ ID NO:311) of a native sequence PR01487 cDNA, wherein SEQ ID NO:311 is a clone designated herein as "DNA68836-1656".
  • Figure 312 shows the amino acid sequence (SEQ ID NO:312) derived from the coding sequence of SEQ ID NO:311 shown in Figures 311A-311B.
  • Figure 313 shows a nucleotide sequence (SEQ ID NO:313) of a native sequence PR03579 cDNA, wherein SEQ ID NO:313 is a clone designated herein as "DNA68862-2546".
  • Figure 314 shows the amino acid sequence (SEQ ID NO:314) derived from the coding sequence of SEQ ID NO-.313 shown in Figure 313.
  • Figure 315 shows a nucleotide sequence (SEQ ID NO:315) of a native sequence PR01472 cDNA, wherein SEQ ID NO:315 is a clone designated herein as "DNA68866-1644".
  • Figure 316 shows the amino acid sequence (SEQ ID NO:316) derived from the coding sequence of SEQ ID NO:315 shown in Figure 315.
  • Figure 317 shows a nucleotide sequence (SEQ ID NO:317) of a native sequence PR01385 cDNA, wherein SEQ ID NO:317 is a clone designated herein as "DNA68869-1610" .
  • Figure 318 shows the amino acid sequence (SEQ ID NO:318) derived from the coding sequence of SEQ ID NO:317 shown in Figure 317.
  • Figure 319 shows a nucleotide sequence (SEQ ID NO:319) of a native sequence PR01461 cDNA, wherein SEQ ID NO:319 is a clone designated herein as "DNA68871-1638".
  • Figure 320 shows the amino acid sequence (SEQ ID NO:320) derived from the coding sequence of SEQ
  • Figure 321 shows a nucleotide sequence (SEQ ID NO:321) of a native sequence PR01429 cDNA, wherein SEQ ID NO:321 is a clone designated herein as "DNA68879-1631".
  • Figure 322 shows the amino acid sequence (SEQ ID NO: 322) derived from the coding sequence of SEQ ID NO:321 shown in Figure 321.
  • Figure 323 shows a nucleotide sequence (SEQ ID NO:323) of a native sequence PR01568 cDNA, wherein SEQ ID NO:323 is a clone designated herein as "DNA68880-1676".
  • Figure 324 shows the amino acid sequence (SEQ ID NO: 324) derived from the coding sequence of SEQ ID NO: 323 shown in Figure 323.
  • Figure 325 shows a nucleotide sequence (SEQ ID NO:325) of a native sequence PR01569 cDNA, wherein SEQ ID NO:325 is a clone designated herein as "DNA68882-1677".
  • Figure 326 shows the amino acid sequence (SEQ ID NO: 326) derived from the coding sequence of SEQ ID NO: 325 shown in Figure 325.
  • Figure 327 shows a nucleotide sequence (SEQ ID NO:327) of a native sequence PR01753 cDNA, wherein SEQ ID NO:327 is a clone designated herein as "DNA68883-1691 " .
  • Figure 328 shows the amino acid sequence (SEQ ID NO: 328) derived from the coding sequence of SEQ ID NO:327 shown in Figure 327.
  • Figure 329 shows a nucleotide sequence (SEQ ID NO:329) of a native sequence PRO1570 cDNA, wherein SEQ ID NO:329 is a clone designated herein as "DNA68885-1678".
  • Figure 330 shows the amino acid sequence (SEQ ID NO:330) derived from the coding sequence of SEQ
  • Figure 331 shows a nucleotide sequence (SEQ ID NO:331) of a native sequence PR01559 cDNA, wherein SEQ ID NO: 331 is a clone designated herein as "DNA68886".
  • Figure 332 shows the amino acid sequence (SEQ ID NO: 332) derived from the coding sequence of SEQ ID NO:331 shown in Figure 331.
  • Figure 333 shows a nucleotide sequence (SEQ ID NO:333) of a native sequence PR01486 cDNA, wherein SEQ ID NO:333 is a clone designated herein as "DNA71180-1655".
  • Figure 334 shows the amino acid sequence (SEQ ID NO:334) derived from the coding sequence of SEQ ID NO:333 shown in Figure 333.
  • Figure 335 shows a nucleotide sequence (SEQ ID NO:335) of a native sequence PRO 1433 cDNA, wherein SEQ ID NO: 335 is a clone designated herein as "DNA71184-1634".
  • Figure 336 shows the amino acid sequence (SEQ ID NO:336) derived from the coding sequence of SEQ ID NO:335 shown in Figure 335.
  • Figure 337 shows a nucleotide sequence (SEQ ID NO:337) of a native sequence PRO1490 cDNA, wherein SEQ ID NO:337 is a clone designated herein as "DNA71213-1659".
  • Figure 338 shows the amino acid sequence (SEQ ID NO: 338) derived from the coding sequence of SEQ ID NO:337 shown in Figure 337.
  • Figure 339 shows a nucleotide sequence (SEQ ID NO:339) of a native sequence PR01482 cDNA, wherein SEQ ID NO:339 is a clone designated herein as "DNA71234-1651".
  • Figure 340 shows the amino acid sequence (SEQ ID NO: 340) derived from the coding sequence of SEQ ID NO:339 shown in Figure 339.
  • Figure 341 shows a nucleotide sequence (SEQ ID NO:341) of a native sequence PRO1409 cDNA, wherein SEQ ID NO:341 is a clone designated herein as "DNA71269-1621 " .
  • Figure 342 shows the amino acid sequence (SEQ ID NO: 342) derived from the coding sequence of SEQ ID NO:341 shown in Figure 341.
  • Figure 343 shows a nucleotide sequence (SEQ ID NO:343) of a native sequence PR01446 cDNA, wherein SEQ ID NO:343 is a clone designated herein as "DNA71277-1636".
  • Figure 344 shows the amino acid sequence (SEQ ID NO: 344) derived from the coding sequence of SEQ
  • Figure 345 shows a nucleotide sequence (SEQ ID NO:345) of a native sequence PRO1604 cDNA, wherein SEQ ID NO:345 is a clone designated herein as "DNA71286-1687".
  • Figure 346 shows the amino acid sequence (SEQ ID NO: 346) derived from the coding sequence of SEQ ID NO:345 shown in Figure 345.
  • Figure 347 shows a nucleotide sequence (SEQ ID NO:347) of a native sequence PR01491 cDNA, wherein SEQ ID NO:347 is a clone designated herein as "DNA71883-1660".
  • Figure 348 shows the amino acid sequence (SEQ ID NO: 348) derived from the coding sequence of SEQ ID NO: 347 shown in Figure 347.
  • Figure 349 shows a nucleotide sequence (SEQ ID NO:349) of a native sequence PR01431 cDNA, wherein SEQ ID NO:349 is a clone designated herein as "DNA73401-1633 " .
  • Figure 350 shows the amino acid sequence (SEQ ID NO:350) derived from the coding sequence of SEQ ID NO:349 shown in Figure 349.
  • Figures 351A-351B show a nucleotide sequence (SEQ ID NO:351) of a native sequence PR01563 " cDNA, wherein SEQ ID NO:351 is a clone designated herein as "DNA73492-1671".
  • Figure 352 shows the amino acid sequence (SEQ ID NO:352) derived from the coding sequence of SEQ ID NO:351 shown in Figures 351A-351B.
  • Figure 353 shows a nucleotide sequence (SEQ ID NO:353) of a native sequence PR01571 cDNA, wherein SEQ ID NO:353 is a clone designated herein as "DNA73730-1679".
  • Figure 354 shows the amino acid sequence (SEQ ID NO: 354) derived from the coding sequence of SEQ ID NO:353 shown in Figure 353.
  • Figure 355 shows a nucleotide sequence (SEQ ID NO:355) of a native sequence PR01572 cDNA, wherein SEQ ID NO:355 is a clone designated herein as "DNA73734-1680".
  • Figure 356 shows the amino acid sequence (SEQ ID NO:356) derived from the coding sequence of SEQ ID NO:355 shown in Figure 355.
  • Figure 357 shows a nucleotide sequence (SEQ ID NO:357) of a native sequence PR01573 cDNA, wherein SEQ ID NO:357 is a clone designated herein as "DNA73735-1681".
  • Figure 358 shows the amino acid sequence (SEQ ID NO:358) derived from the coding sequence of SEQ
  • Figure 359 shows a nucleotide sequence (SEQ ID NO:359) of a native sequence PRO1508 cDNA, wherein SEQ ID NO:359 is a clone designated herein as "DNA73742-1662".
  • Figure 360 shows the amino acid sequence (SEQ ID NO:360) derived from the coding sequence of SEQ ID NO:359 shown in Figure 359.
  • Figure 361 shows a nucleotide sequence (SEQ ID NO:361) of a native sequence PR01485 cDNA, wherein SEQ ID NO:361 is a clone designated herein as "DNA73746-1654".
  • Figure 362 shows the amino acid sequence (SEQ ID NO:362) derived from the coding sequence of SEQ ID NO:361 shown in Figure 361.
  • Figure 363 shows a nucleotide sequence (SEQ ID NO:363) of a native sequence PR01564 cDNA, wherein SEQ ID NO:363 is a clone designated herein as "DNA73760-1672".
  • Figure 364 shows the amino acid sequence (SEQ ID NO:364) derived from the coding sequence of SEQ ID NO:363 shown in Figure 363.
  • Figure 365 shows a nucleotide sequence (SEQ ID NO:365) of a native sequence PRO1550 cDNA, wherein SEQ ID NO:365 is a clone designated herein as "DNA76393-1664".
  • Figure 366 shows the amino acid sequence (SEQ ID NO: 366) derived from the coding sequence of SEQ ID NO:365 shown in Figure 365.
  • Figure 367 shows a nucleotide sequence (SEQ ID NO:367) of a native sequence PR01757 cDNA, wherein SEQ ID NO:367 is a clone designated herein as "DNA76398-1699".
  • Figure 368 shows the amino acid sequence (SEQ ID NO:368) derived from the coding sequence of SEQ
  • Figure 369 shows a nucleotide sequence (SEQ ID NO:369) of a native sequence PR01758 cDNA, wherein SEQ ID NO:369 is a clone designated herein as "DNA76399-1700".
  • Figure 370 shows the amino acid sequence (SEQ ID NO: 370) derived from the coding sequence of SEQ ID NO:369 shown in Figure 369.
  • Figure 371 shows a nucleotide sequence (SEQ ID NO:371) of a native sequence PR01781 cDNA, wherein SEQ ID NO:371 is a clone designated herein as "DNA76522-2500”.
  • Figure 372 shows the amino acid sequence (SEQ ID NO: 372) derived from the coding sequence of SEQ ID NO:371 shown in Figure 371.
  • Figure 373 shows a nucleotide sequence (SEQ ID NO:373) of a native sequence PRO1606 cDNA, wherein SEQ ID NO:373 is a clone designated herein as "DNA76533-1689".
  • Figure 374 shows the amino acid sequence (SEQ ID NO: 374) derived from the coding sequence of SEQ ID NO:373 shown in Figure 373.
  • Figure 375 shows a nucleotide sequence (SEQ ID NO:375) of a native sequence PR01784 cDNA, wherein SEQ ID NO:375 is a clone designated herein as "DNA77303-2502".
  • Figure 376 shows the amino acid sequence (SEQ ID NO:376) derived from the coding sequence of SEQ ID NO:375 shown in Figure 375.
  • Figure 377 shows a nucleotide sequence (SEQ ID NO:377) of a native sequence PR01774 cDNA, wherein SEQ ID NO:377 is a clone designated herein as "DNA77626-1705".
  • Figure 378 shows the amino acid sequence (SEQ ID NO:378) derived from the coding sequence of SEQ ID NO:377 shown in Figure 377.
  • Figure 379 shows a nucleotide sequence (SEQ ID NO:379) of a native sequence PRO1605 cDNA, wherein SEQ ID NO:379 is a clone designated herein as "DNA77648-1688" .
  • Figure 380 shows the amino acid sequence (SEQ ID NO:380) derived from the coding sequence of SEQ ID NO:379 shown in Figure 379.
  • Figure 381 shows a nucleotide sequence (SEQ ID NO:381) of a native sequence PR01928 cDNA, wherein SEQ ID NO:381 is a clone designated herein as "DNA81754-2532".
  • Figure 382 shows the amino acid sequence (SEQ ID NO:382) derived from the coding sequence of SEQ
  • Figure 383 shows a nucleotide sequence (SEQ ID NO:383) of a native sequence PR01865 cDNA, wherein SEQ ID NO:383 is a clone designated herein as "DNA81757-2512".
  • Figure 384 shows the amino acid sequence (SEQ ID NO:384) derived from the coding sequence of SEQ ID NO:383 shown in Figure 383.
  • Figure 385 shows a nucleotide sequence (SEQ ID NO:385) of a native sequence PR01925 cDNA, wherein SEQ ID NO:385 is a clone designated herein as "DNA82302-2529".
  • Figure 386 shows the amino acid sequence (SEQ ID NO:386) derived from the coding sequence of SEQ ID NO:385 shown in Figure 385.
  • Figure 387 shows a nucleotide sequence (SEQ ID NO:387) of a native sequence PR01926 cDNA, wherein SEQ ID NO:387 is a clone designated herein as "DNA82340-2530".
  • Figure 388 shows the amino acid sequence (SEQ ID NO:388) derived from the coding sequence of SEQ ID NO:387 shown in Figure 387.
  • Figure 389 shows a nucleotide sequence (SEQ ID NO:389) of a native sequence PRO2630 cDNA, wherein SEQ ID NO:389 is a clone designated herein as "DNA83551".
  • Figure 390 shows the amino acid sequence (SEQ ID NO:390) derived from the coding sequence of SEQ ID NO:389 shown in Figure 389.
  • Figure 391 shows a nucleotide sequence (SEQ ID NO:391) of a native sequence PR03443 cDNA, wherein SEQ ID NO:391 is a clone designated herein as "DNA87991-2540".
  • Figure 392 shows the amino acid sequence (SEQ ID NO:392) derived from the coding sequence of SEQ ID NO:391 shown in Figure 391.
  • Figure 393 shows a nucleotide sequence (SEQ ID NO:393) of a native sequence PRO3301 cDNA, wherein SEQ ID NO:393 is a clone designated herein as "DNA88002" .
  • Figure 394 shows the amino acid sequence (SEQ ID NO: 394) derived from the coding sequence of SEQ ID NO:393 shown in Figure 393.
  • Figure 395 shows a nucleotide sequence (SEQ ID NO:395) of a native sequence PR03442 cDNA, wherein SEQ ID NO:395 is a clone designated herein as "DNA92238-2539".
  • Figure 396 shows the amino acid sequence (SEQ ID NO:396) derived from the coding sequence of SEQ
  • Figure 397 shows a nucleotide sequence (SEQ ID NO:397) of a native sequence PR04978 cDNA, wherein SEQ ID NO:397 is a clone designated herein as "DNA95930".
  • Figure 398 shows the amino acid sequence (SEQ ID NO:398) derived from the coding sequence of SEQ ID NO:397 shown in Figure 397.
  • Figure 399 shows a nucleotide sequence (SEQ ID NO:399) of a native sequence PRO5801 cDNA, wherein SEQ ID NO:399 is a clone designated herein as "DNA115291-2681".
  • Figure 400 shows the amino acid sequence (SEQ ID NO: 400) derived from the coding sequence of SEQ ID NO:399 shown in Figure 399.
  • Figure 401 shows a nucleotide sequence (SEQ ID NO:401) of a native sequence PRO19630 cDNA, wherein SEQ ID NO:401 is a clone designated herein as "DNA23336-2861".
  • Figure 402 shows the amino acid sequence (SEQ ID NO: 402) derived from the coding sequence of SEQ ID NO:401 shown in Figure 401.
  • Figure 403 shows a nucleotide sequence (SEQ ID NO:403) of a native sequence PRO203 cDNA, wherein SEQ ID NO:403 is a clone designated herein as "DNA30862-1396" .
  • Figure 404 shows the amino acid sequence (SEQ ID NO: 404) derived from the coding sequence of SEQ ID NO:403 shown in Figure 403.
  • Figure 405 shows anucleotide sequence (SEQ ID NO:405) of anative sequence PRO204 cDNA, wherein SEQ ID NO:405 is a clone designated herein as "DNA30871-1157”.
  • Figure 406 shows the amino acid sequence (SEQ ID NO:406) derived from the coding sequence of SEQ
  • Figure 407 shows a nucleotide sequence (SEQ ID NO:407) of anative sequence PRO210 cDNA, wherein SEQ ID NO:407 is a clone designated herein as "DNA32279-1131".
  • Figure 408 shows the amino acid sequence (SEQ ID NO: 408) derived from the coding sequence of SEQ ID NO:407 shown in Figure 407.
  • Figure 409 shows a nucleotide sequence (SEQ ID NO:409) of a native sequence PR0223 cDNA, wherein SEQ ID NO:409 is a clone designated herein as "DNA33206-1165".
  • Figure 410 shows the amino acid sequence (SEQ ID NO:410) derived from the coding sequence of SEQ ID NO:409 shown in Figure 409.
  • Figure 411 shows anucleotide sequence (SEQ ID NO:411) of anative sequence PR0247 cDNA, wherein SEQ ID N0:411 is a clone designated herein as "DNA35673-1201".
  • Figure 412 shows the amino acid sequence (SEQ ID NO:412) derived from the coding sequence of SEQ ID NO:411 shown in Figure 411.
  • Figure 413 shows a nucleotide sequence (SEQ ID NO:413) of a native sequence PR0358 cDNA, wherein SEQ ID NO:413 is a clone designated herein as "DNA47361-1154-2".
  • Figure 414 shows the amino acid sequence (SEQ ID NO:414) derived from the coding sequence of SEQ ID NO:413 shown in Figure 413.
  • Figure 415 shows anucleotide sequence (SEQ ID NO:415) of anative sequence PR0724 cDNA, wherein
  • SEQ ID NO:415 is a clone designated herein as "DNA49631-1328".
  • Figure 416 shows the amino acid sequence (SEQ ID NO:416) derived from the coding sequence of SEQ ID NO:415 shown in Figure 415.
  • Figure 417 shows anucleotide sequence (SEQ ID NO:417) of anative sequence PR0868 cDNA, wherein SEQ ID NO:417 is a clone designated herein as "DNA52594-1270".
  • Figure 418 shows the amino acid sequence (SEQ ID NO:418) derived from the coding sequence of SEQ ID NO:417 shown in Figure 417.
  • Figure 419 shows a nucleotide sequence (SEQ ID NO:419) of a native sequence PRO740 cDNA, wherein SEQ ID NO:419 is a clone designated herein as "DNA55800-1263".
  • Figure 420 shows the amino acid sequence (SEQ ID NO: 420) derived from the coding sequence of SEQ
  • Figure 421 shows a nucleotide sequence (SEQ ID NO:421) of a native sequence PR01478 cDNA, wherein SEQ ID NO:421 is a clone designated herein as "DNA56531-1648".
  • Figure 422 shows the amino acid sequence (SEQ ID NO: 422) derived from the coding sequence of SEQ ID NO:421 shown in Figure 421.
  • Figure 423 shows anucleotide sequence (SEQ ID NO: 423) of anative sequence PRO 162 cDNA, wherein SEQ ID NO:423 is a clone designated herein as "DNA56965-1356".
  • Figure 424 shows the amino acid sequence (SEQ ID NO: 424) derived from the coding sequence of SEQ ID NO:423 shown in Figure 423.
  • Figure 425 shows anucleotide sequence (SEQ ID NO: 425) of a native sequence PR0828 cDNA, wherein
  • SEQ ID NO:425 is a clone designated herein as "DNA57037-1444".
  • Figure 426 shows the amino acid sequence (SEQ ID NO:426) derived from the coding sequence of SEQ ID NO:425 shown in Figure 425.
  • Figure 427 shows anucleotide sequence (SEQ ID NO:427) of a native sequence PR0819 cDNA, wherein SEQ ID NO:427 is a clone designated herein as "DNA57695-1340" .
  • Figure 428 shows the amino acid sequence (SEQ ID NO: 428) derived from the coding sequence of SEQ ID NO:427 shown in Figure 427.
  • Figure 429 shows anucleotide sequence (SEQ ID NO: 429) of a native sequence PR0813 cDNA, wherein SEQ ID NO:429 is a clone designated herein as "DNA57834-1339".
  • Figure 430 shows the amino acid sequence (SEQ ID NO:430) derived from the coding sequence of SEQ ID NO:429 shown in Figure 429.
  • Figure 431 shows a nucleotide sequence (SEQ ID NO:431) of a native sequence PR01194 cDNA, wherein SEQ ID NO:431 is a clone designated herein as "DNA57841-1522".
  • Figure 432 shows the amino acid sequence (SEQ ID NO:432) derived from the coding sequence of SEQ ID NO: 431 shown in Figure 431.
  • Figure 433 shows anucleotide sequence (SEQ ID NO:433) of a native sequence PR0887 cDNA, wherein SEQ ID NO:433 is a clone designated herein as "DNA58130".
  • Figure 434 shows the amino acid sequence (SEQ ID NO:434) derived from the coding sequence of SEQ
  • Figure 435 shows a nucleotide sequence (SEQ ID NO:435) of a native sequence PRO1071 cDNA, wherein SEQ ID NO:435 is a clone designated herein as "DNA58847-1383".
  • Figure 436 shows the amino acid sequence (SEQ ID NO:436) derived from the coding sequence of SEQ ID NO:435 shown in Figure 435.
  • Figure 437 shows a nucleotide sequence (SEQ ID NO:437) of a native sequence PRO1029 cDNA, wherein SEQ ID NO:437 is a clone designated herein as "DNA59493-1420".
  • Figure 438 shows the amino acid sequence (SEQ ID NO:438) derived from the coding sequence of SEQ ID NO:437 shown in Figure 437.
  • Figure 439 shows a nucleotide sequence (SEQ ID NO:439) of a native sequence PRO1190 cDNA, wherein SEQ ID NO:439 is a clone designated herein as "DNA59586-1520".
  • Figure 440 shows the amino acid sequence (SEQ ID NO: 440) derived from the coding sequence of SEQ ID NO:439 shown in Figure 439.
  • Figure 441 shows a nucleotide sequence (SEQ ID NO:441) of a native sequence PR04334 cDNA, wherein SEQ ID NO:441 is a clone designated herein as "DNA59608-2577".
  • Figure 442 shows the amino acid sequence (SEQ ID NO:442) derived from the coding sequence of SEQ ID NO:441 shown in Figure 441.
  • Figure 443 shows a nucleotide sequence (SEQ ID NO:443) of a native sequence PR01155 cDNA, wherein SEQ ID NO:443 is a clone designated herein as "DNA59849-1504".
  • Figure 444 shows the amino acid sequence (SEQ ID NO: 444) derived from the coding sequence of SEQ
  • Figure 445 shows a nucleotide sequence (SEQ ID NO: 445) of a native sequence PRO 1157 cDNA, wherein SEQ ID NO:445 is a clone designated herein as "DNA60292-1506".
  • Figure 446 shows the amino acid sequence (SEQ ID NO: 446) derived from the coding sequence of SEQ ID NO:445 shown in Figure 445.
  • Figure 447 shows a nucleotide sequence (SEQ ID NO:447) of a native sequence PR01122 cDNA, wherein SEQ ID NO:447 is a clone designated herein as "DNA62377-1381-1".
  • Figure 448 shows the amino acid sequence (SEQ ID NO: 448) derived from the coding sequence of SEQ ID NO:447 shown in Figure 447.
  • Figure 449 shows a nucleotide sequence (SEQ ID NO:449) of a native sequence PR01183 cDNA, wherein SEQ ID NO:449 is a clone designated herein as "DNA62880-1513".
  • Figure 450 shows the amino acid sequence (SEQ ID NO: 450) derived from the coding sequence of SEQ ID NO:449 shown in Figure 449.
  • Figure 451 shows a nucleotide sequence (SEQ ID NO:451) of a native sequence PR01337 cDNA, wherein SEQ ID NO:451 is a clone designated herein as "DNA66672-1586".
  • Figure 452 shows the amino acid sequence (SEQ ID NO: 452) derived from the coding sequence of SEQ ID NO:451 shown in Figure 451.
  • Figure 453 shows a nucleotide sequence (SEQ ID NO:453) of a native sequence PRO1480 cDNA, wherein SEQ ID NO:453 is a clone designated herein as "DNA67962-1649".
  • Figure 454 shows the amino acid sequence (SEQ ID NO:454) derived from the coding sequence of SEQ ID NO:453 shown in Figure 453.
  • Figure 455 shows a nucleotide sequence (SEQ ID NO:455) of a native sequence PR019645 cDNA, wherein SEQ ID NO:455 is a clone designated herein as "DNA69555-2867" .
  • Figure 456 shows the amino acid sequence (SEQ ID NO:456) derived from the coding sequence of SEQ ID NO:455 shown in Figure 455.
  • Figure 457 shows a nucleotide sequence (SEQ ID NO:457) of a native sequence PR09782 cDNA, wherein SEQ ID NO:457 is a clone designated herein as "DNA71162-2764".
  • Figure 458 shows the amino acid sequence (SEQ ID NO:458) derived from the coding sequence of SEQ
  • Figure 459 shows a nucleotide sequence (SEQ ID NO:459) of a native sequence PR01419 cDNA, wherein SEQ ID NO:459 is a clone designated herein as "DNA71290-1630".
  • Figure 460 shows the amino acid sequence (SEQ ID NO: 460) derived from the coding sequence of SEQ ID NO:459 shown in Figure 459.
  • Figure 461 shows a nucleotide sequence (SEQ ID NO:461) of a native sequence PR01575 cDNA, wherein SEQ ID NO-.461 is a clone designated herein as "DNA76401-1683".
  • Figure 462 shows the amino acid sequence (SEQ ID NO:462) derived from the coding sequence of SEQ ID NO:461 shown in Figure 461.
  • Figure 463 shows a nucleotide sequence (SEQ ID NO:463) of a native sequence PR01567 cDNA, wherein SEQ ID NO:463 is a clone designated herein as "DNA76541-1675".
  • Figure 464 shows the amino acid sequence (SEQ ID N0:464) derived from the coding sequence of SEQ ID NO: 463 shown in Figure 463.
  • Figure 465 shows a nucleotide sequence (SEQ ID NO:465) of a native sequence PR01891 cDNA, wherein SEQ ID NO:465 is a clone designated herein as "DNA76788-2526" .
  • Figure 466 shows the amino acid sequence (SEQ ID NO: 466) derived from the coding sequence of SEQ ID NO:465 shown in Figure 465.
  • Figure 467 shows a nucleotide sequence (SEQ ID NO:467) of a native sequence PR01889 cDNA, wherein SEQ ID NO:467 is a clone designated herein as "DNA77623-2524".
  • Figure 468 shows the amino acid sequence (SEQ ID NO:468) derived from the coding sequence of SEQ ID NO:467 shown in Figure 467.
  • Figure 469 shows a nucleotide sequence (SEQ ID NO:469) of a native sequence PR01785 cDNA, wherein SEQ ID NO:469 is a clone designated herein as "DNA80136-2503" .
  • Figure 470 shows the amino acid sequence (SEQ ID NO:470) derived from the coding sequence of SEQ ID NO:469 shown in Figure 469.
  • Figure 471 shows a nucleotide sequence (SEQ ID NO:471) of a native sequence PRO6003 cDNA, wherein SEQ ID NO:471 is a clone designated herein as "DNA83568-2692".
  • Figure 472 shows the amino acid sequence (SEQ ID NO:472) derived from the coding sequence of SEQ
  • Figure 473 shows a nucleotide sequence (SEQ ID NO:473) of a native sequence PR04333 cDNA, wherein SEQ ID NO:473 is a clone designated herein as "DNA84210-2576".
  • Figure 474 shows the amino acid sequence (SEQ ID NO:474) derived from the coding sequence of SEQ ID NO:473 shown in Figure 473.
  • Figure 475 shows a nucleotide sequence (SEQ ID NO:475) of a native sequence PR04356 cDNA, wherein SEQ ID NO:475 is a clone designated herein as "DNA86576-2595".
  • Figure 476 shows the amino acid sequence (SEQ ID NO: 476) derived from the coding sequence of SEQ ID NO:475 shown in Figure 475.
  • Figure 477 shows a nucleotide sequence (SEQ ID NO:477) of a native sequence PR04352 cDNA, wherein SEQ ID NO:477 is a clone designated herein as "DNA87976-2593".
  • Figure 478 shows the amino acid sequence (SEQ ID NO:478) derived from the coding sequence of SEQ ID NO:477 shown in Figure 477.
  • Figure 479 shows a nucleotide sequence (SEQ ID NO:479) of a native sequence PR04354 cDNA, wherein SEQ ID NO:479 is a clone designated herein as "DNA92256-2596".
  • Figure 480 shows the amino acid sequence (SEQ ID NO: 480) derived from the coding sequence of SEQ ID NO:479 shown in Figure 479.
  • Figure 481 shows a nucleotide sequence (SEQ ID NO:481) of a native sequence PR04369 cDNA, wherem SEQ ID NO:481 is a clone designated herein as "DNA92289-2598".
  • Figure 482 shows the amino acid sequence (SEQ ID NO:482) derived from the coding sequence of SEQ
  • Figure 483 shows a nucleotide sequence (SEQ ID NO:483) of a native sequence PRO6030 cDNA, wherein SEQ ID NO:483 is a clone designated herein as "DNA96850-2705".
  • Figure 484 shows the amino acid sequence (SEQ ID NO: 484) derived from the coding sequence of SEQ ID NO:483 shown in Figure 483.
  • Figure 485 shows a nucleotide sequence (SEQ ID NO:485) of a native sequence PR04433 cDNA, wherein SEQ ID NO:485 is a clone designated herein as "DNA96855-2629".
  • Figure 486 shows the amino acid sequence (SEQ ID NO:486) derived from the coding sequence of SEQ ID NO:485 shown in Figure 485.
  • Figure 487 shows a nucleotide sequence (SEQ ID NO:487) of a native sequence PR04424 cDNA, wherein SEQ ID NO:487 is a clone designated herein as "DNA96857-2636".
  • Figure 488 shows the amino acid sequence (SEQ ID NO:488) derived from the coding sequence of SEQ ID NO:487 shown in Figure 487.
  • Figure 489 shows a nucleotide sequence (SEQ ID NO:489) of a native sequence PRO6017 cDNA, wherein SEQ ID NO:489 is a clone designated herein as "DNA96860-2700".
  • Figure 490 shows the amino acid sequence (SEQ ID NO:490) derived from the coding sequence of SEQ ID NO:489 shown in Figure 489.
  • Figure 491 shows a nucleotide sequence (SEQ ID NO:491) of a native sequence PR019563 cDNA, wherein SEQ ID NO:491 is a clone designated herein as "DNA96861-2844".
  • Figure 492 shows the amino acid sequence (SEQ ID NO: 492) derived from the coding sequence of SEQ ID NO:491 shown in Figure 491.
  • Figure 493 shows a nucleotide sequence (SEQ ID NO:493) of a native sequence PRO6015 cDNA, wherein SEQ ID NO:493 is a clone designated herein as "DNA96866-2698".
  • Figure 494 shows the amino acid sequence (SEQ ID NO:494) derived from the coding sequence of SEQ ID NO:493 shown in Figure 493.
  • Figure 495 shows a nucleotide sequence (SEQ ID NO:495) of a native sequence PR05779 cDNA, wherein SEQ ID NO:495 is a clone designated herein as "DNA96870-2676".
  • Figure 496 shows the amino acid sequence (SEQ ID NO: 496) derived from the coding sequence of SEQ
  • Figure 497 shows a nucleotide sequence (SEQ ID NO:497) of a native sequence PR05776 cDNA, wherein SEQ ID NO:497 is a clone designated herein as "DNA96872-2674".
  • Figure 498 shows the amino acid sequence (SEQ ID NO:498) derived from the coding sequence of SEQ ID NO:497 shown in Figure 497.
  • Figure 499 show ' s a nucleotide sequence (SEQ ID NO:499) of a native sequence PRO4430 cDNA, wherein SEQ ID NO: 499 is a clone designated herein as "DNA96878-2626".
  • Figure 500 shows the amino acid sequence (SEQ ID NO: 500) derived from the coding sequence of SEQ ID NO.-499 shown in Figure 499.
  • Figure 501 shows a nucleotide sequence (SEQ ID NO:501) of a native sequence PR04421 cDNA, wherein SEQ ID NO:501 is a clone designated herein as "DNA96879-2619".
  • Figure 502 shows the amino acid sequence (SEQ ID NO: 502) derived from the coding sequence of SEQ ID NO:501 shown in Figure 501.
  • Figure 503 shows a nucleotide sequence (SEQ ID NO: 503) of a native sequence PR04499 cDNA, wherein SEQ ID NO:503 is a clone designated herein as "DNA96889-2641 " .
  • Figure 504 shows the amino acid sequence (SEQ ID NO:504) derived from the coding sequence of SEQ ID NO:503 shown in Figure 503.
  • Figure 505 shows a nucleotide sequence (SEQ ID NO:505) of a native sequence PR04423 cDNA, wherein SEQ ID NO:505 is a clone designated herein as "DNA96893-2621".
  • Figure 506 shows the amino acid sequence (SEQ ID NO: 506) derived from the coding sequence of SEQ ID NO:505 shown in Figure 505.
  • Figure 507 shows a nucleotide sequence (SEQ ID NO:507) of a native sequence PR05998 cDNA, wherein SEQ ID NO:507 is a clone designated herein as "DNA96897-2688".
  • Figure 508 shows the amino acid sequence (SEQ ID NO: 508) derived from the coding sequence of SEQ ID NO:507 shown in Figure 507.
  • Figure 509 shows a nucleotide sequence (SEQ ID NO:509) of a native sequence PRO4501 cDNA, wherein SEQ ID NO:509 is a clone designated herein as "DNA98564-2643".
  • Figure 510 shows the amino acid sequence (SEQ ID NO:510) derived from the coding sequence of SEQ
  • Figure 511 shows a nucleotide sequence (SEQ ID NO:511) of a native sequence PRO6240 cDNA, wherein SEQ ID NO:511 is a clone designated herein as "DNA107443-2718".
  • Figure 512 shows the amino acid sequence (SEQ ID NO:512) derived from the coding sequence of SEQ ID NO:511 shown in Figure 511.
  • Figure 513 shows a nucleotide sequence (SEQ ID NO:513) of a native sequence PR06245 cDNA, wherein SEQ ID NO:513 is a clone designated herein as "DNA107786-2723".
  • Figure 514 shows the amino acid sequence (SEQ ID NO:514) derived from the coding sequence of SEQ ID NO:513 shown in Figure 513.
  • Figure 515 shows a nucleotide sequence (SEQ ID NO:515) of a native sequence PR06175 cDNA, wherein SEQ ID NO:515 is a clone designated herein as "DNA108682-2712".
  • Figure 516 shows the amino acid sequence (SEQ ID NO:516) derived from the coding sequence of SEQ ID NO:515 shown in Figure 515.
  • Figure 517 shows a nucleotide sequence (SEQ ID NO:517) of a native sequence PR09742 cDNA, wherein SEQ ID NO:517 is a clone designated herein as "DNA108684-2761 " .
  • Figure 518 shows the amino acid sequence (SEQ ID NO:518) derived from the coding sequence of SEQ ID NO:517 shown in Figure 517.
  • Figure 519 shows a nucleotide sequence (SEQ ID NO:519) of a native sequence PR07179 cDNA, wherein SEQ ID NO:519 is a clone designated herein as "DNA108701-2749".
  • Figure 520 shows the amino acid sequence (SEQ ID NO: 520) derived from the coding sequence of SEQ
  • Figure 521 shows a nucleotide sequence (SEQ ID NO:521) of a native sequence PR06239 cDNA, wherein SEQ ID NO:521 is a clone designated herein as "DNA108720-2717".
  • Figure 522 shows the amino acid sequence (SEQ ID NO: 522) derived from the coding sequence of SEQ ID NO:521 shown in Figure 521.
  • Figure 523 shows a nucleotide sequence (SEQ ID NO: 523) of a native sequence PR06493 cDNA, wherein SEQ ID NO:523 is a clone designated herein as "DNA108726-2729".
  • Figure 524 shows the amino acid sequence (SEQ ID NO: 524) derived from the coding sequence of SEQ ID NO: 523 shown in Figure 523.
  • Figures 525A-525B show a nucleotide sequence (SEQ ID NO: 525) of a native sequence PR09741 cDNA, wherein SEQ ID NO:525 is a clone designated herein as "DNA108728-2760".
  • Figure 526 shows the amino acid sequence (SEQ ID NO: 526) derived from the coding sequence of SEQ ID NO:525 shown in Figures 525A-525B.
  • Figure 527 shows a nucleotide sequence (SEQ ID NO:527) of a native sequence PR09822 cDNA, wherein SEQ ID NO:527 is a clone designated herein as "DNA108738-2767".
  • Figure 528 shows the amino acid sequence (SEQ ID NO: 528) derived from the coding sequence of SEQ ID NO:527 shown in Figure 527.
  • Figure 529 shows a nucleotide sequence (SEQ ID NO: 529) of a native sequence PR06244 cDNA, wherein SEQ ID NO:529 is a clone designated herein as "DNA108743-2722".
  • Figure 530 shows the amino acid sequence (SEQ ID NO: 530) derived from the coding sequence of SEQ ID NO:529 shown in Figure 529.
  • Figure 531 shows a nucleotide sequence (SEQ ID NO: 531) of a native sequence PRO9740 cDNA, wherein SEQ ID NO:531 is a clone designated herein as "DNA108758-2759".
  • Figure 532 shows the amino acid sequence (SEQ ID NO: 532) derived from the coding sequence of SEQ ID NO:531 shown in Figure 531.
  • Figure 533 shows a nucleotide sequence (SEQ ID NO: 533) of a native sequence PR09739 cDNA, wherein SEQ ID NO:533 is a clone designated herein as "DNA108765-2758".
  • Figure 534 shows the amino acid sequence (SEQ ID NO: 534) derived from the coding sequence of SEQ
  • Figure 535 shows a nucleotide sequence (SEQ ID NO:535) of a native sequence PR07177 cDNA, wherein SEQ ID NO:535 is a clone designated herein as "DNA108783-2747".
  • Figure 536 shows the amino acid sequence (SEQ ID NO: 536) derived from the coding sequence of SEQ ID NO:535 shown in Figure 535.
  • Figure 537 shows a nucleotide sequence (SEQ ID NO:537) of a native sequence PR07178 cDNA, wherein SEQ ID NO:537 is a clone designated herein as "DNA108789-2748".
  • Figure 538 shows the amino acid sequence (SEQ ID NO:538) derived from the coding sequence of SEQ ID NO:537 shown in Figure 537.
  • Figure 539 shows a nucleotide sequence (SEQ ID NO:539) of a native sequence PR06246 cDNA, wherein SEQ ID NO:539 is a clone designated herein as "DNA108806-2724".
  • Figure 540 shows the amino acid sequence (SEQ ID NO: 540) derived from the coding sequence of SEQ ID NO:539 shown in Figure 539.
  • Figure 541 shows a nucleotide sequence (SEQ ID NO:541) of a native sequence PR06241 cDNA, wherein SEQ ID NO:541 is a clone designated herein as "DNA108936-2719".
  • Figure 542 shows the amino acid sequence (SEQ ID NO: 542) derived from the coding sequence of SEQ ID NO:541 shown in Figure 541.
  • Figure 543 shows a nucleotide sequence (SEQ ID NO:543) of a native sequence PR09835 cDNA, wherein SEQ ID NO:543 is a clone designated herein as "DNA119510-2771".
  • Figure 544 shows the amino acid sequence (SEQ ID NO: 544) derived from the coding sequence of SEQ ID NO:543 shown in Figure 543.
  • Figure 545 shows a nucleotide sequence (SEQ ID NO:545) of a native sequence PR09857 cDNA, wherein SEQ ID NO:545 is a clone designated herein as "DNA119517-2778".
  • Figure 546 shows the amino acid sequence (SEQ ID NO: 546) derived from the coding sequence of SEQ ID NO: 545 shown in Figure 545.
  • Figure 547 shows a nucleotide sequence (SEQ ID NO:547) of a native sequence PR07436 cDNA, wherein SEQ ID NO:547 is a clone designated herein as "DNA119535-2756".
  • Figure 548 shows the amino acid sequence (SEQ ID NO:548) derived from the coding sequence of SEQ
  • Figure 549 shows a nucleotide sequence (SEQ ID NO:549) of a native sequence PR09856 cDNA, wherein SEQ ID NO:549 is a clone designated herein as "DNA119537-2777".
  • Figure 550 shows the amino acid sequence (SEQ ID NO: 550) derived from the coding sequence of SEQ ID NO:549 shown in Figure 549.
  • Figure 551 shows a nucleotide sequence (SEQ ID NO:551) of a native sequence PRO19605 cDNA, wherein SEQ ID NO:551 is a clone designated herein as "DNA119714-2851".
  • Figure 552 shows the amino acid sequence (SEQ ID NO: 552) derived from the coding sequence of SEQ ID NO: 551 shown in Figure 551.
  • Figure 553 shows a nucleotide sequence (SEQ ID NO:553) of a native sequence PR09859 cDNA, wherein SEQ ID NO:553 is a clone designated herein as "DNA125170-2780".
  • Figure 554 shows the amino acid sequence (SEQ ID NO: 554) derived from the coding sequence of SEQ ID NO:553 shown in Figure 553.
  • Figure 555 shows a nucleotide sequence (SEQ ID NO:555) of a native sequence PRO12970 cDNA, wherein SEQ ID NO:555 is a clone designated herein as "DNA129594-2841".
  • Figure 556 shows the amino acid sequence (SEQ ID NO: 556) derived from the coding sequence of SEQ • ID NO: 555 shown in Figure 555.
  • Figure 557 shows a nucleotide sequence (SEQ ID NO:557) of a native sequence PR019626 cDNA, wherein SEQ ID NO:557 is a clone designated herein as "DNA129793-2857".
  • Figure 558 shows the amino acid sequence (SEQ ID NO:558) derived from the coding sequence of SEQ
  • Figure 559 shows a nucleotide sequence (SEQ ID NO:559) of a native sequence PR09833 cDNA, wherein SEQ ID NO:559 is a clone designated herein as "DNA130809-2769".
  • Figure 560 shows the amino acid sequence (SEQ ID NO: 560) derived from the coding sequence of SEQ ID NO:559 shown in Figure 559.
  • Figure 561 shows a nucleotide sequence (SEQ ID NO:561) of a native sequence PRO19670 cDNA, wherein SEQ ID NO:561 is a clone designated herein as "DNA131639-2874".
  • Figure 562 shows the amino acid sequence (SEQ ID NO: 562) derived from the coding sequence of SEQ ID NO:561 shown in Figure 561.
  • Figure 563 shows a nucleotide sequence (SEQ ID NO: 563) of a native sequence PRO 19624 cDNA, wherein SEQ ID NO:563 is a clone designated herein as "DNA131649-2855".
  • Figure 564 shows the amino acid sequence (SEQ ID NO: 564) derived from the coding sequence of SEQ ID NO:563 shown in Figure 563.
  • Figure 565 shows a nucleotide sequence (SEQ ID NO:565) of a native sequence PRO19680 cDNA, wherein SEQ ID NO:565 is a clone designated herein as "DNA131652-2876".
  • Figure 566 shows the amino acid sequence (SEQ ID NO:566) derived from the coding sequence of SEQ ID NO: 565 shown in Figure 565.
  • Figure 567 shows a nucleotide sequence (SEQ ID NO:567) of a native sequence PR019675 cDNA, wherein SEQ ID NO:567 is a clone designated herein as "DNA131658-2875".
  • Figure 568 shows the amino acid sequence (SEQ ID NO: 568) derived from the coding sequence of SEQ ID NO: 567 shown in Figure 567.
  • Figure 569 shows a nucleotide sequence (SEQ ID NO:569) of a native sequence PR09834 cDNA, wherein SEQ ID NO:569 is a clone designated herein as "DNA132162-2770".
  • Figure 570 shows the amino acid sequence (SEQ ID NO: 570) derived from the coding sequence of SEQ ID NO:569 shown in Figure 569.
  • Figure 571 shows a nucleotide sequence (SEQ ID NO:571) of a native sequence PR09744 cDNA, wherein SEQ ID NO:571 is a clone designated herein as "DNA136110-2763".
  • Figure 572 shows the amino acid sequence (SEQ ID NO: 572) derived from the coding sequence of SEQ
  • Figure 573 shows a nucleotide sequence (SEQ ID NO:573) of a native sequence PR019644 cDNA, wherein SEQ ID NO:573 is a clone designated herein as "DNA139592-2866".
  • Figure 574 shows the amino acid sequence (SEQ ID NO: 574) derived from the coding sequence of SEQ ID NO:573 shown in Figure 573.
  • Figure 575 shows a nucleotide sequence (SEQ ID NO:575) of a native sequence PR019625 cDNA, wherein SEQ ID NO:575 is a clone designated herein as "DNA139608-2856".
  • Figure 576 shows the amino acid sequence (SEQ ID NO: 576) derived from the coding sequence of SEQ ID NO:575 shown in Figure 575.
  • Figure 577 shows a nucleotide sequence (SEQ ID NO:577) of a native sequence PR019597 cDNA, wherein SEQ ID NO:577 is a clone designated herein as "DNA143292-2848".
  • Figure 578 shows the amino acid sequence (SEQ ID NO: 578) derived from the coding sequence of SEQ ID NO:577 shown in Figure 577.
  • Figure 579 shows a nucleotide sequence (SEQ ID NO:579) of a native sequence PRO16090 cDNA, wherein SEQ ID NO:579 is a clone designated herein as "DNA144844-2843 " .
  • Figure 580 shows the amino acid sequence (SEQ ID NO:580) derived from the coding sequence of SEQ ID NO:579 shown in Figure 579.
  • Figure 581 shows a nucleotide sequence (SEQ ID NO:581) of a native sequence PR019576 cDNA, wherein SEQ ID NO:581 is a clone designated herein as "DNA144857-2845".
  • Figure 582 shows the amino acid sequence (SEQ ID NO:582) derived from the coding sequence of SEQ ID NO:581 shown in Figure 581.
  • Figure 583 shows a nucleotide sequence (SEQ ID NO:583) of a native sequence PR019646 cDNA, wherein SEQ ID NO:583 is a clone designated herein as "DNA145841-2868" .
  • Figure 584 shows the amino acid sequence (SEQ ID NO:584) derived from the coding sequence of SEQ ID NO: 583 shown in Figure 583.
  • Figure 585 shows a nucleotide sequence (SEQ ID NO:585) of a native sequence PR019814 cDNA, wherein SEQ ID NO:585 is a clone designated herein as "DNA148004-2882".
  • Figure 586 shows the amino acid sequence (SEQ ID NO:586) derived from the coding sequence of SEQ
  • Figure 587 shows a nucleotide sequence (SEQ ID NO:587) of a native sequence PR019669 cDNA, wherein SEQ ID NO:587 is a clone designated herein as "DNA149893-2873".
  • Figure 588 shows the .amino acid sequence (SEQ ID NO:588) derived from the coding sequence of SEQ ID NO:587 shown in Figure 587.
  • Figure 589 shows a nucleotide sequence (SEQ ID NO:589) of a native sequence PR019818 cDNA, wherein SEQ ID NO:589 is a clone designated herein as "DNA149930-2884".
  • Figure 590 shows the amino acid sequence (SEQ ID NO: 590) derived from the coding sequence of SEQ ID NO:589 shown in Figure 589.
  • Figure 591 shows a nucleotide sequence (SEQ ID NO:591) of a native sequence PRO20088 cDNA, wherein SEQ ID NO:591 is a clone designated herein as "DNA150157-2898".
  • Figure 592 shows the amino acid sequence (SEQ ID NO: 592) derived from the coding sequence of SEQ ID NO:591 shown in Figure 591.
  • Figure 593 shows a nucleotide sequence (SEQ ID NO:593) of a native sequence PRO16089 cDNA, wherein SEQ ID NO:593 is a clone designated herein as "DNA 150163-2842" .
  • Figure 594 shows the amino acid sequence (SEQ ID NO: 594) derived from the coding sequence of SEQ ID NO:593 shown in Figure 593.
  • Figure 595 shows a nucleotide sequence (SEQ ID NO:595) of a native sequence PRO20025 cDNA, wherein SEQ ID NO:595 is a clone designated herein as "DNA153579-2894".
  • Figure 596 shows the amino acid sequence (SEQ ID NO:596) derived from the coding sequence of SEQ
  • Figure 597 shows a nucleotide sequence (SEQ ID NO: 597) of a native sequence PRO20040 cDNA, wherein SEQ ID NO:597 is a clone designated herein as "DNA 164625-2890".
  • Figure 598 shows the amino acid sequence (SEQ ID NO:598) derived from the coding sequence of SEQ ID NO:597 shown in Figure 597.
  • Figure 599 shows anucleotide sequence (SEQ ID NO:599) of anative sequence PR0791 cDNA, wherein SEQ ID NO:599 is a clone designated herein as "DNA57838-1337".
  • Figure 600 shows the amino acid sequence (SEQ ID NO: 600) derived from the coding sequence of SEQ ID NO:599 shown in Figure 599.
  • Figure 601 shows a nucleotide sequence (SEQ ID NO:601) of a native sequence PR01131 cDNA, wherein SEQ ID NO:601 is a clone designated herein as "DNA59777-1480".
  • Figure 602 shows the amino acid sequence (SEQ ID NO: 602) derived from the coding sequence of SEQ ID NO:601 shown in Figure 601.
  • Figure 603 shows a nucleotide sequence (SEQ ID NO:603) of a native sequence PR01343 cDNA, wherein SEQ ID NO: 603 is a clone designated herein as "DNA66675-1587".
  • Figure 604 shows the amino acid sequence (SEQ ID NO: 604) derived from the coding sequence of SEQ ID NO:603 shown in Figure 603.
  • Figure 605 shows a nucleotide sequence (SEQ ID NO:605) of a native sequence PRO1760 cDNA, wherein SEQ ID NO:605 is a clone designated herein as "DNA76532-1702".
  • Figure 606 shows the amino acid sequence (SEQ ID NO: 606) derived from the coding sequence of SEQ ID NO:605 shown in Figure 605.
  • Figure 607 shows a nucleotide sequence (SEQ ID NO: 607) of a native sequence PRO6029 cDNA, wherein SEQ ID NO:607 is a clone designated herein as "DNA 105849-2704" .
  • Figure 608 shows the amino acid sequence (SEQ ID NO: 608) derived from the coding sequence of SEQ ID NO:607 shown in Figure 607.
  • Figure 609 shows a nucleotide sequence (SEQ ID NO: 609) of a native sequence PRO 1801 cDNA, wherein SEQ ID NO:609 is a clone designated herein as "DNA83500-2506".
  • Figure 610 shows the amino acid sequence (SEQ ID NO:610) derived from the coding sequence of SEQ
  • PRO polypeptide and "PRO” as used herein and when immediately followed by a numerical designation refer to various polypeptides, wherein the complete designation (i.e. , PRO/number) refers to specific polypeptide sequences as described herein.
  • PRO/number polypeptide and “PRO/number” wherein the term “number” is provided as an actual numerical designation as used herein encompass native sequence polypeptides and polypeptide variants (which are further defined herein) .
  • the PRO polypeptides described herein may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods.
  • PRO polypeptide refers to each individual PRO/number polypeptide disclosed herein. All disclosures in this specification which refer to the "PRO polypeptide” refer to each of the polypeptides individually as well as jointly. For example, descriptions of the preparation of, purification of, derivation of, formation of antibodies to or against, administration of, compositions containing, treatment of a disease with, etc., pertain to each polypeptide of the invention individually.
  • PRO polypeptide also includes variants of the PRO/number polypeptides disclosed herein.
  • a “native sequence PRO polypeptide” comprises a polypeptide having the same amino acid sequence as the corresponding PRO polypeptide derived from nature. Such native sequence PRO polypeptides can be isolated from nature or can be produced by recombinant or synthetic means.
  • the term "native sequence PRO polypeptide” specifically encompasses naturally-occurring truncated or secreted forms of the specific PRO polypeptide (e.g. , an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the polypeptide.
  • the native sequence PRO polypeptides disclosed herein are mature or full-length native sequence polypeptides comprising the full-length amino acids sequences shown in the accompanying figures. Start and stop codons are shown in bold font and underlined in the figures. However, while the PRO polypeptide disclosed in the accompanying figures are shown to begin with methionine residues designated herein as amino acid position 1 in the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the amino acid position 1 in the figures may be employed as the starting amino acid residue for the PRO polypeptides.
  • the PRO polypeptide "extracellular domain” or “ECD” refers to a form of the PRO polypeptide which is essentially free of the tr.ansmembrane and cytoplasmic domains. Ordinarily, a PRO polypeptide ECD will have less than 1 % of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5 % of such domains. It will be understood that any transmembrane domains identified for the PRO polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain as initially identified herein.
  • an extracellular domain of a PRO polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain extracellular domain boundary as identified in the Examples or specification and such polypeptides, with or without the associated signal peptide, and nucleic acid encoding them, are comtemplated by the present invention.
  • cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species.
  • These mature polypeptides, where the signal peptide is cleaved within no more than about 5 amino acids on either side of the C-terminal boundary of the signal peptide as identified herein, and the polynucleotides encoding them, are contemplated by the present invention.
  • PRO polypeptide variant means an active PRO polypeptide as defined above or below having at least about 80% amino acid sequence identity with a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein.
  • Such PRO polypeptide variants include, for instance, PRO polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the full- length native amino acid sequence.
  • a PRO polypeptide variant will have at least about 80% amino acid sequence identity, alternatively at least about 81 % amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a full
  • PRO variant polypeptides are at least about 10 amino acids in length, alternatively at least about 20 amino acids in length, alternatively at least about 30 amino acids in length, alternatively at least about 40 amino acids in length, alternatively at least about 50 amino acids in length, alternatively at least about 60 amino acids in length, alternatively at least about 70 amino acids in length, alternatively at least about 80 amino acids in length, alternatively at least about 90 amino acids in length, alternatively at least about 100 amino acids in length, alternatively at least about 150 amino acids in length, alternatively at least about 200 amino acids in length, alternatively at least about 300 amino acids in length, or more.
  • Percent (%) amino acid sequence identity with respect to the PRO polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific PRO polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below.
  • the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
  • the ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below.
  • the ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
  • % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows:
  • Tables 2 and 3 demonstrate how to calculate the % amino acid sequence identity of the amino acid sequence designated "Comparison Protein” to the amino acid sequence designated "PRO", wherein “PRO” represents the amino acid sequence of a hypothetical PRO polypeptide of interest, “ Comparison Protein” represents the amino acid sequence of a polypeptide against which the "PRO” polypeptide of interest is being compared, and "X, " Y” and “Z” each represent different hypothetical amino acid residues. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.
  • a % amino acid sequence identity value is determined by dividing (a) the number of matching identical amino acid residues between the amino acid sequence of the PRO polypeptide of interest having a sequence derived from the native PRO polypeptide and the comparison amino acid sequence of interest (i.e., the sequence against which the PRO polypeptide of interest is being compared which may be a PRO variant polypeptide) as determined by WU-BLAST-2 by (b) the total number of amino acid residues of the PRO polypeptide of interest.
  • amino acid sequence A is the comparison amino acid sequence of interest and the amino acid sequence B is the amino acid sequence of the PRO polypeptide of interest.
  • Percent amino acid sequence identity may also be dete ⁇ nined using the sequence comparison program
  • NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)).
  • the NCBI-BLAST2 sequence comparison program may be downloaded from http://www.ncbi.nlm.nih.gov or otherwise obtained from the National Institute of Health, Bethesda, MD .
  • % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows:
  • PRO variant polynucleotide or "PRO variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PRO polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein.
  • a PRO variant polynucleotide will have at least about 80% nucleic acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 82 % nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88 % nucleic acid sequence identity, alternatively at least about 89 % nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95 % nucleic acid sequence identity, alternatively at least about at least about
  • PRO variant polynucleotides are at least about 30 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 210 nucleotides in length, alternatively at least about 240 nucleotides in length, alternatively at least about 270 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 900 nucleotides in length, or more.
  • Percent (%) nucleic acid sequence identity with respect to PRO-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the PRO nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software.
  • % nucleic acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below.
  • the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
  • the ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below.
  • the ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
  • the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D is calculated as follows:
  • Tables 4 and 5 demonstrate how to calculate the % nucleic acid sequence identity of the nucleic acid sequence designated "Comparison DNA” to the nucleic acid sequence designated "PRO-DNA”, wherein "PRO-DNA” represents a hypothetical PRO-encoding nucleic acid sequence of interest, “Comparison DNA” represents the nucleotide sequence of a nucleic acid molecule against which the "PRO-DNA” nucleic acid molecule of interest is being compared, and "N", “L” and “V each represent different hypothetical nucleotides.
  • a % nucleic acid sequence identity value is determined by dividing (a) the number of matching identical nucleotides between the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest having a sequence derived from the native sequence PRO polypeptide-encoding nucleic acid and the comparison nucleic acid molecule of interest (i.e. , the sequence against which the PRO polypeptide-encoding nucleic acid molecule of interest is being compared which may be a variant PRO polynucleotide) as determined by WU-BLAST-2 by (b) the total number of nucleotides of the PRO polypeptide-encoding nucleic acid molecule of interest.
  • Percent nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)).
  • NCBI-BLAST2 sequence comparison program may be downloaded from http://www.ncbi.nlm.nih.gov or otherwise obtained from the National Institute of Health, Bethesda, MD .
  • % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D is calculated as follows:
  • PRO variant polynucleotides are nucleic acid molecules that encode an active PRO polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding a full-length PRO polypeptide as disclosed herein.
  • PRO variant polypeptides may be those that are encoded by a PRO variant polynucleotide.
  • Isolated, when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.
  • the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain.
  • Isolated polypeptide includes polypeptide in situ within recombinant cells, since at least one component of the PRO polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.
  • An "isolated" PRO polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding nucleic acid.
  • An isolated polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the specific polypeptide- encoding nucleic acid molecule as it exists in natural cells.
  • an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.
  • control sequences refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism.
  • the control sequences that are suitable for prokaryotes include a promoter, optionally an operator sequence, and a ribosome binding site.
  • Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
  • Nucleic acid is "operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
  • DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • antibody is used in the broadest sense and specifically covers, for example, single anti-PRO monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-PRO antibody compositions withpolyepitopic specificity, single chain anti-PRO antibodies, and fragments of anti-PRO antibodies (see below).
  • monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. , the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.
  • “Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology. Wiley Interscience Publishers, (1995).
  • Stringent conditions or “high stringency conditions” , as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1 % sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1 % sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 ⁇ g/ml), 0.1 % SDS, and 10%
  • Moderately stringent conditions may be identified as described by Sambrook et al . , Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent that those described above.
  • moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C.
  • the skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
  • epitope tagged when used herein refers to a chimeric polypeptide comprising a PRO polypeptide fused to a "tag polypeptide".
  • the tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused.
  • the tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes.
  • Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).
  • immunoadhesin designates antibody-like molecules which combine the binding specificity of a heterologous protein (an “adhesin”) with the effector functions of immunoglobulin constant domains .
  • the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is “heterologous"), and an immunoglobulin constant domain 'sequence.
  • the adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand.
  • the immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.
  • immunoglobulin such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.
  • Active or “activity” for the purposes herein refers to form(s) of a PRO polypeptide which retain a biological and/or an immunological activity of native or naturally-occurring PRO, wherein "biological” activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring PRO other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO and an "immunological” activity refers to the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO.
  • antagonist is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native PRO polypeptide disclosed herein.
  • agonist is used in the broadest sense and includes any molecule that mimics a biological activity of a native PRO polypeptide disclosed herein.
  • Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments or amino acid sequence variants of native PRO polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc.
  • Methods for identifying agonists or antagonists of a PRO polypeptide may comprise contacting a PRO polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the PRO polypeptide.
  • Treatment refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder.
  • Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.
  • Chronic administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time.
  • Intermittent administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.
  • “Mammal” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human.
  • Administration "in combination with" one or more further therapeutic agents includes simultaneous
  • Carriers as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution.
  • physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEENTM, polyethylene glycol (PEG), and PLURONICSTM.
  • buffers such as phosphate, citrate, and other organic acids
  • antioxidants including ascorbic acid
  • proteins such as serum albumin,
  • Antibody fragments comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody.
  • antibody fragments include Fab, Fab', F(ab') 2 , and Fv fragments; diabodies; linear antibodies (Zapata et al., Protein Eng. 8(10): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
  • Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual "Fc” fragment, a designation reflecting the ability to crystallize readily.
  • Pepsin treatment yields an F(ab') 2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen.
  • Fv is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen- binding site on the surface of the V H -V L dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
  • the Fab fragment also contains the constant domain of the light chain and the first constant domain (CHI) of the heavy chain.
  • Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH 1 domain including one or more cysteines from the antibody hinge region.
  • Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.
  • F(ab') 2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
  • the "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains.
  • immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGl, IgG2, IgG3, IgG4, IgA, and IgA2.
  • Single-chain Fv or “sFv” antibody fragments comprise the V H and V L domains of antibody, wherein these domains are present in a single polypeptide chain.
  • the Fv polypeptide further comprises a polypeptide linker between the V H and V L domains which enables the sFv to form the desired structure for antigen binding.
  • diabodies refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (V H ) coimected to a light-chain variable domain (V L ) in the same polypeptide chain (V H -V L ).
  • V H heavy-chain variable domain
  • V L light-chain variable domain
  • the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites.
  • Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA. 90:6444-6448 (1993).
  • an “isolated” antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
  • the antibody will be purified (1) to greater than 95 % by weight of antibody as determined by the Lowry method, and most preferably more than 99 % by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
  • Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
  • An antibody that "specifically binds to” or is “specific for” a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.
  • label when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody.
  • the label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.
  • solid phase is meant a non-aqueous matrix to which the antibody of the present invention can adhere.
  • solid phases encompassed herein include those formed partially or entirely of glass (e.g. , controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones.
  • the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g. , an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.
  • a “liposome” is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as a PRO polypeptide or antibody thereto) to a mammal.
  • a drug such as a PRO polypeptide or antibody thereto
  • the components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.
  • a "small molecule” is defined herein to have a molecular weight below about 500 Daltons.
  • an “effective amount” of a polypeptide disclosed herein or an agonist or antagonist thereof is an amount sufficient to carry out a specifically stated purpose.
  • An “effective amount” may be determined empirically and in a routine manner, in relation to the stated purpose. Table 1
  • filel and file2 are two dna or two protein sequences.
  • Max file length is 65535 (limited by unsigned short x in the jmp struct)
  • a sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
  • the program may create a tmp file in /tmp to hold info about traceback.
  • dumpblockO * putline() put out a line (name, [num.], seq, [num]): dumpblockO
  • static nm matches in core — for checking */ static lmax; /* lengths of stripped file names */ static ij[2]; /* jmp index for a path */ static nc[2]; /* number at start of current line */ static ni[2]; /* current elem number — for gapping */ static siz[2]; static char *ps[2]; /* ptr to current element */ static char *po[2]; /* ptr to next output char slot */ static char oouutt[[22]][[lP_LINE]; /* output line */ static char star[P ] ⁇ ]; /* set by stars() *//
  • *po[i] *ps[i]; if (islower(*ps[i]))
  • *ps[i] toupper(*ps[i]); po[i]+ + ; ps[i] + +;
  • *py+ + *px; else if (islower(*px))
  • *py+ + tou ⁇ per(*px); if (index("ATGCU",*(py-l))) natgc+ + ; ⁇ ⁇
  • the present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO polypeptides.
  • cDNAs encoding various PRO polypeptides have been identified and isolated, as disclosed in further detail in the Examples below. It is noted that proteins produced in separate expression rounds may be given different PRO numbers but the UNQ number is unique for any given DNA and the encoded protein, and will not be changed.
  • PRO/number the protein encoded by the full length native nucleic acid molecules disclosed herein as well as all further native homologues and variants included in the foregoing definition of PRO, will be referred to as "PRO/number", regardless of their origin or mode of preparation.
  • PRO Polypeptide Variants In addition to the full-length native sequence PRO polypeptides described herein, it is contemplated that
  • PRO variants can be prepared.
  • PRO variants can be prepared by introducing appropriate nucleotide changes into the PRO DNA, and/or by synthesis of the desired PRO polypeptide.
  • amino acid changes may alter post-translational processes of the PRO, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.
  • Variations in the native full-length sequence PRO or in v. rious domains of the PRO described herein can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934.
  • Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO that results in a change in the amino acid sequence of the PRO as compared with the native sequence PRO.
  • the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO .
  • Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the PRO with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology.
  • Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e.
  • Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions , deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.
  • PRO polypeptide fragments are provided herein. Such fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native protein. Certain fragments lack amino acid residues that are not essential for a desired biological activity of the PRO polypeptide.
  • PRO fragments may be prepared by any of a number of conventional techniques. Desired peptide fragments may be chemically synthesized. An alternative approach involves generating PRO fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired polypeptide fragment, by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the DNA fragment are employed at the 5' and 3' primers in the PCR. Preferably, PRO polypeptide fragments share at least one biological and/or immunological activity with the native PRO polypeptide disclosed herein.
  • PCR polymerase chain reaction
  • conservative substitutions of interest are shown in Table 6 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and the products screened.
  • Substantial modifications in function or immunological identity of the PRO polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
  • Naturally occurring residues are divided into groups based on common side-chain properties: (1) hydrophobic: norleucine, met, ala, val, leu, ile;
  • Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.
  • Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence.
  • preferred scanning amino acids are relatively small, neutral amino acids.
  • amino acids include alanine, glycine, serine, and cysteine.
  • Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main- chain conformation of the variant [Cunningham and Wells, Science. 244: 1081-1085 (1989)].
  • Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins. (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol.. 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.
  • Covalent modifications of PRO are included within the scope of this invention.
  • One type of covalent modification includes reacting targeted amino acid residues of a PRO polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of the PRO.
  • Derivatization with bifunctional agents is useful, for instance, for crosslinking PRO to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO antibodies, and vice-versa.
  • crosslinking agents include, e.g., l,l-bis(diazoacetyl)-2-phenylefhane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-ditluobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-l,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate.
  • Another type of covalent modification of the PRO polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide.
  • "Altering the native glycosylation pattern” is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence PRO (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence PRO.
  • the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.
  • Addition of glycosylation sites to the PRO polypeptide may be accomplished by altering the amino acid sequence.
  • the alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence PRO (for O-linked glycosylation sites).
  • the PRO amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the PRO polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.
  • Another means of increasing the number of carbohydrate moieties on the PRO polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem.. pp. 259-306 (1981).
  • Removal of carbohydrate moieties present on the PRO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation.
  • Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem.. 118: 131 (1981).
  • Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. EnzvmoL. 138:350 (1987).
  • PRO polypeptide comprises linking the PRO polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.
  • PEG polyethylene glycol
  • the PRO of the present invention may also be modified in a way to form a chimeric molecule comprising
  • PRO fused to another, heterologous polypeptide or amino acid sequence.
  • such a chimeric molecule comprises a fusion of the PRO with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind.
  • the epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO. The presence of such epitope-tagged forms of the PRO can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the PRO to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag.
  • tag polypeptides and their respective antibodies are well known in the art.
  • poly-histidine poly-his
  • poly-histidine-glycine poly-his-gly
  • flu HA tag polypeptide and its antibody 12CA5 [Field et al. , Mol. Cell. Biol.. 8:2159-2165 (1988)]
  • c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology. 5:3610-3616 (1985)]
  • the flu HA tag polypeptide and its antibody 12CA5 [Field et al. , Mol. Cell. Biol.. 8:2159-2165 (1988)]
  • c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology. 5:3610-3616 (1985)]
  • the flu HA tag polypeptide and its antibody 12CA5 [Field et
  • tag polypeptides include the Flag-peptide [Hopp et al. , BioTechnology, 6: 1204-1210 (1988)] ; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an ⁇ -tubulin epitope peptide [Skinner et al., J. Biol. Chem.. 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA. 87:6393-6397 (1990)].
  • the chimeric molecule may comprise a fusion of the PRO with an immunoglobulin or a particular region of an immunoglobulin.
  • an immunoglobulin also referred to as an ''immunoadhesin
  • a fusion could be to the Fc region of an IgG molecule.
  • the Ig fusions preferably include the substitution of a soluble (tr ⁇ smembrane domain deleted or inactivated) form of a PRO polypeptide in place of at least one variable region within an Ig molecule.
  • the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CHI, CH2 and CH3 regions of an IgGl molecule.
  • PRO sequence or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g. , Stewart et al. , Solid- Phase Peptide Synthesis. W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc. 85:2149-2154 (1963)]. In vitro protein synthesis may be performed using manual techniques or by automation.
  • Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions.
  • Various portions of the PRO may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PRO.
  • DNA encoding PRO may be obtained from a cDNA library prepared from tissue believed to possess the PRO mRNA and to express it at a detectable level. Accordingly, human PRO DNA can be conveniently obtained from a cDNA library prepared from human tissue, such as described in the Examples.
  • the PRO-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).
  • Probes such as antibodies to the PRO or oligonucleotides of at least about 20-80 bases
  • Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989).
  • An alternative means to isolate the gene encoding PRO is to use PCR methodology [Sambrook et al., supra: Dieffenbach et al. , PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press * , 1995)] .
  • the oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized.
  • the oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like 32 P-labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., supra.
  • Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein. Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.
  • Host cells are transfected or transformed with expression or cloning vectors described herein for PRO production and cultured in conventions nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
  • the culture conditions such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach. M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.
  • Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example, CaCl 2 , CaP0 4 , liposome-mediated and electroporation.
  • transformation is performed using standard techniques appropriate to such cells.
  • the calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes.
  • Infection with Agrobacterium tumefatiens is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989.
  • polybrene polyornithine
  • polybrene polyornithine
  • transforming mammalian cells see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).
  • Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells.
  • Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as E. coli.
  • Various E. coli strains are publicly available, such as E. coli K12 strain MM294 (ATCC 31,446); E. coli X1776 (ATCC 31,537); E. coli strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635).
  • suitable prokaryotic host cells include Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis (e.g., B. Mcheniformis 41P disclosed in DD 266,710 published 12 April 1989), Pseudomonas such as P. aeruginosa, and Streptomyces. These examples are illustrative rather than limiting.
  • Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations.
  • the host cell secretes minimal amounts of proteolytic enzymes.
  • strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including E. coli W3110 strain 1A2, which has the complete genotype tonA ; E. coli W3110 strain 9E4, which has the complete genotype tonA ptr3; E. coli W3110 strain 27C7 (ATCC 55,244), which has the complete genotype tonAptr3phoA E15 (argF-lac)169 degP ompTkan r ; E.
  • E. coli W3110 strain 37D6 which has the complete genotype tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kan r ; E. coli W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant degP deletion mutation; and an E. coli strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990.
  • in vitro methods of cloning e.g., PCR or other nucleic acid polymerase reactions, are suitable.
  • eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for PRO-encoding vectors.
  • Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism.
  • Others include Schizosaccharomycespom.be (Beach and Nurse, Nature. 290: 140 [1981]; EP 139,383 published 2 May 1985); Kluyveromyces hosts (U.S. Patent No. 4,943,529; Fleer et al., Bio/Technology. 9:968-975 (1991)) such as, e.g., K.
  • lactis (MW98-8C, CBS683, CBS4574; Louvencourt et al., J. Bacteriol.. 154(2):737-742 [1983]), K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906; Van den Berg et al., Bio/Technology, 8:135 (1990)), K. thermotolerans, and K. marxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070; Sreekrishna et al., J.
  • Candida Trichoderma reesia (EP 244,234); Neurospora crassa (Case et al., Proc. Natl. Acad. Sci. USA, 76:5259-5263 [1979]); Schwanniomyces such as Schwanniomyces occidentalis (EP 394,538 published 31 October 1990); and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium (WO 91/00357 published 10 January 1991), and Aspergillus hosts such as A. nidulans (Ballance et al., Biochem. Biophys. Res. Commun..
  • Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of Hansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Mefhylotrophs. 269 (1982).
  • Suitable host cells for the expression of glycosylated PRO are derived from multicellular organisms.
  • invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells.
  • useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al. , J. Gen Virol.. 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA.
  • mice sertoli cells TM4, Mather, Biol. Reprod..23:243-251 (1980)
  • human lung cells W138, ATCC CCL 75
  • human liver cells Hep G2, HB 8065
  • mouse mammary tumor MMT 060562, ATCC CCL51. The selection of the appropriate host cell is deemed to be within the skill in the art.
  • the nucleic acid (e.g., cDNA or genomic DNA) encoding PRO may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression.
  • a replicable vector for cloning (amplification of the DNA) or for expression.
  • the vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage.
  • the appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art.
  • Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.
  • the PRO may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide.
  • a heterologous polypeptide which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide.
  • the signal sequence may be a component of the vector, or it may be a part of the PRO-encoding DNA that is inserted into the vector.
  • the signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders.
  • the signal sequence may be, e.g. , the yeast invertase leader, alpha factor leader (including Saccharomyces and Kluyveromyces ⁇ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the C. albicans glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990.
  • mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.
  • Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses.
  • the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 ⁇ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.
  • Selection genes will typically contain a selection gene, also termed a selectable marker.
  • Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
  • suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PRO-encoding nucleic acid, such as DHFR or thymidine kinase.
  • DHFR DHFR activity
  • yeast plasmid YRp7 yeast plasmid YRp7
  • the trpl gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics. 85:12 (1977)].
  • Expression and cloning vectors usually contain a promoter operably linked to the PRO-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the ⁇ -lactamase and lactose promoter systems [Chang et al., Nature, 275:615 (1978); Goeddel et al., Nature.
  • Suitable promoting sequences for use with yeast hosts include the promoters for 3- phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem.. 255:2073 (1980)] or other glycolytic enzymes [Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry.
  • enolase such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6- phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
  • enolase such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6- phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
  • yeast promoters which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3- phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.
  • PRO transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.
  • viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, he
  • Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription.
  • Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, ⁇ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus.
  • Examples include the SV40 enhancer on the late side of the replication origin (bp 100- 270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • the enhancer may be spliced into the vector at a position 5' or 3' to the PRO coding sequence, but is preferably located at a site 5' from the promoter.
  • Expression vectors used in eukaryotic host cells will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding PRO.
  • Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA. 77:5201-5205 (1980)], dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein.
  • antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.
  • Gene expression may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product.
  • Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence PRO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PRO DNA and encoding a specific antibody epitope.
  • PRO may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of PRO can be disrupted by various physical or chemical means, such as freeze-fhaw cycling, sonication, mechanical disruption, or cell lysing agents.
  • a suitable detergent solution e.g. Triton-X 100
  • Cells employed in expression of PRO can be disrupted by various physical or chemical means, such as freeze-fhaw cycling, sonication, mechanical disruption, or cell lysing agents.
  • the following procedures are exemplary of suitable purification procedures : by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, SephadexG-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope- tagged forms of the PRO .
  • PRO Nucleotide sequences (or their complement) encoding PRO have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA and DNA.
  • PRO nucleic acid will also be useful for the preparation of PRO polypeptides by the recombinant techniques described herein.
  • the full-length native sequence PRO gene, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the full-length PRO cDNA or to isolate still other cDNAs (for instance, those encoding naturally-occurring variants of PRO or PRO from other species) which have a desired sequence identity to the native PRO sequence disclosed herein.
  • the length of the probes will be about 20 to about 50 bases.
  • the hybridization probes may be derived from at least partially novel regions of the full length native nucleotide sequence wherein those regions may be determined without undue experimentation or from genomic sequences including promoters, enhancer elements and introns of native sequence PRO.
  • a screening method will comprise isolating the coding region of the PRO gene using the known DNA sequence to synthesize a selected probe of about 40 bases.
  • Hybridization probes may be labeled by a variety of labels, including radionucleotides such as 32 P or 35 S, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the PRO gene of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes to. Hybridization techniques are described in further detail in the Examples below.
  • antisense or sense oligonucleotides comprising a singe-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target PRO mRNA (sense) or PRO DNA (antisense) sequences.
  • Antisense or sense oligonucleotides comprise a fragment of the coding region of PRO DNA. Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to 30 nucleotides.
  • Stein and Cohen Cancer Res. 48:2659, 1988
  • van der Krol et al. BioTechniques 6:958, 1988.
  • binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block transcription or translation of the target sequence by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means.
  • the antisense oligonucleotides thus may be used to block expression of PRO proteins.
  • Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO 91/06629) and wherein such sugar linkages are resistant to endogenous nucleases.
  • Such oligonucleotides with resistant sugar linkages are stable in vivo (i.e., capable of resisting enzymatic degradation) but retain sequence specificity to be able to bind to target nucleotide sequences.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de nouveaux polypeptides et des molécules d'acides nucléiques codant ces polypeptides ainsi que des vecteurs et des cellules hôtes comprenant ces séquences d'acides nucléiques, des molécules de polypeptides chimères comprenant les polypeptides de l'invention fusionnés à des séquences de polypeptides hétérologues, des anticorps se liant aux polypeptides de la présente invention et des procédés pour produire les polypeptides de la présente invention.
PCT/US2001/006520 1996-11-06 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides WO2001068848A2 (fr)

Priority Applications (1288)

Application Number Priority Date Filing Date Title
AU6802801A AU6802801A (en) 2000-03-01 2000-11-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2001567332A JP2004508805A (ja) 2000-03-01 2001-02-28 分泌及び膜貫通ポリペプチドとそれをコードする核酸
CA002401448A CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
AU2001268028A AU2001268028A1 (en) 2000-03-01 2001-02-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP01945919A EP1259614A2 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US09/816,744 US6579520B2 (en) 1998-05-15 2001-03-22 IL-17 related mammalian cytokine polypeptides (IL-17E)
US09/866,028 US6642360B2 (en) 1997-12-03 2001-05-25 Secreted polypeptides that stimulate release of proteoglycans from cartilage
AU6531101A AU6531101A (en) 2000-06-02 2001-05-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP05024027A EP1666596A1 (fr) 2000-06-02 2001-06-01 Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP04005726A EP1489095A1 (fr) 2000-06-02 2001-06-01 Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer
CA002591841A CA2591841A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
AU2001265311A AU2001265311A1 (en) 2000-06-02 2001-06-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA002591930A CA2591930A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
EP05024038A EP1702928A3 (fr) 2000-06-02 2001-06-01 Polypeptides secrétées ou transmembranaire, ainsi que les acides nucléiques qui les codent
CA002585822A CA2585822A1 (fr) 2000-06-02 2001-06-01 Marqueur polypeptidique pro19628 pour tumeur du sein, du rectum, du colon ou du poumon et acide nucleique encodant
EP01939834A EP1286749A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
EP05024035A EP1666594A3 (fr) 2000-06-02 2001-06-01 Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer
JP2002501551A JP2004510409A (ja) 2000-06-02 2001-06-01 分泌及び膜貫通ポリペプチドとそれをコードする核酸
EP05024025A EP1666597A3 (fr) 2000-06-02 2001-06-01 Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
CA002591583A CA2591583A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
CA002410162A CA2410162A1 (fr) 2000-06-02 2001-06-01 Polypeptide pro 4332 marqueur de tumeurs du poumon, du colon, du rectum et du sein et acide nucleique codant pour ce polypeptide
EP05024032A EP1659177A3 (fr) 2000-06-02 2001-06-01 Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP05024023A EP1683864A3 (fr) 2000-06-02 2001-06-01 Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP05024030A EP1666491A1 (fr) 2000-06-02 2001-06-01 Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
CA002591656A CA2591656A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
CA002594659A CA2594659A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
CA002591929A CA2591929A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
EP05024033A EP1666493A1 (fr) 2000-06-02 2001-06-01 Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP05024031A EP1666492A1 (fr) 2000-06-02 2001-06-01 Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP05024037A EP1700867A3 (fr) 2000-06-02 2001-06-01 Polypeptide secrétée et transmembranaire, ainsi que les acides nucléiques qui les codent
CA002591814A CA2591814A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
CA002591630A CA2591630A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
EP05024034A EP1666497A3 (fr) 2000-06-02 2001-06-01 Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer
CA002591590A CA2591590A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
EP05024028A EP1686174A1 (fr) 2000-06-02 2001-06-01 Polypeptides sécrétés et transmembranaires, ainsi que les acides nucléiques codant pour ceux-ci
PCT/US2001/017800 WO2001093983A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
US09/874,503 US20020177188A1 (en) 1998-05-15 2001-06-05 IL-17 homologous polypeptides and therapeutic uses thereof
AU2001278852A AU2001278852A1 (en) 2000-06-23 2001-06-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2002505812A JP2004506413A (ja) 2000-06-23 2001-06-20 血管形成に関与する疾患の診断と治療のための組成物と方法
CA002648051A CA2648051A1 (fr) 2000-06-23 2001-06-20 Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
EP09004415A EP2168980A1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse
EP01957073A EP1309620A2 (fr) 2000-06-23 2001-06-20 Compositions et procedes de diagnose et traitement de maladies faisant intervenir l'angiogenese
PCT/US2001/019692 WO2002000690A2 (fr) 2000-06-23 2001-06-20 Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
CA002648046A CA2648046A1 (fr) 2000-06-23 2001-06-20 Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
EP08019420.2A EP2042597B1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
EP14166919.2A EP2792747A1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse
DK08019420.2T DK2042597T3 (da) 2000-06-23 2001-06-20 Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
EP09004417A EP2077276A1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse
CA2709771A CA2709771A1 (fr) 2000-06-23 2001-06-20 Compositions et methode de diagnostic et de traitement des troubles mettant en cause l'angiogenese
CA002648048A CA2648048A1 (fr) 2000-06-23 2001-06-20 Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
EP10182597A EP2275549A1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
EP09004418A EP2075253A1 (fr) 2000-06-23 2001-06-20 Méthodes et composés pour la diagnose et le traitement de troubles associés à l'angiogenèse
CA002412211A CA2412211A1 (fr) 2000-06-23 2001-06-20 Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
CA002420140A CA2420140A1 (fr) 2000-08-24 2001-06-22 Compositions et procedes de diagnostic et traitement de tumeurs
KR10-2003-7002685A KR20030029847A (ko) 2000-08-24 2001-06-22 종양의 진단 및 치료를 위한 조성물 및 방법
JP2002521524A JP2004520806A (ja) 2000-08-24 2001-06-22 腫瘍の診断と治療のための組成物と方法
MXPA03001645A MXPA03001645A (es) 2000-08-24 2001-06-22 Composiciones y metodos para el diagnostico y tratamiento de tumores.
EP04011151A EP1445317A3 (fr) 2000-08-24 2001-06-22 Compositions et procédés de diagnostic et traitement de tumeurs
EP01948667A EP1311674A2 (fr) 2000-08-24 2001-06-22 Compositions et procedes de diagnostic et traitement de tumeurs
AU2001270118A AU2001270118A1 (en) 2000-08-24 2001-06-22 Compositions and methods for the diagnosis and treatment of tumor
PCT/US2001/020118 WO2002016429A2 (fr) 2000-08-24 2001-06-22 Compositions et procedes de diagnostic et traitement de tumeurs
EP04011258A EP1445318A2 (fr) 2000-08-24 2001-06-22 Composition et méthodes pour le diagnostic et pour le traitement d'une tumeur
US09/888,257 US20030060612A1 (en) 1997-10-28 2001-06-22 Compositions and methods for the diagnosis and treatment of tumor
CA002416456A CA2416456A1 (fr) 2000-07-20 2001-06-29 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
PCT/US2001/021066 WO2002008288A2 (fr) 2000-07-20 2001-06-29 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
JP2002514192A JP2004514420A (ja) 2000-07-20 2001-06-29 分泌及び膜貫通ポリペプチドとそれをコードする核酸
AU2001273150A AU2001273150A1 (en) 2000-07-20 2001-06-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU7315001A AU7315001A (en) 2000-07-20 2001-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/021735 WO2002008284A2 (fr) 2000-07-20 2001-07-09 Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
JP2002514188A JP2004516013A (ja) 2000-07-20 2001-07-09 血管形成に関連する障害を診断及び治療するための組成物と方法
EP01951036A EP1309685A2 (fr) 2000-07-20 2001-07-09 COMPOSITIONs ET PROCEDEs DE DIAGNOSE ET TRAITEMENT DE MALADIES IMPLICANT ANGIOGENESIS
CA002416538A CA2416538A1 (fr) 2000-07-20 2001-07-09 Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
AU2001271973A AU2001271973A1 (en) 2000-07-20 2001-07-09 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US09/908,827 US20030054442A1 (en) 1998-05-15 2001-07-18 IL-17 homologous polypeptides and therapeutic uses thereof
US09/918,585 US20030060406A1 (en) 1997-10-17 2001-07-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/025464 WO2002016581A2 (fr) 2000-08-24 2001-08-14 Compositions et methodes pour le diagnostic et le traitement de tumeurs
AU2001284906A AU2001284906A1 (en) 2000-08-24 2001-08-14 Compositions and methods for the diagnosis and treatment of tumor
MXPA03001644A MXPA03001644A (es) 2000-08-24 2001-08-14 Composiciones y metodos para el diagnostico y tratamiento de tumor.
EP01964006A EP1311662A2 (fr) 2000-08-24 2001-08-14 Compositions et methodes pour le diagnostic et le traitement de tumeurs
JP2002522254A JP2004520808A (ja) 2000-08-24 2001-08-14 腫瘍の診断と治療のための組成物と方法
KR10-2003-7002671A KR20040014392A (ko) 2000-08-24 2001-08-14 종양의 진단 및 치료용 조성물 및 방법
CA002420176A CA2420176A1 (fr) 2000-08-24 2001-08-14 Compositions et methodes pour le diagnostic et le traitement de tumeurs
US09/929,769 US6914130B2 (en) 1998-06-17 2001-08-14 Compositions and methods for the diagnosis and treatment of tumor
US09/931,836 US7435793B2 (en) 1998-05-15 2001-08-16 Peptides that induce chondrocyte redifferentiation
EP01966255A EP1311668A2 (fr) 2000-08-24 2001-08-23 Compositions et procedes con us pour le diagnostic et le traitement de tumeur
US09/938,418 US20020161199A1 (en) 1998-04-08 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor
CA002420193A CA2420193A1 (fr) 2000-08-24 2001-08-23 Compositions et procedes concus pour le diagnostic et le traitement de tumeur
JP2002522275A JP2004520810A (ja) 2000-08-24 2001-08-23 腫瘍の診断と治療のための組成物と方法
AU8678501A AU8678501A (en) 2000-08-24 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor
AU2001286785A AU2001286785B2 (en) 2000-08-24 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor
PCT/US2001/026626 WO2002016602A2 (fr) 2000-08-24 2001-08-23 Compositions et procedes conçus pour le diagnostic et le traitement de tumeur
MXPA03001643A MXPA03001643A (es) 2000-08-24 2001-08-23 Composiciones y metodos para el diagnostico y tratamiento de tumores.
KR1020037002672A KR100607611B1 (ko) 2000-08-24 2001-08-23 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US09/941,992 US20030082546A1 (en) 1996-11-06 2001-08-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/027099 WO2002024888A2 (fr) 2000-09-01 2001-08-29 Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci
CA002421056A CA2421056A1 (fr) 2000-09-01 2001-08-29 Polypeptide servant de marqueur diagnostique de presence de tumeurs du colon
CA002632702A CA2632702A1 (fr) 2000-09-01 2001-08-29 Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci
EP07022176A EP1944317A3 (fr) 2000-09-01 2001-08-29 Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
JP2002529483A JP4451059B2 (ja) 2000-09-01 2001-08-29 分泌及び膜貫通ポリペプチドとそれをコードする核酸
EP01985272A EP1341814A2 (fr) 2000-09-01 2001-08-29 Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci
AU2002216610A AU2002216610A1 (en) 2000-09-01 2001-08-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/943,664 US20040091972A1 (en) 1997-12-03 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,457 US6734288B2 (en) 1997-12-03 2001-08-30 Antibodies against a secreted polypeptide that stimulates release of proteoglycans from cartilage
US09/944,396 US20020132981A1 (en) 1997-12-03 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/943,851 US20020150976A1 (en) 1997-12-03 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/943,780 US20030096742A1 (en) 1997-12-03 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,413 US20020156004A1 (en) 1998-09-16 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,432 US20020142419A1 (en) 1998-09-16 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,449 US20020102647A1 (en) 1997-12-03 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,403 US20020165143A1 (en) 1997-12-03 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/943,762 US20020142958A1 (en) 1998-09-16 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/945,015 US20020132768A1 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,862 US20020115145A1 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,896 US7189566B2 (en) 1997-12-03 2001-08-31 PRO347 nucleic acids
US09/944,929 US7550573B2 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,852 US20030083479A1 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,884 US7018837B2 (en) 1997-12-03 2001-08-31 Nucleic acids encoding secreted polypeptides that stimulate release of proteoglycans from cartilage
US09/944,907 US20020198147A1 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,944 US6929947B2 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/945,584 US6908993B2 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/945,587 US6936254B2 (en) 1997-12-03 2001-08-31 Method of inducing fetal hemoglobin synthesis
US09/944,654 US20020142959A1 (en) 1998-09-16 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/946,374 US20030073129A1 (en) 1998-09-01 2001-09-04 Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1661002A AU1661002A (en) 2000-09-01 2001-09-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/964,994 US6740520B2 (en) 2000-03-21 2001-09-26 Cytokine receptor and nucleic acids encoding the same
US09/978,298 US20030134785A1 (en) 1997-10-17 2001-10-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,191 US20030050239A1 (en) 1997-10-17 2001-10-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,188 US20030139328A1 (en) 1997-10-17 2001-10-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,189 US6972325B2 (en) 1997-10-17 2001-10-15 PRO273 polypeptides
US09/978,299 US20030199435A1 (en) 1997-10-17 2001-10-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,194 US20030195333A1 (en) 1997-10-17 2001-10-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,193 US20030073624A1 (en) 1997-10-17 2001-10-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,192 US20020177553A1 (en) 1997-10-17 2001-10-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,295 US20020156006A1 (en) 1997-10-17 2001-10-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,585 US20030049633A1 (en) 1997-10-17 2001-10-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,681 US20030195148A1 (en) 1997-10-17 2001-10-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,403 US20030050240A1 (en) 1997-10-17 2001-10-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,643 US20030104998A1 (en) 1997-10-17 2001-10-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,697 US20020169284A1 (en) 1997-10-17 2001-10-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,757 US20030083248A1 (en) 1997-10-17 2001-10-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,423 US20030069178A1 (en) 1997-10-17 2001-10-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,375 US7196165B2 (en) 1997-10-17 2001-10-16 PRO363 polypeptides
US09/978,802 US20030199674A1 (en) 1997-10-17 2001-10-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,564 US7195760B2 (en) 1997-10-17 2001-10-16 Anti-pro363 antibodies
US09/978,824 US20050124789A9 (en) 1997-10-17 2001-10-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,665 US7294700B2 (en) 1997-10-17 2001-10-16 Anti-PRO846 antibodies
US09/981,915 US20030054986A1 (en) 1997-10-17 2001-10-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/981,915 US7285623B2 (en) 1997-10-17 2001-10-16 PRO337 polypeptides
US09/978,544 US20030199436A1 (en) 1997-10-17 2001-10-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,824 US20030055216A1 (en) 1997-10-17 2001-10-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/210,028 US20030203446A1 (en) 1998-10-07 2001-10-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/152,388 US20040223964A1 (en) 1998-03-17 2001-10-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/160,502 US7220835B2 (en) 1998-07-30 2001-10-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/166,709 US20030104536A1 (en) 1998-10-07 2001-10-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/145,017 US20030186365A1 (en) 1998-03-26 2001-10-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/165,067 US7279553B2 (en) 1998-05-13 2001-10-19 PRO1083 polypeptides
US10/145,124 US20030190701A1 (en) 1998-04-30 2001-10-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/143,029 US7105640B2 (en) 1997-10-17 2001-10-19 Anti-pro792 antibodies
US10/164,829 US20030194780A1 (en) 1998-04-29 2001-10-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/165,036 US20050227342A1 (en) 1998-10-07 2001-10-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/162,521 US7067628B2 (en) 1998-03-17 2001-10-19 PRO788 polypeptides
US10/145,089 US7208575B2 (en) 1998-10-07 2001-10-19 PRO531 polypeptides
US10/165,247 US7112657B2 (en) 1998-10-07 2001-10-19 PRO697 polypeptides
US10/164,929 US20030194781A1 (en) 1998-03-30 2001-10-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/164,728 US20030186368A1 (en) 1998-05-13 2001-10-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/164,749 US20040029218A1 (en) 1998-10-07 2001-10-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,922 US20030195345A1 (en) 1997-10-17 2001-10-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,081 US20030049684A1 (en) 1997-10-17 2001-10-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/999,832 US7132283B2 (en) 1997-10-17 2001-10-24 PRO273 polypeptides
US09/999,829 US20030195344A1 (en) 1997-10-17 2001-10-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/999,834 US20030064407A1 (en) 1997-10-17 2001-10-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,083 US20030148376A1 (en) 1997-10-17 2001-10-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/020,445 US20030198994A1 (en) 1997-10-17 2001-10-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,084 US20030203402A1 (en) 1997-10-17 2001-10-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/999,832 US20020192706A1 (en) 1997-10-17 2001-10-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/999,830 US20030077700A1 (en) 1997-10-17 2001-10-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,086 US7122375B2 (en) 1997-10-17 2001-10-24 PRO274 nucleic acids
US10/002,967 US20030148373A1 (en) 1997-10-17 2001-10-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,085 US6974696B2 (en) 1997-10-17 2001-10-24 PRO853 nucleic acids
US09/999,833 US6916648B2 (en) 1997-10-17 2001-10-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/016,177 US20030073131A1 (en) 1997-10-17 2001-10-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,929 US7019124B2 (en) 1997-10-17 2001-10-25 PRO788 nucleic acids
US10/013,926 US7074593B2 (en) 1998-04-01 2001-10-25 PRO 703 nucleic acids
US10/013,928 US20030215905A1 (en) 1998-10-07 2001-10-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,920 US20040006219A1 (en) 1997-10-17 2001-10-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,918 US20030211091A1 (en) 1997-10-17 2001-10-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,917 US7029874B2 (en) 1998-03-17 2001-10-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,923 US7169912B2 (en) 1997-10-17 2001-10-25 PRO1017 nucleic acids
US10/013,921 US20030068648A1 (en) 1997-10-17 2001-10-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,927 US7189529B2 (en) 1997-10-17 2001-10-25 PRO792 nucleic acids
US10/013,925 US7037710B2 (en) 1997-10-17 2001-10-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/000,157 US20020182673A1 (en) 1998-05-15 2001-10-30 IL-17 homologous polypedies and therapeutic uses thereof
US09/991,073 US20020127576A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/993,748 US20030069403A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/990,436 US20020198148A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/990,711 US20030032023A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/992,521 US20030083461A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/990,442 US20020132252A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/990,427 US20030073809A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/990,562 US20030027985A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/993,687 US20020198149A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/990,456 US20020137890A1 (en) 1997-03-31 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/990,440 US20030060407A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/991,854 US20030059780A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/993,583 US7074897B2 (en) 1997-06-16 2001-11-14 Pro943 polypeptides
US09/990,438 US20030027754A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/993,469 US20030068623A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/990,443 US20030054987A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/990,444 US6930170B2 (en) 1997-06-16 2001-11-14 PRO1184 polypeptides
US09/993,667 US20030022187A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/992,598 US6956108B2 (en) 1997-06-16 2001-11-14 PRO1184 antibodies
US09/990,726 US20030054359A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/991,163 US20020132253A1 (en) 1997-06-16 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,559 US20030054403A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/002,796 US20030032057A1 (en) 1997-08-26 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,641 US7112656B2 (en) 1997-06-16 2001-11-15 PRO1312 polypeptides
US09/997,628 US20030059782A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,614 US20030124531A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,384 US20030087305A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,542 US20030068647A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,440 US20030059833A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,666 US20030027163A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,529 US20030134284A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,683 US20030059783A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/998,041 US7309775B2 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,641 US20030224358A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,601 US20030054404A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,333 US6953836B2 (en) 1997-06-16 2001-11-15 PRO844 polypeptides
US09/997,653 US7034122B2 (en) 1997-06-16 2001-11-15 Antibodies to PRO1159 polypeptides
US09/997,384 US7119177B2 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,585 US20030119055A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,601 US7189814B2 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,585 US7166282B2 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,666 US7244816B2 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,857 US20030064375A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,573 US20030049682A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,529 US7309761B2 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,514 US7019116B2 (en) 1997-06-16 2001-11-15 PRO 1387 polypeptides
US09/997,428 US20030027162A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/998,156 US20030044806A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/998,041 US20030119001A1 (en) 1997-06-16 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/997,349 US7034106B2 (en) 1997-06-16 2001-11-15 Pro1159 polypeptides
US09/991,172 US20030050457A1 (en) 1997-06-16 2001-11-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/990,441 US7041804B2 (en) 1997-06-16 2001-11-16 Antibodies to PRO1387 polypeptides
US09/991,181 US6913919B2 (en) 1997-06-16 2001-11-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/990,437 US20030045463A1 (en) 1997-06-16 2001-11-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/991,150 US20030194760A1 (en) 1997-06-16 2001-11-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/991,157 US7101687B2 (en) 1997-06-16 2001-11-16 Nucleic acids encoding PRO943
US09/989,727 US20020072497A1 (en) 1997-06-16 2001-11-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/989,726 US7018811B2 (en) 1997-06-16 2001-11-19 Nucleic acids encoding PRO189 polypeptides
US09/989,862 US20030130182A1 (en) 1997-11-05 2001-11-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/989,328 US7056736B2 (en) 1997-06-16 2001-11-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/989,721 US20020142961A1 (en) 1997-06-16 2001-11-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/989,279 US7083978B2 (en) 1997-06-16 2001-11-19 Nucleic acid encoding PRO1111 polypeptides
US09/989,723 US20020072092A1 (en) 1997-06-16 2001-11-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/989,735 US6972185B2 (en) 1997-06-16 2001-11-19 Nucleic acids encoding PRO844 polypeptides
US09/989,734 US7491529B2 (en) 1997-06-16 2001-11-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/989,729 US20030059831A1 (en) 1997-06-16 2001-11-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/989,732 US7037679B2 (en) 1997-06-16 2001-11-19 Nucleic acids encoding PRO1184 polypeptides
US09/989,722 US20020072067A1 (en) 1997-06-16 2001-11-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/989,293 US7034136B2 (en) 1997-06-16 2001-11-20 Nucleic acids encoding PRO1159 polypeptides
US09/989,725 US20030139329A1 (en) 1997-06-16 2001-11-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/989,728 US7029873B2 (en) 1997-06-16 2001-11-20 Nucleic acids to PRO1387 polypeptides
US09/989,731 US20020103125A1 (en) 1997-06-16 2001-11-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/989,724 US7060812B2 (en) 1997-06-16 2001-11-20 PRO1312 nucleic acids
US09/989,730 US7157247B2 (en) 1997-06-16 2001-11-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/001,054 US20020192209A1 (en) 1997-09-17 2001-11-30 Methods and compositions for inhibiting neoplastic cell growth
US10/006,063 US20030114652A1 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/007,194 US7041805B2 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,746 US7026449B2 (en) 1999-01-05 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,867 US7160985B2 (en) 1997-10-29 2001-12-06 Pro180 polypeptide
US10/007,236 US7034123B2 (en) 1998-09-01 2001-12-06 Anti-PRO1347 antibodies
US10/006,818 US20030054406A1 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,172 US7081514B2 (en) 1998-09-01 2001-12-06 PRO1347 polypeptides
US10/006,117 US7071304B2 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,130 US7098312B2 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,485 US7026448B2 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,768 US6936697B2 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,856 US7538086B2 (en) 1998-09-01 2001-12-06 PRO1303 polypeptides
US10/006,041 US6951921B2 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,116 US20030082626A1 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES01986152T ES2295224T3 (es) 2001-02-28 2001-12-07 Anticuerpo antagonista anti-pro842.
US10/012,121 US7022817B2 (en) 1998-09-01 2001-12-07 PRO1325 polypeptides
EP07016434A EP1873245A1 (fr) 2001-02-28 2001-12-07 Polypeptides homologue à l'interleukine-8 et utilisations thérapeutiques correspondantes
US10/012,752 US7026455B2 (en) 1998-09-01 2001-12-07 Anti-pro 1343 antibodies
US10/012,064 US6953841B2 (en) 1999-01-05 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK01986152T DK1366161T3 (da) 2001-02-28 2001-12-07 Antagonist anti-PRO842-antistof
JP2002570731A JP4424646B2 (ja) 2001-02-28 2001-12-07 インターロイキン−８と相同なポリペプチドとその治療用途
US10/012,755 US20030096955A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
AT01986152T ATE374819T1 (de) 2001-02-28 2001-12-07 Antagonistischer antikörper gegen pro842
US10/015,967 US20030065154A1 (en) 2000-03-30 2001-12-07 Interleukin-8 homologous polypeptides and therapeutic uses thereof
US10/012,137 US20030187189A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,967 US7291712B2 (en) 1998-06-25 2001-12-07 Interleukin-8 homologous polypeptides and therapeutic uses thereof
CA002439594A CA2439594A1 (fr) 2001-02-28 2001-12-07 Polypeptides homologues a l'interleukine-8 et utilisations therapeutiques associees
US10/012,149 US7038019B2 (en) 1998-09-01 2001-12-07 Antibodies to PRO1410
AU2002236618A AU2002236618B2 (en) 2001-02-28 2001-12-07 Interleukin-8 homologous polypeptides and therapeutic uses thereof
US10/011,692 US20030109672A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/011,671 US20030096954A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR10-2003-7011325A KR20040055731A (ko) 2001-02-28 2001-12-07 인터루킨-8 동종 폴리펩티드 및 이의 치료적 용도
US10/012,754 US7375184B2 (en) 1998-09-01 2001-12-07 PRO1382 polypeptides
EP01986152A EP1366161B1 (fr) 2001-02-28 2001-12-07 Anticorps antagoniste contre le pro842
US10/011,795 US7012131B2 (en) 1998-09-01 2001-12-07 Pro1410 polypeptides
DE60130804T DE60130804T2 (de) 2001-02-28 2001-12-07 Antagonistischer antikörper gegen pro842
US10/011,833 US6951920B2 (en) 1998-09-01 2001-12-07 PRO1340 polypeptides
US10/012,231 US6924355B2 (en) 1998-09-01 2001-12-07 PRO1343 polypeptides
PT01986152T PT1366161E (pt) 2001-02-28 2001-12-07 Anticorpo anatagonista anti-pro842
US10/012,754 US20030187191A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/012,101 US20030187239A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/048060 WO2002070706A2 (fr) 2001-02-28 2001-12-07 Polypeptides homologues a l'interleukine-8 et utilisations therapeutiques associees
US10/012,237 US20030191281A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/012,753 US7488796B2 (en) 1998-09-01 2001-12-07 PRO1269 polypeptides
US10/013,915 US20030204053A1 (en) 1998-09-01 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,907 US20030064925A1 (en) 1998-09-01 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,911 US20030187193A1 (en) 1998-09-01 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,910 US7057018B2 (en) 1999-01-05 2001-12-10 Pro 1474 polypeptides
US10/013,906 US20030191282A1 (en) 1998-09-01 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,430 US20030092883A1 (en) 1998-09-01 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,913 US20030083462A1 (en) 1999-01-05 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,909 US20030186318A1 (en) 1999-01-05 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,822 US20030130491A1 (en) 1998-09-01 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,499 US20030065142A1 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,869 US7189530B2 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,393 US6951737B2 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,671 US6946263B2 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,389 US6936436B2 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,480 US7074912B2 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,519 US7033785B2 (en) 1998-09-01 2001-12-11 PRO1347 nucleic acids
US10/015,653 US20030187195A1 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,869 US20030073130A1 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,385 US20030195347A1 (en) 1998-09-01 2001-12-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,391 US20030120053A1 (en) 1998-09-01 2001-12-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,390 US20030216562A1 (en) 1998-09-01 2001-12-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,386 US7022498B2 (en) 1998-09-01 2001-12-12 Pro 1325 nucleic acids
US10/015,715 US7033786B2 (en) 1998-09-01 2001-12-12 Pro1340 nucleic acids
US10/015,388 US20030191299A1 (en) 1998-09-01 2001-12-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,387 US20030135034A1 (en) 1998-09-01 2001-12-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,610 US20030113795A1 (en) 1998-09-01 2001-12-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,306 US20030170718A1 (en) 1998-09-01 2001-12-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/020,063 US20030119097A1 (en) 1999-01-05 2001-12-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,867 US20030180792A1 (en) 1998-09-01 2001-12-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,527 US20030082628A1 (en) 1998-09-01 2001-12-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,407 US20030125535A1 (en) 1998-09-01 2001-12-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/036,342 US7193045B2 (en) 1998-05-15 2001-12-26 Polypeptides that induce cell proliferation
US10/035,958 US7241862B2 (en) 1998-05-15 2001-12-26 Polypeptides that induce cell proliferation or induce fetal hemoglobin
US10/036,041 US20020192751A1 (en) 1998-05-15 2001-12-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/035,977 US20030134327A1 (en) 1998-05-15 2001-12-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/036,150 US7256039B2 (en) 1998-05-15 2001-12-26 PRO4405 nucleic acids
US10/036,160 US7125959B2 (en) 1998-05-15 2001-12-26 PRO4405 polypeptides
US10/036,063 US20030092063A1 (en) 1998-05-15 2001-12-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/035,719 US20030036114A1 (en) 1998-05-15 2001-12-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/035,855 US7105639B2 (en) 1998-05-15 2001-12-26 Anti-PRO 4405 antibodies
US10/036,214 US20030032061A1 (en) 1998-05-15 2001-12-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/052,586 US20020127584A1 (en) 1997-09-18 2002-01-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/978,187 US20030096744A1 (en) 1997-10-17 2002-01-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,203 US20030180796A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,500 US20020177165A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding
US10/066,494 US20030032063A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,211 US20030044844A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,269 US20030040014A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,193 US20030044902A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,198 US20030170721A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,273 US7317092B2 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/081,056 US20040043927A1 (en) 1997-09-19 2002-02-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US10/119,480 US20040087769A1 (en) 1998-09-10 2002-04-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,045 US20030073210A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,040 US20030082759A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,042 US20030096386A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,047 US20030077778A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,041 US20030077776A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,051 US20030092147A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,044 US20030190717A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,046 US20030194791A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,059 US20030190721A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,043 US7220831B2 (en) 1997-03-31 2002-04-12 PRO235 polypeptides
US10/121,057 US20030190719A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,049 US20030022239A1 (en) 1997-06-18 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,052 US20030199052A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,060 US20030190722A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,050 US20030054516A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,054 US20030199054A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,061 US20030082761A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,055 US20030190718A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,048 US20030199051A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,053 US20030199053A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,056 US20030082760A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,063 US20030199055A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,058 US20030190720A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,062 US20030077779A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,235 US20030082762A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,262 US20030049816A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,215 US7291329B2 (en) 1997-03-31 2002-04-15 Antibodies against PRO4406
US10/123,213 US20030199057A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,154 US20030190724A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,155 US20030068794A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,771 US20030199060A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,292 US20030073211A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,157 US20030190725A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,156 US20030194792A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,322 US20030199059A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,109 US20030190723A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,108 US7635478B2 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,214 US7343721B2 (en) 1997-03-31 2002-04-15 PRO4406 polypeptide
US10/123,236 US20030068795A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,291 US20030199058A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,213 US7193048B2 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,212 US7276577B2 (en) 1997-03-31 2002-04-15 PRO1866 polypeptides
US10/123,261 US20030068796A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,906 US20030190726A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,907 US7084258B2 (en) 1997-03-31 2002-04-16 Antibodies against the PRO862 polypeptides
US10/123,903 US20030073212A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,911 US7408032B2 (en) 1997-03-31 2002-04-16 PRO1188 polypeptides
US10/123,904 US20030022328A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,902 US20030077781A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,905 US7285625B2 (en) 1997-06-18 2002-04-16 PRO536 polypeptides
US10/123,913 US20030203462A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,905 US20030087344A1 (en) 1997-06-18 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,912 US20030100087A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,909 US7193049B2 (en) 1997-03-31 2002-04-16 PRO862 polypeptides
US10/123,910 US7329404B2 (en) 1997-03-31 2002-04-16 Antibodies against PRO1310
US10/123,908 US7335728B2 (en) 1997-03-31 2002-04-16 PRO1310 polypeptides
US10/125,805 US20030194794A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,824 US20030077659A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,813 US7312307B2 (en) 1997-03-31 2002-04-17 PRO1056 polypeptides
US10/124,823 US20030199062A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,814 US7105335B2 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,820 US20030190729A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,819 US7285626B2 (en) 1997-03-31 2002-04-17 PRO1076 polypeptides
US10/124,818 US20030082763A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,822 US7109305B2 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,795 US7304131B2 (en) 1997-03-31 2002-04-17 PRO1483 polypeptides
US10/124,816 US20030190728A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,817 US20030077786A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,704 US7357926B2 (en) 1997-03-31 2002-04-17 Antibodies against PRO1879 and the use thereof
US10/124,821 US20030199023A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,166 US20030039648A1 (en) 1998-09-16 2002-04-17 Compositions and methods for the diagnosis and treatment of tumor
US10/125,927 US20030190731A1 (en) 1997-03-31 2002-04-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,924 US7342097B2 (en) 1997-03-31 2002-04-19 PRO1309 polypeptides
US10/125,922 US7309762B2 (en) 1997-03-31 2002-04-19 PRO1360 polypeptides
US10/125,932 US7317079B2 (en) 1997-03-31 2002-04-19 PRO812 polypeptides
US10/125,931 US20030199063A1 (en) 1997-03-31 2002-04-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/127,831 US20030082689A1 (en) 1997-03-31 2002-04-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/127,966 US20030003507A1 (en) 1999-06-02 2002-04-23 Compositions and methods for the diagnosis and treatment of tumor
US10/128,689 US20030087365A1 (en) 1997-03-31 2002-04-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/131,817 US7291701B2 (en) 1997-03-31 2002-04-24 PRO1777 polypeptides
US10/131,823 US7304132B2 (en) 1997-03-31 2002-04-24 PRO1693 polypeptides
US10/131,825 US7282566B2 (en) 1997-03-31 2002-04-24 PRO1779 polypeptide
US10/063,520 US20030187196A1 (en) 1998-12-30 2002-05-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,517 US7232889B2 (en) 1999-03-08 2002-05-01 PRO300 antibodies
US10/063,510 US7109292B2 (en) 1999-03-08 2002-05-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,518 US7465785B2 (en) 1999-03-08 2002-05-01 Polypeptide encoded by a nucleic acid over-expressed in melanoma
US10/063,521 US20030190669A1 (en) 1998-12-30 2002-05-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,519 US20030009013A1 (en) 1998-12-30 2002-05-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,560 US7232882B2 (en) 1999-03-08 2002-05-02 Polypeptide uder-expressed in melanoma
US10/063,569 US7378491B2 (en) 1999-03-08 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,563 US20030060602A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,541 US20030060601A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,567 US20030069394A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,570 US7507404B2 (en) 1999-03-08 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,569 US20030018168A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,530 US7193059B2 (en) 1999-03-08 2002-05-02 Antibodies that recognize a polypeptide overexpressed in rectal tumors
US10/063,532 US7202336B2 (en) 1999-03-08 2002-05-02 Polypeptide encoded by a nucleic acid overexpressed in kidney tumor and underexpressed in lung tumor
US10/063,545 US7256261B2 (en) 1999-03-08 2002-05-02 Polypeptides encoded by a nucleic acid over expressed in normal stomach normal skin and kidney tumor
US10/063,545 US20020183505A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,568 US20030181668A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,562 US20030181697A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,538 US7253255B2 (en) 1999-03-08 2002-05-02 Polypeptide encoded by a nucleic acid underexpressed in esophageal tumor and melanoma
US10/063,536 US7259238B2 (en) 1999-03-08 2002-05-02 Polypeptide encoded by a nucleic acid under-expressed in stomach and lung tumor
US10/063,554 US7223841B2 (en) 1999-03-08 2002-05-02 PR0994 antibodies
US10/063,555 US20030065143A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,553 US7235630B2 (en) 1999-03-08 2002-05-02 PRO994 polypeptides
US10/063,564 US20030180794A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,548 US20030187228A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,566 US20030073821A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,526 US20030171550A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,549 US7253256B2 (en) 1999-03-08 2002-05-02 Polypeptides encoded by a nucleic acid are expressed in esophageal and kidney tumor
US10/063,551 US7214777B2 (en) 1999-03-08 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,553 US20030045684A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,540 US20030181667A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,534 US7193060B2 (en) 1999-03-08 2002-05-02 Antibodies to a polypeptides encoded by a nucleic acid overexpressed in kidney tumor and underexpressed in lung tumor
US10/063,561 US7271247B2 (en) 1999-03-08 2002-05-02 Antibodies to a polypeptide encoded by a nucleic acid differentially expressed in melanoma
US10/063,523 US7220830B2 (en) 1999-03-08 2002-05-02 Polypeptide underexpressed in stomach tumors
US10/063,525 US20030036634A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,547 US7294690B2 (en) 1999-03-08 2002-05-02 Polypeptides encoded by a nucleic acid differentially expressed in lung tumor
US10/063,551 US20020183494A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,527 US20030181637A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,524 US7205391B2 (en) 1999-03-08 2002-05-02 Antibodies to a polypeptide suppressed in stomach tumors
US10/063,546 US7435798B2 (en) 1999-03-08 2002-05-02 Antibodies to a polypeptide encoded by a nucleic acid overexpressed in normal stomach, normal skin and kidney tumor
US10/063,524 US20030027992A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,565 US20030180904A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,528 US20030181666A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,544 US20030027212A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,548 US7232892B2 (en) 1999-03-08 2002-05-02 Antibodies to a polypeptide encoded by a nucleic acid differentailly expressed in stomach, lung and melanoma tumor
US10/063,540 US7193061B2 (en) 1999-03-08 2002-05-02 Antibodies to a polypeptide encoded by a nucleic acid underexpressed in esophageal tumor and melanoma
US10/063,547 US20020182638A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,536 US20030181696A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,537 US7276586B2 (en) 1999-03-08 2002-05-02 Antibodies to a polypeptide encoded by a nucleic acid under-expressed in stomach and lung tumor
US10/063,523 US20030181636A1 (en) 1998-12-30 2002-05-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,604 US7390876B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,582 US7205389B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,591 US7196174B2 (en) 1998-10-27 2002-05-03 PRO1557 polypeptide encoded by a nucleic acid highly expressed in esophageal and kidney tumors
US10/063,596 US7285624B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/137,868 US20030082764A1 (en) 1997-03-31 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,602 US7230082B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,577 US7423130B2 (en) 1999-03-08 2002-05-03 PRO1158 polypeptides
US10/063,614 US7393931B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,592 US7220841B2 (en) 1998-10-27 2002-05-03 Antibody to PRO1557 polypeptide encoded by a nucleic acid highly expressed in esophageal and kidney tumors
US10/137,865 US20030032155A1 (en) 1997-03-31 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,578 US7417125B2 (en) 1999-03-08 2002-05-03 Antibodies that bind a PRO1158 polypeptide
US10/063,612 US7399828B2 (en) 1998-09-24 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,611 US20030181677A1 (en) 1998-12-30 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,581 US7189803B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,606 US20030181675A1 (en) 1998-12-30 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,592 US20030181672A1 (en) 1998-12-30 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,579 US20030181638A1 (en) 1998-12-30 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,597 US7227000B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,587 US7244428B2 (en) 1998-09-10 2002-05-03 PRO1357 antibodies
US10/063,611 US7378501B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,610 US20030180907A1 (en) 1998-12-30 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,615 US7405269B2 (en) 1998-10-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,593 US7189805B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/137,867 US20030207349A1 (en) 1997-03-31 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,591 US20030180906A1 (en) 1998-12-30 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,617 US7423119B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,600 US7230076B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,618 US7468424B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,583 US7189804B2 (en) 1999-03-08 2002-05-03 PRO1335 polypeptides
US10/063,607 US7345145B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,588 US20030130483A1 (en) 1998-12-30 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,616 US7358339B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,610 US7371814B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,598 US7223838B2 (en) 1999-03-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,609 US7402661B2 (en) 1998-10-06 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,589 US20030181641A1 (en) 1998-12-30 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,470 US20030022331A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,023 US20030207416A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,024 US20040058424A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/139,980 US7247710B2 (en) 1997-03-31 2002-05-06 PRO4395 antibodies
US10/139,963 US7288625B2 (en) 1997-03-31 2002-05-06 PRO4395 polypeptides
US10/140,020 US20030207415A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,474 US20030032156A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,928 US20030068798A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,640 US7354997B2 (en) 1999-03-08 2002-05-07 Polypeptide encoded by a nucleic acid underexpressed in stomach tumor
US10/140,808 US7425621B2 (en) 1997-03-31 2002-05-07 Antibodies against the PRO4401 polypeptide
US10/063,665 US7427664B2 (en) 1999-03-08 2002-05-07 Antibodies to polypeptides that stimulate TNF-α release
US10/063,674 US20030180841A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,650 US7217787B2 (en) 1999-03-08 2002-05-07 Polypeptide encoded by a nucleic acid underexpressed in rectal tumor
US10/063,662 US20030180795A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,660 US7189822B2 (en) 1999-03-08 2002-05-07 Antibodies to a polypeptide encoded by a nucleic acid underexpressed in stomach and lung tumor
US10/140,809 US20030207418A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,860 US7307151B2 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,651 US7193057B2 (en) 1997-10-29 2002-05-07 Antibodies to a polypeptide encoded by a nucleic acid underexpressed in rectal tumor
US10/063,659 US7186801B2 (en) 1999-03-08 2002-05-07 Polypeptide encoded by a nucleic acid underexpressed in stomach tumor and lung tumor
US10/063,670 US20030180839A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,921 US7317080B2 (en) 1997-03-31 2002-05-07 PRO4303 polypeptides
US10/063,653 US7238787B2 (en) 1999-03-08 2002-05-07 Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma
US10/140,865 US20030207420A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,666 US7411037B2 (en) 1999-03-08 2002-05-07 Polypeptides encoded by a nucleic acid underexpressed in melanoma
US10/063,671 US20030180840A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,647 US7193046B2 (en) 1998-10-20 2002-05-07 Polypeptide encoded by a nucleic acid overexpressed in esophageal and lung tumor, and underexpressesd in kidney tumor and melanoma
US10/063,652 US7230077B2 (en) 1999-03-08 2002-05-07 Polypeptide encoded by a nucleic acid underexpressed in melanoma
US10/063,639 US7081520B2 (en) 1998-10-08 2002-05-07 Anti-pro 1570 antibodies
US10/063,646 US7189821B2 (en) 1998-10-20 2002-05-07 Antibodies to a polypeptide encoded by a nucleic acid underexpressed in lung tumor
US10/063,661 US7193047B2 (en) 1999-03-08 2002-05-07 Polypeptide encoded by a nucleic acid underexpressed in esophageal tumor
US10/140,925 US20030073215A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,677 US20030187242A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,654 US7202337B2 (en) 1999-03-08 2002-05-07 Polypeptide encoded by a nucleic acid overexpressed in esophageal tumor, normal stomach and melanoma
US10/063,657 US7193063B2 (en) 1999-03-08 2002-05-07 Antibodies to a polypeptide encoded by a nucleic acid overexpressed in esophageal tumor, normal stomach and melanoma
US10/063,673 US20030180908A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,676 US20030180843A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,646 US20030181681A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,643 US20030181680A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,864 US20030207419A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,647 US20030187197A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,638 US7101970B2 (en) 1999-03-08 2002-05-07 PRO1570 polypeptides
US10/063,648 US7193062B2 (en) 1998-10-20 2002-05-07 Antibodies to a polypeptide encoded by a nucleic acid over expressed in esoprageal and lung tumor, and under expressed in kidney tumor and melanoma
US10/063,664 US7256262B2 (en) 1999-03-08 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,672 US20030181700A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,644 US7196167B2 (en) 1998-10-20 2002-05-07 Polypeptide underexpressed in lung tumor
US10/140,805 US20030207417A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,668 US20030191290A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,642 US20030181650A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,669 US20030180838A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,644 US20030181651A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,649 US20030181652A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,675 US20030180842A1 (en) 1998-12-30 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,693 US20030180847A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,723 US20030181703A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,720 US20030180917A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/141,701 US20030207421A1 (en) 1997-03-31 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,686 US20030180844A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,707 US20030180853A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,682 US20030181701A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,732 US20030180922A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,735 US20030138882A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,731 US20030180921A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,705 US7220850B2 (en) 1999-03-08 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,688 US20030186408A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,727 US20030180857A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,736 US20030180860A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/141,756 US7488586B2 (en) 1997-03-31 2002-05-08 PRO4409 polypeptides
US10/063,744 US20030180863A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,718 US20030190698A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,722 US20030180918A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,692 US20030180846A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,712 US20030180912A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,689 US20030180845A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,730 US20030180858A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,684 US20030186407A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,717 US20030180916A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,709 US7189564B2 (en) 1999-03-08 2002-05-08 PRO1335 nucleic acids
US10/063,726 US20030180919A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/141,760 US7342104B2 (en) 1997-03-31 2002-05-08 Antibodies against the PRO4320 polypeptide
US10/063,724 US20030180856A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,703 US7189563B2 (en) 1999-03-08 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,713 US20030180855A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/141,755 US7297764B2 (en) 1997-03-31 2002-05-08 PRO4318 polypeptides
US10/063,715 US20030180914A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,698 US20030180849A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,714 US20030180913A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,711 US20030180911A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,728 US20030180920A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,734 US20030180859A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,694 US20030180848A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,710 US20030180910A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,699 US20030180850A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,702 US7193074B2 (en) 1999-03-08 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/141,754 US7361732B2 (en) 1997-03-31 2002-05-08 PRO4400 polypeptides
US10/063,721 US20030181702A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,716 US20030180915A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,685 US20030180909A1 (en) 1998-12-30 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/142,425 US20030207424A1 (en) 1997-03-31 2002-05-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/143,114 US20030036180A1 (en) 1997-03-31 2002-05-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,743 US20030180862A1 (en) 1998-12-30 2002-05-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,742 US7189532B2 (en) 1999-03-08 2002-05-09 Nucleic acid underexpressed in stomach tumor and lung tumor
US10/142,417 US7304133B2 (en) 1997-03-31 2002-05-09 PRO4389 polypeptides
US10/143,113 US7329730B2 (en) 1997-03-31 2002-05-09 PRO4348 polypeptides
US10/142,430 US7309766B2 (en) 1997-03-31 2002-05-09 PRO5774 polypeptides
US10/063,741 US7118887B2 (en) 1999-03-08 2002-05-09 Nucleic acid overexpressed in esophageal tumor, normal stomach and melanoma
US10/063,745 US20040058411A1 (en) 1998-12-30 2002-05-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/142,419 US7153941B2 (en) 1997-03-31 2002-05-10 Antibodies that bind PRO4994 polypeptides
US10/142,431 US7285629B2 (en) 1997-03-31 2002-05-10 Pro5005 polypeptides
US10/143,032 US7408033B2 (en) 1997-03-31 2002-05-10 PRO5995 polypeptides
US10/142,423 US20030049817A1 (en) 1997-03-31 2002-05-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/146,730 US20030207427A1 (en) 1997-03-31 2002-05-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/146,792 US20030207428A1 (en) 1997-03-31 2002-05-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,528 US20030219885A1 (en) 1997-03-31 2002-05-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,519 US20030077791A1 (en) 1997-03-31 2002-05-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,536 US20040077064A1 (en) 1997-03-31 2002-05-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,492 US20030082765A1 (en) 1997-03-31 2002-05-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/152,395 US7189534B2 (en) 1997-03-31 2002-05-21 PRO4320 polynucleotide
US10/153,934 US20030129695A1 (en) 1997-03-31 2002-05-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/156,843 US20030207805A1 (en) 1997-06-18 2002-05-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/157,782 US20030077792A1 (en) 1997-03-31 2002-05-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/157,786 US20030208055A1 (en) 1997-03-31 2002-05-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/158,782 US20030082766A1 (en) 1997-03-31 2002-05-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/158,791 US20030207429A1 (en) 1997-03-31 2002-05-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/160,498 US20030073216A1 (en) 1997-03-31 2002-05-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,702 US20030170793A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,700 US20030027262A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,704 US20030170795A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,690 US20030166105A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,692 US20030166188A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,695 US20030032101A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,703 US20030170794A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,696 US20030082767A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,699 US20030166109A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,707 US20030166110A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,694 US20030166107A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,701 US20030104538A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,698 US20030166108A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,705 US20030032103A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,693 US20030073169A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,706 US20030022293A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,691 US20030166106A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,689 US20030166104A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,697 US20030032102A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,569 US20030166111A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,581 US7153939B2 (en) 1997-09-18 2002-06-18 PRO354 antibodies
US10/174,590 US20030008352A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,570 US20030211572A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,574 US20030170796A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,572 US20030027263A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,575 US20030096351A1 (en) 1998-03-27 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,589 US20030166114A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,591 US20030166115A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,588 US20030027266A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,578 US20030073170A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,579 US20030027264A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,585 US20030032105A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,571 US20030068679A1 (en) 1998-05-05 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,583 US7211645B2 (en) 1997-09-18 2002-06-18 PRO268 polypeptides
US10/174,587 US20030166113A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,582 US20030027265A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,586 US20030032106A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,576 US7125962B2 (en) 1997-09-18 2002-06-18 Anti-Pro268 antibodies
US10/175,753 US20030077732A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,735 US20030082715A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,752 US20030022295A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,738 US20030022294A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,736 US20030166117A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,746 US20030027270A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,748 US20030166121A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,745 US20030166120A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,747 US20030032107A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,751 US20030166122A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,742 US20030166118A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,743 US20030027269A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,750 US20030073172A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,744 US20030166119A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,754 US20030166123A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,739 US20030027267A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,749 US20050196832A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,741 US20030073171A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,485 US20030032109A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,988 US20030170802A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,913 US20030022298A1 (en) 1997-09-15 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,483 US20030017541A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,754 US7709602B2 (en) 1997-09-18 2002-06-20 PRO1078 polypeptides
US10/176,759 US20030166128A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,914 US20030017543A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,493 US20030032111A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,749 US20030017542A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,753 US20030044917A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,484 US20030059876A9 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,479 US20030040054A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,482 US20030022296A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,746 US20030068680A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,920 US20030166129A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,919 US20030032114A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,757 US7317082B2 (en) 1997-09-18 2002-06-20 PRO1018 polypeptides
US10/176,917 US20030044918A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,993 US20030027280A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,989 US20030170803A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,747 US20030027273A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,981 US20030170800A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,921 US20030027276A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,918 US7495083B2 (en) 1997-09-18 2002-06-20 PRO940 antibodies
US10/176,911 US20030032113A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,491 US20030087373A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,487 US20030032110A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,490 US20030170798A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,760 US7339033B2 (en) 1998-06-26 2002-06-21 Pro1481
US10/176,486 US7354999B2 (en) 1997-09-18 2002-06-21 PRO1481 polypeptides
US10/176,987 US20030027278A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,751 US20030036117A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,924 US20030166131A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,986 US20030073173A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,925 US20030032115A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,922 US20030166130A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,923 US20030068681A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,488 US20030027271A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,481 US20030032108A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,991 US20030027324A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,489 US20030166125A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,992 US20030027279A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,755 US20030166127A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,748 US20030040055A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,752 US20030170799A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,916 US20030040056A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,985 US20030027277A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,983 US20030170801A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,480 US20030166124A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,915 US20030017544A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,756 US20030032112A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,979 US20030087374A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,492 US20030027272A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,750 US20030027274A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,982 US20030044919A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,758 US20030008353A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,978 US20030032116A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,984 US20030166132A1 (en) 1998-08-26 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,521 US20030170806A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,509 US20030207392A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,519 US7339024B2 (en) 1997-09-18 2002-06-24 PRO1772 polypeptides
US10/179,507 US20030040057A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,514 US20030044922A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,516 US20030040058A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,508 US20030166133A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,506 US20030044920A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,513 US20030044921A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,520 US20030096353A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,511 US20030104539A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,518 US20030104540A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,522 US20030044923A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,523 US20030215909A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,517 US20030170805A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,526 US20030100061A1 (en) 1998-06-26 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,512 US20030166134A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,510 US20030032117A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,515 US20030166135A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,525 US20030040060A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,552 US7348415B2 (en) 1997-09-18 2002-06-25 PRO1316 antibodies
US10/180,551 US20030036123A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,559 US20030032124A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,550 US20030064440A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,557 US20030022301A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,560 US20030044925A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,554 US20050202526A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,540 US20030040061A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,545 US20030040062A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,549 US20030032122A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,541 US20030036120A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,544 US20030032119A1 (en) 1998-06-26 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,556 US7355000B2 (en) 1997-09-18 2002-06-25 PRO1380 polypeptides
US10/180,555 US20030032123A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,543 US20030032118A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,542 US20030036121A1 (en) 1998-06-26 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,553 US7365156B2 (en) 1997-09-18 2002-06-25 PRO1316 polypeptides
US10/180,547 US20030032121A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,546 US20030032120A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,548 US7696319B2 (en) 1997-09-18 2002-06-25 PRO1772 antibodies
US10/183,010 US20030032126A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,005 US7317093B2 (en) 1997-09-18 2002-06-26 PRO1339 antibodies
US10/183,015 US20030044926A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,008 US20030040064A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,019 US7425605B2 (en) 1997-09-18 2002-06-26 PRO1486 polypeptides
US10/183,011 US20030068682A1 (en) 1998-06-26 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,018 US20030104541A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,003 US20030082716A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,014 US20030064441A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,009 US7339034B2 (en) 1997-09-18 2002-06-26 PRO1305 antibodies
US10/183,013 US7309769B2 (en) 1997-09-18 2002-06-26 PRO1487 polypeptides
US10/181,000 US7319137B2 (en) 1997-09-18 2002-06-26 PRO1339 polypeptides
US10/183,012 US7718770B2 (en) 1997-09-18 2002-06-26 PRO1305-polypeptides
US10/183,001 US7084255B2 (en) 1997-09-18 2002-06-26 PRO1278 polypeptides
US10/180,998 US7087421B2 (en) 1997-09-18 2002-06-26 Pro1278 polypeptides
US10/183,017 US20030040065A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,999 US7297767B2 (en) 1997-09-18 2002-06-26 PRO1374 polypeptides
US10/183,016 US20030082717A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,006 US7297776B2 (en) 1997-09-18 2002-06-26 PRO1374 antibodies
US10/183,002 US20030054454A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,630 US7304143B2 (en) 1997-09-18 2002-06-27 PRO1571 antibodies
US10/184,615 US20030044927A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,612 US20030036127A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,633 US20030068683A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,613 US20030119105A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,654 US7378486B2 (en) 1997-09-18 2002-06-27 PRO1482 antibodies
US10/184,630 US20030036133A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,628 US7309770B2 (en) 1997-09-18 2002-06-27 PRO1757 polypeptides
US10/184,651 US7291704B2 (en) 1997-09-18 2002-06-27 PRO1758 polypeptides
US10/184,638 US20030054456A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,642 US7332573B2 (en) 1997-09-18 2002-06-27 PRO1571 polypeptides
US10/184,618 US7393917B2 (en) 1997-09-18 2002-06-27 PRO1482 polypeptides
US10/184,639 US7291703B2 (en) 1998-10-08 2002-06-27 PRO1508 polypeptides
US10/184,631 US20030036134A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,627 US20030040070A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,641 US20030073174A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,652 US20030032134A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,616 US20030036128A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,619 US20030049738A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,640 US7271250B2 (en) 1998-06-26 2002-06-27 PRO1757 antibodies
US10/184,627 US7282569B2 (en) 1997-09-18 2002-06-27 PRO1508 antibodies
US10/184,614 US20030032128A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,657 US20030104543A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,645 US7291718B2 (en) 1998-06-26 2002-06-28 PRO1758 antibodies
US10/184,632 US20030036135A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,623 US20030032129A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,643 US20030044929A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,644 US20030044930A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,625 US20030040068A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,646 US20030032132A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,637 US20030032131A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,658 US20030027281A1 (en) 1998-06-26 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,636 US20030036136A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,656 US20030044931A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,647 US20030032133A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,620 US20030044928A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,635 US20030032130A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,629 US20030036132A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,617 US20030036129A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,626 US20030040069A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,621 US20030054455A1 (en) 1998-06-26 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,624 US20030104542A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,650 US20030036138A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,655 US20030040073A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,634 US20030068684A1 (en) 1998-06-26 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,622 US20030036130A1 (en) 1997-09-18 2002-06-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,750 US20030049740A1 (en) 2000-03-01 2002-07-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,886 US7291708B2 (en) 1997-09-18 2002-07-01 PRO1785 polypeptides
US10/187,592 US7314913B2 (en) 2000-03-03 2002-07-01 PRO1891 polypeptides
US10/187,747 US7291707B2 (en) 1997-09-18 2002-07-01 PRO1337 polypeptides
US10/187,884 US20030036155A1 (en) 1997-09-18 2002-07-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,888 US20030073175A1 (en) 2000-03-03 2002-07-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,597 US20030036141A1 (en) 1997-09-18 2002-07-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,755 US7312309B2 (en) 2000-06-05 2002-07-01 PRO6017 polypeptides
US10/187,601 US7291705B2 (en) 1997-09-18 2002-07-01 PRO19645 polypeptides
US10/187,588 US7351795B2 (en) 1998-06-26 2002-07-01 PRO19563 polypeptides
US10/187,748 US20030068687A1 (en) 2000-03-03 2002-07-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,591 US7709603B2 (en) 1998-09-29 2002-07-01 PRO1190 polypeptides
US10/187,887 US7285645B2 (en) 1997-09-18 2002-07-01 PRO4356 antibodies
US10/187,740 US20030064443A1 (en) 1998-10-26 2002-07-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,599 US7355013B2 (en) 2000-06-05 2002-07-01 PRO6017 antibodies
US10/187,594 US7294335B2 (en) 1998-06-26 2002-07-01 PRO19645 antibodies
US10/187,598 US20030036142A1 (en) 1997-09-18 2002-07-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,739 US7291706B2 (en) 1998-06-26 2002-07-01 PRO4352 polypeptides
US10/187,595 US7563867B2 (en) 1999-03-23 2002-07-01 PRO4356 polypeptides
US10/187,752 US20030054457A1 (en) 1999-04-05 2002-07-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,738 US20030064442A1 (en) 1998-09-29 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,766 US7351804B2 (en) 1998-06-26 2002-07-02 Antibodies against PRO4421
US10/187,753 US20030036152A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,774 US20030040074A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,749 US20030153036A1 (en) 1998-06-10 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,603 US20030036146A1 (en) 1998-06-26 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,743 US20030036148A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,773 US20030036159A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,602 US20030036145A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,746 US20030036149A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,596 US20030032136A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,780 US7268217B2 (en) 1998-06-26 2002-07-02 PRO4421 polypeptides
US10/187,885 US20030032138A1 (en) 1998-06-24 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,757 US7276578B2 (en) 1997-09-18 2002-07-02 PRO4334 polypeptides
US10/187,754 US20030036153A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,771 US20030068689A1 (en) 2000-06-05 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,770 US7358340B2 (en) 1997-09-18 2002-07-02 PRO19563 antibodies
US10/187,745 US7250490B2 (en) 1997-09-18 2002-07-02 PRO1480 polypeptides
US10/188,769 US20030036157A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,767 US7312310B2 (en) 1997-09-18 2002-07-02 PRO6015 polypeptides
US10/187,741 US20030036147A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,600 US20030036143A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,751 US20030036151A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,775 US20030040075A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,747 US20030036150A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,742 US20030068686A1 (en) 1998-07-02 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,883 US20030064444A1 (en) 1998-10-01 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,781 US20030036160A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/192,008 US20030068693A1 (en) 2000-06-05 2002-07-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/192,016 US20030068697A1 (en) 2000-06-05 2002-07-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/192,006 US20030068692A1 (en) 2000-06-05 2002-07-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/192,010 US20030044932A1 (en) 1997-09-18 2002-07-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/192,009 US20030068694A1 (en) 2000-06-05 2002-07-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/192,011 US20030207395A1 (en) 2000-03-03 2002-07-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/192,014 US7312315B2 (en) 2000-09-15 2002-07-09 PRO9742 antibodies
US10/192,012 US7304134B2 (en) 2000-09-15 2002-07-09 PRO9742 polypeptides
US10/192,007 US7317083B2 (en) 2000-03-03 2002-07-09 PRO4501 polypeptides
US10/192,015 US20030049742A1 (en) 2000-06-05 2002-07-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,488 US20030068704A1 (en) 2000-06-05 2002-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,457 US20030153037A1 (en) 2000-09-15 2002-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,486 US20030207396A1 (en) 2000-06-05 2002-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,463 US20030064447A1 (en) 2000-06-05 2002-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,485 US7449549B2 (en) 2000-09-15 2002-07-11 PRO9822 polypeptides
US10/194,459 US7307144B2 (en) 2000-06-05 2002-07-11 PRO 6493 polypeptides
US10/194,425 US20030049744A1 (en) 2000-06-05 2002-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,395 US7326773B2 (en) 2000-06-05 2002-07-11 PRO6493 antibodies
US10/194,394 US7390886B2 (en) 2000-09-15 2002-07-11 PRO9822 antibodies
US10/194,460 US20030064446A1 (en) 2000-09-15 2002-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,458 US20030068702A1 (en) 2000-06-05 2002-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,363 US20030064445A1 (en) 2000-06-05 2002-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,362 US20030068698A1 (en) 2000-06-05 2002-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,364 US7314918B2 (en) 2000-06-05 2002-07-12 PRO6246 antibodies
US10/194,456 US20030059879A1 (en) 2000-09-15 2002-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,461 US20030054459A1 (en) 1998-06-26 2002-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,361 US20030036161A1 (en) 1998-06-26 2002-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,487 US7427667B2 (en) 2000-09-15 2002-07-12 PRO9835 antibodies
US10/194,359 US8063186B2 (en) 2000-06-05 2002-07-12 Antibodies to PRO7436 polypeptides
US10/194,365 US7381791B2 (en) 1998-06-26 2002-07-12 PRO9739 polypeptides
US10/194,424 US7335730B2 (en) 2000-06-05 2002-07-12 PRO7436 polypeptides
US10/194,462 US7388073B2 (en) 1998-06-26 2002-07-12 PRO9835 polypeptides
US10/194,484 US20030064448A1 (en) 2000-09-15 2002-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,423 US7339025B2 (en) 1998-06-26 2002-07-12 PRO6246 polypeptides
US10/194,360 US20030073176A1 (en) 2000-06-05 2002-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,895 US7378487B2 (en) 2000-04-11 2002-07-15 PRO19675 polypeptides
US10/195,894 US20030043176A1 (en) 1998-06-26 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,891 US7304135B2 (en) 2000-09-15 2002-07-15 PRO9859 polypeptides
US10/195,889 US7534856B2 (en) 1998-06-26 2002-07-15 PRO19624 antibodies
US10/195,884 US20030064449A1 (en) 2000-09-15 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,901 US20030036165A1 (en) 1998-06-26 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,898 US20030071834A1 (en) 2000-04-25 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,885 US7399824B2 (en) 2000-04-04 2002-07-15 PRO19680 antibodies
US10/195,892 US7385033B2 (en) 1998-06-26 2002-07-15 PRO12970 polypeptides
US10/195,900 US7351789B2 (en) 2000-03-14 2002-07-15 PRO19624 polypeptides
US10/195,883 US20060073544A1 (en) 1998-06-26 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,887 US7375179B2 (en) 2000-04-04 2002-07-15 PRO19680 polypeptides
US10/195,886 US20030068705A1 (en) 2000-09-15 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,899 US20030049747A1 (en) 2000-04-18 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,893 US20030206188A1 (en) 1998-06-26 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,897 US20030036164A1 (en) 1997-09-18 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,888 US20060073545A1 (en) 1998-06-26 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,902 US20030038826A1 (en) 1998-06-26 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,890 US7309776B2 (en) 2000-03-14 2002-07-15 PRO12970 antibodies
US10/195,896 US20030063112A1 (en) 2000-04-25 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,762 US20030040078A1 (en) 1998-06-26 2002-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,748 US20030049748A1 (en) 2000-04-11 2002-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,755 US20030064451A1 (en) 2000-03-21 2002-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,744 US7465786B2 (en) 1998-10-30 2002-07-16 PRO1801 polypeptides
US10/196,751 US7309771B2 (en) 2000-04-11 2002-07-16 PRO19646 polypeptides
US10/196,750 US7288628B2 (en) 2000-05-03 2002-07-16 PRO20088 polypeptides
US10/196,749 US7312316B2 (en) 2000-03-21 2002-07-16 PRO16090 antibodies
US10/196,747 US20030162250A1 (en) 2000-04-11 2002-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,752 US20030068708A1 (en) 1998-10-30 2002-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,756 US7304145B2 (en) 1998-06-26 2002-07-16 PRO19646 antibodies
US10/196,757 US7375196B2 (en) 2000-04-25 2002-07-16 PRO19814 antibodies
US10/196,745 US7423120B2 (en) 1997-09-18 2002-07-16 PRO19814 polypeptides
US10/196,759 US20030071835A1 (en) 1998-06-26 2002-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,753 US7371815B2 (en) 2000-03-29 2002-07-16 PRO19644 polypeptides
US10/196,746 US7345147B2 (en) 2000-03-21 2002-07-16 PRO16089 polypeptides
US10/196,760 US7408034B2 (en) 1998-06-26 2002-07-16 PRO20025 polypeptides
US10/196,761 US20030068710A1 (en) 2000-04-18 2002-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,754 US7282561B2 (en) 2000-03-21 2002-07-16 PRO16090 polypeptides
US10/196,743 US20030038827A1 (en) 1998-06-26 2002-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,758 US20030059880A1 (en) 2000-03-29 2002-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,693 US20030068712A1 (en) 1997-11-24 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,703 US20030068715A1 (en) 1998-06-04 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,699 US20030049750A1 (en) 1998-06-02 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,710 US20030064453A1 (en) 1998-05-07 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,707 US20030054464A1 (en) 1998-06-04 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,711 US20030068716A1 (en) 1997-10-21 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,692 US20030068711A1 (en) 1997-10-28 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,709 US20040023321A1 (en) 1997-12-18 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,705 US20030049752A1 (en) 1998-03-20 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,698 US20030068714A1 (en) 1998-10-27 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,697 US20030054463A1 (en) 1997-10-24 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,708 US20030049753A1 (en) 1998-05-05 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,694 US20030054462A1 (en) 1999-08-25 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,706 US20030104548A1 (en) 1997-10-31 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,700 US20030049751A1 (en) 1997-09-18 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,695 US20030040079A1 (en) 1997-12-12 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,704 US20030064452A1 (en) 1997-10-29 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,691 US20030092121A1 (en) 1998-03-27 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,696 US20030068713A1 (en) 1997-10-29 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,701 US20030104547A1 (en) 1997-10-28 2002-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,460 US20030068729A1 (en) 1998-03-11 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,309 US20030064457A1 (en) 1998-05-15 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,763 US20030068720A1 (en) 1998-05-07 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,463 US20030215910A1 (en) 1998-06-09 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,667 US20030068731A1 (en) 1997-12-17 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,461 US20030068730A1 (en) 1998-08-17 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,758 US20030064454A1 (en) 1998-05-07 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,769 US20030049757A1 (en) 1998-05-15 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,315 US20030068725A1 (en) 1998-06-05 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,458 US20030054467A1 (en) 1998-06-25 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/200,617 US20030059884A1 (en) 1998-04-01 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,456 US20030064459A1 (en) 1998-06-25 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,942 US20030175882A1 (en) 1998-09-10 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,301 US20030068722A1 (en) 1998-05-28 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,759 US20030207398A1 (en) 1998-04-22 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,764 US20030049754A1 (en) 1998-04-08 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,666 US20030049765A1 (en) 1998-06-05 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,673 US20030068732A1 (en) 1998-04-01 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,761 US20030068718A1 (en) 1998-03-31 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,760 US20030113842A1 (en) 1998-03-11 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,307 US20030068723A1 (en) 1998-06-04 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,766 US20030064455A1 (en) 1998-05-28 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,313 US20030064458A1 (en) 1998-08-26 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,665 US20030049764A1 (en) 1998-03-31 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,672 US20030148442A1 (en) 1998-03-10 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,765 US20030049755A1 (en) 1998-04-08 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,768 US20030049756A1 (en) 1998-06-26 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,317 US20030049763A1 (en) 1998-09-29 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,464 US20030032140A1 (en) 1997-09-18 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,457 US20030068727A1 (en) 1998-09-18 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,305 US20030049758A1 (en) 1998-06-10 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,303 US20030054465A1 (en) 1998-06-24 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,312 US20030068724A1 (en) 1998-05-22 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,670 US20040033560A1 (en) 2001-02-28 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,306 US20030049759A1 (en) 1998-09-30 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,771 US20030092122A1 (en) 1998-08-26 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,314 US20030049762A1 (en) 1998-09-23 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,302 US20030073179A1 (en) 1998-06-24 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,767 US20030068721A1 (en) 2001-02-28 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,762 US20030068719A1 (en) 1998-05-15 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,757 US20030068717A1 (en) 1998-09-01 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,770 US20030059882A1 (en) 1998-05-15 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,308 US20030059883A1 (en) 1998-09-29 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,318 US20030054466A1 (en) 1998-06-25 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,311 US20030049761A1 (en) 1998-06-25 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,459 US20030068728A1 (en) 1998-09-16 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,462 US20030054468A1 (en) 1998-06-26 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,310 US20030049760A1 (en) 1998-06-05 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,304 US20030064456A1 (en) 1998-10-28 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,669 US20030049766A1 (en) 1998-06-05 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,316 US20030068726A1 (en) 1998-06-26 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,532 US20030068736A1 (en) 1998-10-26 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,325 US20030096357A1 (en) 1998-07-02 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,533 US20030068737A1 (en) 1998-06-18 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,329 US20030064460A1 (en) 1998-09-02 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,328 US20030054470A1 (en) 1998-06-24 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,323 US20030073180A1 (en) 1998-07-02 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,528 US20030054472A1 (en) 1998-08-18 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,324 US20030054469A1 (en) 1998-09-09 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,326 US20030068735A1 (en) 1998-08-04 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,530 US20030054474A1 (en) 1998-06-22 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,322 US20030068734A1 (en) 1998-06-10 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,321 US20030068733A1 (en) 1998-11-03 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,529 US20030054473A1 (en) 1998-06-16 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,771 US20030068740A1 (en) 1998-08-26 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,534 US20030049767A1 (en) 2000-03-03 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,327 US20030077736A1 (en) 1998-11-17 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,770 US20030049768A1 (en) 1998-09-02 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,527 US20030054471A1 (en) 1998-11-18 2002-07-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,772 US20030113843A1 (en) 1998-10-22 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,413 US20030104550A1 (en) 1998-09-30 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,855 US20030049769A1 (en) 1998-09-10 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,471 US20030215911A1 (en) 1998-10-07 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,858 US20040038337A1 (en) 1998-11-17 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,535 US20030068738A1 (en) 1998-10-08 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding tha same
US10/202,408 US20030054475A1 (en) 1998-09-18 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,769 US7087737B2 (en) 1998-10-06 2002-07-23 Pro1278 nucleic acids
US10/201,857 US20030104549A1 (en) 1998-09-23 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,473 US20030068743A1 (en) 1998-10-27 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,469 US20030049771A1 (en) 1998-10-29 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,853 US20040053358A1 (en) 1998-11-18 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,472 US20030054478A1 (en) 1998-06-11 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,856 US20030049770A1 (en) 1998-10-27 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,475 US20030180881A1 (en) 1998-08-26 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,410 US20030068742A1 (en) 1998-09-17 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,474 US20030068744A1 (en) 1998-11-17 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,409 US20030054476A1 (en) 1998-06-11 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,470 US20030049772A1 (en) 1998-10-14 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,411 US20030054477A1 (en) 1998-11-17 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,412 US20030064461A1 (en) 1998-10-28 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,476 US20030049773A1 (en) 1998-10-02 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/201,854 US20030068741A1 (en) 1998-11-03 2002-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,509 US20030049779A1 (en) 1998-03-20 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,934 US20030049774A1 (en) 1998-05-06 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,502 US20030054479A1 (en) 1998-06-04 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,507 US20030054480A1 (en) 1998-05-22 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,510 US20030073181A1 (en) 1998-07-02 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,503 US20030068745A1 (en) 1998-06-17 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,504 US20030049778A1 (en) 1998-10-28 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,940 US20030104552A1 (en) 1998-04-29 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,511 US20030054481A1 (en) 1998-06-24 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,941 US20030096358A1 (en) 1998-09-29 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,936 US20030049776A1 (en) 2000-05-22 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,938 US20030104551A1 (en) 1997-10-31 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,508 US20030104554A1 (en) 1998-06-10 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,506 US20030207399A1 (en) 1998-10-28 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,935 US20030049775A1 (en) 1998-06-03 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/202,939 US20030049777A1 (en) 2000-04-11 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,512 US20030068746A1 (en) 1998-11-03 2002-07-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,896 US20030068749A1 (en) 1998-10-01 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,928 US20030064465A1 (en) 1998-10-26 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,908 US20030045700A1 (en) 2000-03-03 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,897 US20030059886A1 (en) 2000-06-05 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,913 US20030068757A1 (en) 1999-04-05 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,909 US20030049783A1 (en) 2000-03-03 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,927 US20030068764A1 (en) 1999-08-03 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,902 US20030054482A1 (en) 2000-04-04 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,904 US20030073813A1 (en) 1998-06-26 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,914 US20030068758A1 (en) 2000-03-01 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,907 US20030119110A1 (en) 2000-06-05 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,893 US20030059885A1 (en) 2000-03-03 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,926 US20030068763A1 (en) 1999-07-20 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,911 US20030068755A1 (en) 2000-03-01 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,903 US20030068752A1 (en) 2000-06-05 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,895 US20030049780A1 (en) 1999-03-23 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,905 US20030104555A1 (en) 1998-10-01 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,891 US20030073182A1 (en) 2000-06-05 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,894 US20030068748A1 (en) 2000-06-05 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,892 US20030068747A1 (en) 2000-06-05 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,920 US20030068759A1 (en) 2000-09-15 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,898 US20030068750A1 (en) 2000-06-05 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,912 US20030068756A1 (en) 2000-09-15 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,915 US20040029221A1 (en) 2000-06-05 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,917 US20030073183A1 (en) 2000-09-15 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,899 US20030049781A1 (en) 2000-06-05 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,909 US20030068753A1 (en) 2000-06-05 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,918 US20030104556A1 (en) 2000-06-05 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,900 US20030049782A1 (en) 2000-03-03 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,921 US20030068760A1 (en) 2000-09-15 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,925 US20030068762A1 (en) 2000-06-05 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,923 US20030068761A1 (en) 2000-06-05 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,916 US20040091959A1 (en) 2000-06-05 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,890 US20040048334A1 (en) 2000-09-15 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,910 US20030068754A1 (en) 2000-03-21 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,907 US20030054483A1 (en) 2000-06-05 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,901 US20030068751A1 (en) 2000-06-05 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,919 US20030064462A1 (en) 2000-09-15 2002-07-26 Secreted and transmembrance polypeptides and nucleic acids encoding the same
US10/206,924 US20030064464A1 (en) 2000-06-05 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,910 US20030096359A1 (en) 2000-09-15 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/206,922 US20030064463A1 (en) 2000-09-15 2002-07-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/208,024 US20040048335A1 (en) 2000-09-15 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/207,923 US20030073184A1 (en) 2000-09-15 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/207,920 US20030068769A1 (en) 2000-04-18 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/208,022 US20030068772A1 (en) 2000-03-21 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/208,028 US20030073186A1 (en) 2000-04-04 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/208,030 US20030068776A1 (en) 2000-04-11 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/207,919 US20030068768A1 (en) 2000-03-29 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/208,029 US20030068775A1 (en) 1999-03-23 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/208,025 US20030104557A1 (en) 1999-03-23 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/208,023 US20030068773A1 (en) 2000-09-15 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/208,026 US20030068774A1 (en) 2000-05-03 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/207,918 US20030068767A1 (en) 2000-03-14 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/207,922 US20030064468A1 (en) 2000-04-11 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/207,914 US20030064466A1 (en) 1998-10-30 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/207,924 US20030073185A1 (en) 2000-04-18 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/207,925 US20030068770A1 (en) 2000-03-29 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/208,027 US20030064469A1 (en) 2000-04-11 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/208,021 US20030068771A1 (en) 2000-03-14 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/207,915 US20030215912A1 (en) 2000-04-25 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/207,921 US20030064467A1 (en) 2000-03-21 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/207,916 US7189838B2 (en) 2000-09-15 2002-07-29 PRO9834 nucleic acids
US10/207,917 US20030068766A1 (en) 2000-04-25 2002-07-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/226,739 US7390879B2 (en) 1999-06-15 2002-08-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/232,225 US20030096969A1 (en) 2000-06-02 2002-08-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/232,232 US20030069407A1 (en) 1998-04-21 2002-08-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/244,990 US20030113852A1 (en) 2000-09-01 2002-09-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/293,654 US7235633B2 (en) 2000-03-21 2002-11-13 Cytokine receptors and nucleic acids encoding the same
ZA2003/01204A ZA200301204B (en) 2000-08-24 2003-02-13 Compositions and methods for the diagnosis and treatment of tumor
US10/410,927 US20030180255A1 (en) 2000-08-24 2003-04-09 IL-17 homologous polypeptides and therapeutic uses thereof
US10/429,667 US20030207401A1 (en) 1997-12-03 2003-05-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/458,573 US7718397B2 (en) 2000-03-21 2003-06-10 Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US10/458,442 US20030203451A1 (en) 2000-08-24 2003-06-10 IL-17 homologous polypeptides and therapeutic uses thereof
US10/617,573 US7771719B1 (en) 2000-01-11 2003-07-11 Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US10/700,992 US20040086970A1 (en) 2000-03-22 2003-11-03 Novel cytokine receptors and nucleic acids encoding the same
US10/735,014 US7442772B2 (en) 1997-12-03 2003-12-12 Antibodies to PRO361 polypeptide
US10/758,377 US20040126807A1 (en) 1999-06-02 2004-01-15 Compositions and methods for the diagnosis and treatment of tumor
US10/795,503 US20060210991A1 (en) 1998-06-25 2004-03-09 Interleukin-8 homologous polypeptides and therapeutic uses thereof
US10/795,482 US20060019307A1 (en) 1998-06-25 2004-03-09 Interleukin-8 homologous polypeptides and therapeutic uses thereof
US10/886,040 US20070003545A9 (en) 1999-06-02 2004-07-08 Interleukin-8 homologous polypeptides and therapeutic uses thereof
US10/805,667 US20050037458A1 (en) 1999-03-10 2004-07-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/916,250 US7368250B2 (en) 1997-10-28 2004-08-11 Compositions and methods for the diagnosis and treatment of tumor
US10/943,353 US20050059115A1 (en) 1997-12-03 2004-09-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/021,330 US20050159588A1 (en) 1999-06-02 2004-12-21 Compositions and methods for the diagnosis and treatment of tumor
US11/021,329 US20050159591A1 (en) 1999-06-02 2004-12-21 Compositions and methods for the diagnosis and treatment of tumor
US11/025,607 US20050181478A1 (en) 1998-09-01 2004-12-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/026,279 US20050176041A1 (en) 1998-06-04 2004-12-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/030,464 US20050214819A1 (en) 1998-06-25 2005-01-05 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/036,582 US20050164266A1 (en) 1998-06-05 2005-01-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/038,549 US20060246461A1 (en) 1998-10-27 2005-01-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/038,328 US20050202475A1 (en) 1998-05-05 2005-01-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/039,623 US20060068404A1 (en) 1998-08-26 2005-01-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/040,638 US20050244852A1 (en) 1998-06-25 2005-01-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/042,889 US20050272058A1 (en) 1998-09-02 2005-01-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/042,449 US20050221352A1 (en) 1998-03-20 2005-01-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/046,650 US7547507B2 (en) 1998-08-18 2005-01-28 Methods for the diagnosis of tumors
US11/067,573 US20050260622A1 (en) 1998-05-28 2005-02-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/078,280 US20050250136A1 (en) 1999-06-02 2005-03-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/084,458 US20050260632A1 (en) 1998-06-24 2005-03-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/084,792 US20060051777A1 (en) 1998-04-21 2005-03-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/090,729 US20060068413A1 (en) 1998-09-18 2005-03-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/100,159 US7425613B2 (en) 1997-11-05 2005-04-05 PRO1375 polypeptides
US11/122,524 US20060003355A1 (en) 1998-08-17 2005-05-04 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/124,327 US20050266461A1 (en) 1997-11-21 2005-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/149,801 US20060040289A1 (en) 1998-06-24 2005-06-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/150,463 US20060051783A1 (en) 1998-08-26 2005-06-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/150,758 US20060051784A1 (en) 1998-07-02 2005-06-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/150,881 US20060084084A1 (en) 1998-07-02 2005-06-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/151,868 US20060051785A1 (en) 1998-06-18 2005-06-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/172,714 US20060019287A1 (en) 1998-06-05 2005-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/190,075 US20060088854A1 (en) 1998-05-07 2005-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/189,442 US20060246465A1 (en) 1998-06-04 2005-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/194,054 US20060194219A1 (en) 1998-06-24 2005-07-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/199,816 US20060068423A1 (en) 2000-06-05 2005-08-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/216,875 US20060029966A1 (en) 1998-06-16 2005-08-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/240,891 US20060246540A1 (en) 1997-08-26 2005-09-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/258,349 US7470774B2 (en) 1998-09-30 2005-10-24 Anti-pro1477 antibodies
US11/258,348 US7462692B2 (en) 1998-09-30 2005-10-24 PRO1477 polypeptides
US11/296,155 US20060127983A1 (en) 1997-12-03 2005-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2005363921A JP2006104212A (ja) 2000-08-24 2005-12-16 腫瘍の診断と治療のための組成物と方法
US11/323,117 US20070092941A1 (en) 1998-09-16 2005-12-29 PRO1298 polypeptides
US11/341,175 US7468427B2 (en) 1997-03-31 2006-01-27 Antibodies to PRO1275 polypeptide
JP2006024604A JP2006223304A (ja) 2000-09-01 2006-02-01 分泌及び膜貫通ポリペプチドとそれをコードする核酸
US11/369,228 US20060188914A1 (en) 1997-10-28 2006-03-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/367,172 US20060257897A1 (en) 1998-10-28 2006-03-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/407,991 US20060183169A1 (en) 1998-06-25 2006-04-21 Interleukin-8 homologous polypeptides and therapeutic uses thereof
US11/457,750 US20070031901A1 (en) 1999-03-08 2006-07-14 Compositions and methods for the diagnosis and treatment of tumor
JP2006252159A JP2007077155A (ja) 2000-08-24 2006-09-19 腫瘍の診断と治療のための組成物と方法
US11/535,718 US7691978B2 (en) 1998-08-18 2006-09-27 Antibodies that bind TAT294
US11/528,596 US20070025962A1 (en) 1998-06-25 2006-09-28 Interleukin-8 homologous polypeptides and therapeutic uses thereof
JP2006266069A JP2007049999A (ja) 2000-06-02 2006-09-28 分泌及び膜貫通ポリペプチドとそれをコードする核酸
US11/529,324 US8273703B2 (en) 1998-05-15 2006-09-29 IL-17 receptor-like polypeptides and therapeutic uses thereof
US11/697,201 US20070178539A1 (en) 2000-03-30 2007-04-05 Novel Cytokine Receptors and Nucleic Acids Encoding the Same
US11/786,466 US20080182275A1 (en) 1998-12-22 2007-04-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/796,725 US20090197301A1 (en) 1998-09-01 2007-04-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/802,794 US20090291097A1 (en) 2000-03-21 2007-05-25 IL-17 homologous polypeptides and therapeutic uses thereof
US11/907,316 US20090117114A1 (en) 2000-08-24 2007-10-11 IL-17 homologous polypeptides and therapeutic uses thereof
US11/907,754 US20090087429A1 (en) 2000-03-21 2007-10-17 IL-17 homologous polypeptides and therapeutic uses thereof
US11/949,633 US20080160021A1 (en) 2000-01-11 2007-12-03 Il-17 homologous polypeptides and therapeutic uses thereof
US12/031,612 US7514538B2 (en) 1997-10-28 2008-02-14 Compositions and methods for the diagnosis and treatment of tumor
US12/079,178 US20090170158A1 (en) 1997-12-03 2008-03-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US12/214,762 US20090035261A1 (en) 2000-03-21 2008-06-19 IL-17 homologous polypeptides and therapeutic uses thereof
JP2008194678A JP2009039117A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194721A JP2009039118A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194764A JP2009039119A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
US12/319,421 US7786272B2 (en) 1998-03-27 2009-01-06 Antibodies to PRO352
US12/393,224 US20090227776A1 (en) 1997-10-28 2009-02-26 Compositions and methods for the diagnosis and treatment of tumor
US12/412,796 US8338132B2 (en) 2000-03-21 2009-03-27 Nucleic acids encoding receptor for IL-17 homologous polypeptides and therapeutic uses thereof
US12/549,497 US8034342B2 (en) 2000-01-11 2009-08-28 Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
JP2009209981A JP2010046065A (ja) 2001-02-28 2009-09-11 インターロイキン−８と相同なポリペプチドとその治療用途
US12/702,086 US8097700B2 (en) 1998-08-18 2010-02-08 TAT294 polypeptides
US12/825,263 US20110064728A1 (en) 2000-03-21 2010-06-28 IL-17 Homologous Polypeptides and Therapeutic Uses Thereof
JP2011173336A JP6033531B2 (ja) 2000-07-20 2011-08-08 血管形成に関連する障害を診断及び治療するための組成物と方法
US13/270,006 US20120064073A1 (en) 2000-01-11 2011-10-10 Il-17 homologous polypeptides and therapeutic uses thereof
US13/269,984 US20120058909A1 (en) 2000-01-11 2011-10-10 Il-17 homologous polypeptides and therapeutic uses thereof
US13/593,362 US20130064827A1 (en) 1998-05-15 2012-08-23 Il-17 homologous polypeptides and thereapeutic uses thereof
JP2014187275A JP2015037408A (ja) 2000-07-20 2014-09-16 血管形成に関連する障害を診断及び治療するための組成物と方法
US14/489,167 US20150141283A1 (en) 2000-01-11 2014-09-17 Il-17 homologous polypeptides and therapeutic uses thereof
US14/581,971 US20150266953A1 (en) 1998-05-15 2014-12-23 Il-17 homologous polypeptides and therapeutic uses thereof

Applications Claiming Priority (79)

Application Number Priority Date Filing Date Title
PCT/US2000/005601 WO2000056889A2 (fr) 1999-03-23 2000-03-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
USPCT/US00/05601 2000-03-01
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
USPCT/US00/05841 2000-03-02
US18720200P 2000-03-03 2000-03-03
US60/187,202 2000-03-03
US18696800P 2000-03-06 2000-03-06
US60/186,968 2000-03-06
US18932800P 2000-03-14 2000-03-14
US18932000P 2000-03-14 2000-03-14
US60/189,320 2000-03-14
US60/189,328 2000-03-14
PCT/US2000/006884 WO2001005972A1 (fr) 1999-07-20 2000-03-15 Compositions et methodes pour traiter des maladies d'ordre immunologique
USPCT/US00/06884 2000-03-15
US19104800P 2000-03-21 2000-03-21
US19082800P 2000-03-21 2000-03-21
US19131400P 2000-03-21 2000-03-21
US19100700P 2000-03-21 2000-03-21
US60/191,048 2000-03-21
US60/190,828 2000-03-21
US60/191,314 2000-03-21
US60/191,007 2000-03-21
US19265500P 2000-03-28 2000-03-28
US60/192,655 2000-03-28
US19305300P 2000-03-29 2000-03-29
US19303200P 2000-03-29 2000-03-29
US60/193,032 2000-03-29
US60/193,053 2000-03-29
USPCT/US00/08439 2000-03-30
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
US19444900P 2000-04-04 2000-04-04
US19464700P 2000-04-04 2000-04-04
US60/194,449 2000-04-04
US60/194,647 2000-04-04
US19682000P 2000-04-11 2000-04-11
US19669000P 2000-04-11 2000-04-11
US19618700P 2000-04-11 2000-04-11
US19600000P 2000-04-11 2000-04-11
US19597500P 2000-04-11 2000-04-11
US60/196,000 2000-04-11
US60/196,187 2000-04-11
US60/196,820 2000-04-11
US60/196,690 2000-04-11
US60/195,975 2000-04-11
US19858500P 2000-04-18 2000-04-18
US19812100P 2000-04-18 2000-04-18
US60/198,121 2000-04-18
US60/198,585 2000-04-18
US19939700P 2000-04-25 2000-04-25
US19955000P 2000-04-25 2000-04-25
US19965400P 2000-04-25 2000-04-25
US60/199,654 2000-04-25
US60/199,397 2000-04-25
US60/199,550 2000-04-25
US20151600P 2000-05-03 2000-05-03
US60/201,516 2000-05-03
USPCT/US00/13705 2000-05-17
PCT/US2000/013705 WO2000073445A2 (fr) 1999-06-02 2000-05-17 Promotion ou inhibition de l'angiogenese et de la cardiovascularisation
PCT/US2000/014042 WO2000077037A2 (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant
USPCT/US00/14042 2000-05-22
PCT/US2000/014941 WO2000073348A2 (fr) 1999-06-02 2000-05-30 Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
USPCT/US00/14941 2000-05-30
PCT/US2000/015264 WO2000073452A2 (fr) 1999-06-02 2000-06-02 Compositions et methodes de traitement de maladies liees a l'immunite
USPCT/US00/15264 2000-06-02
US20983200P 2000-06-05 2000-06-05
US60/209,832 2000-06-05
PCT/US2000/020710 WO2001009327A2 (fr) 1999-07-28 2000-07-28 Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
USPCT/US00/20710 2000-07-28
US64484800A 2000-08-22 2000-08-22
US09/644,848 2000-08-22
USPCT/US00/23328 2000-08-24
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US60/000,000 2000-09-15
USPCT/US00/30952 2000-11-08
PCT/US2000/030952 WO2001049715A2 (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
USPCT/US00/32678 2000-12-01
PCT/US2000/032678 WO2001040466A2 (fr) 1999-12-01 2000-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
PCT/US2000/034956 WO2001046420A2 (fr) 1999-12-23 2000-12-20 Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
USPCT/US00/34956 2000-12-20

Related Parent Applications (25)

Application Number Title Priority Date Filing Date
PCT/US1998/019330 Continuation-In-Part WO1999014328A2 (fr) 1994-09-08 1998-09-16 Polypeptides secretes et transmembranaires et acides nucleiques les codant
PCT/US1998/025108 Continuation-In-Part WO1999028462A2 (fr) 1994-09-08 1998-12-01 Polypeptides et acides nucleiques codant ces derniers
US09254311 Continuation-In-Part 1999-03-03
PCT/US1999/005028 Continuation-In-Part WO1999046281A2 (fr) 1996-11-06 1999-03-08 Nouveaux polypeptides et acides nucleiques les codant
US38013799A Continuation-In-Part 1997-06-18 1999-06-02
PCT/US1999/012252 Continuation-In-Part WO1999063088A2 (fr) 1996-11-06 1999-06-02 Proteines membranaires et acides nucleiques codant ces proteines
US09380139 Continuation-In-Part 1999-08-25
US38013899A Continuation-In-Part 1996-11-06 1999-08-25
US38013999A Continuation-In-Part 1996-11-06 1999-08-25
PCT/US1999/020111 Continuation-In-Part WO2000012708A2 (fr) 1997-03-31 1999-09-01 Nouveaux pro-polypeptides et sequences correspondantes
US40329799A Continuation-In-Part 1997-08-26 1999-09-01
PCT/US2000/004342 Continuation-In-Part WO2000078961A1 (fr) 1997-03-31 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US2000/005601 Continuation-In-Part WO2000056889A2 (fr) 1997-03-31 2000-03-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
PCT/US2000/008439 Continuation-In-Part WO2000073454A1 (fr) 1994-09-08 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
PCT/US2000/014042 Continuation-In-Part WO2000077037A2 (fr) 1994-09-08 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant
US66535000A Continuation-In-Part 1994-09-08 2000-09-18
US70923800A Continuation-In-Part 1996-11-06 2000-11-08
PCT/US2000/030952 Continuation-In-Part WO2001049715A2 (fr) 1996-11-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
US70923800A Continuation 1996-11-06 2000-11-08
PCT/US2000/032678 Continuation WO2001040466A2 (fr) 1996-11-06 2000-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
PCT/US2000/032678 Continuation-In-Part WO2001040466A2 (fr) 1996-11-06 2000-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
US09/747,259 Continuation-In-Part US6569645B2 (en) 1997-03-31 2000-12-20 IL-17 homologous polypeptides and therapeutic uses thereof
PCT/US2000/034956 Continuation-In-Part WO2001046420A2 (fr) 1997-03-31 2000-12-20 Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
US09/747,259 Continuation US6569645B2 (en) 1997-03-31 2000-12-20 IL-17 homologous polypeptides and therapeutic uses thereof
US09/767,609 Continuation-In-Part US20020042367A1 (en) 1997-08-26 2001-01-22 Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders

Related Child Applications (27)

Application Number Title Priority Date Filing Date
PCT/US1999/028301 Continuation-In-Part WO2000032776A2 (fr) 1994-09-08 1999-12-01 Polypeptides secretes et transmembranaires et acides nucleiques les codant
US10052586 A-371-Of-International 2001-02-28
PCT/US2001/006666 Continuation-In-Part WO2001066740A2 (fr) 1997-03-31 2001-03-01 Compositions et methodes de traitement de maladies d'origine immune
PCT/US2001/006666 Continuation WO2001066740A2 (fr) 1997-03-31 2001-03-01 Compositions et methodes de traitement de maladies d'origine immune
US80270601A Continuation-In-Part 1997-03-31 2001-03-09
US09/816,744 Continuation-In-Part US6579520B2 (en) 1997-03-31 2001-03-22 IL-17 related mammalian cytokine polypeptides (IL-17E)
US09/866,028 Continuation US6642360B2 (en) 1996-11-06 2001-05-25 Secreted polypeptides that stimulate release of proteoglycans from cartilage
US09/866,028 Continuation-In-Part US6642360B2 (en) 1996-11-06 2001-05-25 Secreted polypeptides that stimulate release of proteoglycans from cartilage
US87203501A Continuation-In-Part 1996-11-06 2001-06-01
US09/888,257 Continuation US20030060612A1 (en) 1997-10-28 2001-06-22 Compositions and methods for the diagnosis and treatment of tumor
US09/904,553 Continuation-In-Part US20030059828A1 (en) 1997-09-17 2001-07-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/938,418 Continuation-In-Part US20020161199A1 (en) 1998-04-08 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor
US09/938,418 Continuation US20020161199A1 (en) 1998-04-08 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor
US09/941,992 Continuation-In-Part US20030082546A1 (en) 1996-11-06 2001-08-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/941,992 Continuation US20030082546A1 (en) 1996-11-06 2001-08-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,862 Continuation US20020115145A1 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,967 Continuation US20030065154A1 (en) 1998-06-25 2001-12-07 Interleukin-8 homologous polypeptides and therapeutic uses thereof
US10/052,586 Continuation-In-Part US20020127584A1 (en) 1997-09-15 2002-01-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/052,586 Continuation US20020127584A1 (en) 1997-09-15 2002-01-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/081,056 Continuation US20040043927A1 (en) 1997-09-19 2002-02-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US10/119,480 Continuation US20040087769A1 (en) 1998-09-10 2002-04-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,166 Continuation-In-Part US20030039648A1 (en) 1997-10-28 2002-04-17 Compositions and methods for the diagnosis and treatment of tumor
US10/125,166 Continuation US20030039648A1 (en) 1997-10-28 2002-04-17 Compositions and methods for the diagnosis and treatment of tumor
US10/127,966 Continuation US20030003507A1 (en) 1998-08-18 2002-04-23 Compositions and methods for the diagnosis and treatment of tumor
US10/187,599 Continuation US7355013B2 (en) 2000-06-05 2002-07-01 PRO6017 antibodies
US10/197,942 Continuation US20030175882A1 (en) 1998-03-27 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/758,377 Continuation US20040126807A1 (en) 1999-06-02 2004-01-15 Compositions and methods for the diagnosis and treatment of tumor

Publications (2)

Publication Number Publication Date
WO2001068848A2 true WO2001068848A2 (fr) 2001-09-20
WO2001068848A3 WO2001068848A3 (fr) 2002-08-29

Family

ID=40231083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006520 WO2001068848A2 (fr) 1996-11-06 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Country Status (5)

Country Link
EP (1) EP1259614A2 (fr)
JP (3) JP2004508805A (fr)
AU (2) AU6802801A (fr)
CA (10) CA2533903A1 (fr)
WO (1) WO2001068848A2 (fr)

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1015488A1 (fr) * 1997-09-17 2000-07-05 Human Genome Sciences, Inc. Proteine de type recepteur d'interleukine 17
WO2001083781A2 (fr) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, un nouveau membre dans la famille de la trypsine humaine et son utilisation
EP1157035A1 (fr) * 1999-03-03 2001-11-28 The Board Of Trustees Of The University Of Arkansas Serine protease transmembranaire surexprimee dans le carcinome ovarien et ses applications
WO2001098360A2 (fr) * 2000-06-22 2001-12-27 Biogen, Inc. Acides nucleiques et polypeptides de gp354
WO2002000857A2 (fr) * 2000-06-15 2002-01-03 Millennium Pharmaceuticals, Inc. Acyltransférase humaine 53320 nouvellement découverte et ses utilisations
WO2002002624A2 (fr) * 2000-06-30 2002-01-10 Amgen, Inc. Molecules de type b7 et utilisation de ces molecules
WO2002020800A2 (fr) * 2000-09-01 2002-03-14 Millennium Pharmaceuticals, Inc. Kinases 16658, 14223, et 16002, et utilisations
WO2002026834A2 (fr) * 2000-09-25 2002-04-04 Millennium Pharmaceuticals Inc. Element de la famille de udp-glucuronosyle et glycosyle transferase humaine, 32624, et utilisations correspondantes
WO2002064769A1 (fr) * 2001-02-15 2002-08-22 Shionogi & Co., Ltd. Nouveau marqueur de maladies
WO2003000021A2 (fr) * 2001-06-22 2003-01-03 Biogen, Inc. Acides nucleiques et polypeptides pancam
WO2003004530A1 (fr) * 2001-07-06 2003-01-16 Bayer Aktiengesellschaft Régulation de la protéine semblable à un récepteur de la somatostatine humaine
WO2003010314A2 (fr) * 2001-07-26 2003-02-06 Genset S.A. Polynucleotides et polypeptides gmg-2 et leurs utilisations
WO2003012099A1 (fr) * 2001-08-01 2003-02-13 The New Industry Research Organization Synthase de chondroitine
WO2003018805A1 (fr) * 2001-08-23 2003-03-06 Japan Science And Technology Agency Regulateurs de la proliferation de cellules souches hematopoietiques et polynucleotides codant ces regulateurs
WO2003025162A2 (fr) * 2001-09-20 2003-03-27 Bayer Healthcare Ag Regulation du precurseur de la sous-unite alpha de prolyl 4-hydroxylase humaine
EP1317472A1 (fr) * 2000-08-28 2003-06-11 Human Genome Sciences, Inc. 17 proteines humaines secretees
WO2003054164A2 (fr) * 2001-12-19 2003-07-03 Immunex Corporation Polypeptide de lectine de type c, polynucleotide et procedes de fabrication et d'utilisation correspondant
WO2002064776A3 (fr) * 2001-02-14 2003-08-21 Axaron Bioscience Ag Proteines de transduction de signal 15b3, 15b3-1 et 15b3-2 et sequences d'adn associees
WO2003102193A1 (fr) * 2002-05-31 2003-12-11 Seikagaku Corporation Chondroitine synthetase et acide nucleique codant pour cette enzyme
WO2003102182A1 (fr) * 2002-05-31 2003-12-11 Hidetoshi Inoko Gene slurp-2 associe a une maladie de peau inflammatoire et utilisation de ce gene
WO2004024077A2 (fr) * 2002-09-11 2004-03-25 Genentech, Inc. Nouvelle composition et nouveaux procedes pour le traitement du psoriasis
WO2004029631A2 (fr) * 2002-09-11 2004-04-08 Frankgen Biotechnologie Ag Procede pour identifier des proteines, specifiques de la barriere hemato-encephalique (bhe), et des fragments de ces dernieres
EP1409655A2 (fr) * 2001-03-12 2004-04-21 Incyte Genomics, Inc. Proteines de la superfamille des immunoglobulines
WO2004058817A1 (fr) * 2002-12-26 2004-07-15 Takeda Pharmaceutical Company Limited Nouvelles proteines et leur utilisation
WO2004063226A2 (fr) * 2002-12-27 2004-07-29 Applied Research Systems Ars Holding N.V. Nouveaux polypeptides de type fibrilline
EP1469877A2 (fr) * 2001-11-02 2004-10-27 Tanox, Inc. Antigene specifique du lymphome des lymphocytes b destine a etre utilise dans le diagnostic et le traitement des malignites des lymphocytes b
EP1487877A2 (fr) * 2001-09-18 2004-12-22 Genentech, Inc. Compositions et procedes pour le diagnostic et le traitement des tumeurs
EP1494709A2 (fr) * 2002-04-17 2005-01-12 Genentech, Inc. Compositions et procedes pour le diagnostic et le traitement de tumeurs
WO2005019418A2 (fr) 2003-08-18 2005-03-03 Isis Pharmaceuticals Inc. Modulation de l'expression de la diacylglycerol acyltransferase 2
US6881823B2 (en) 1997-08-19 2005-04-19 Human Genome Sciences, Inc. Human protein HFXJW48
WO2005061704A1 (fr) * 2003-12-24 2005-07-07 Takeda Pharmaceutical Company Limited Substance destinee a la prevention et au traitement du cancer
EP1563068A2 (fr) * 2002-11-22 2005-08-17 Ganymed Pharmaceuticals AG Produits geniques exprimes de maniere differentielle dans des tumeurs et leur utilisation
EP1588167A2 (fr) * 2003-01-16 2005-10-26 University Of Virginia Patent Foundation Proteines lysozymoides specifiques du sperme
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
EP1621620A2 (fr) * 1999-09-01 2006-02-01 Genetech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
US7049096B2 (en) 2001-04-11 2006-05-23 Bristol-Meyers Squibb Company Polynucleotides encoding a novel human G-protein coupled receptor splice variant HGPRBMY29sv1
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US7193047B2 (en) 1999-03-08 2007-03-20 Genentech, Inc. Polypeptide encoded by a nucleic acid underexpressed in esophageal tumor
US7223852B2 (en) 1997-09-12 2007-05-29 Biogen Idec Ma Inc. Nucleic acids encoding TRAIN-R: a cysteine rich member of the TNF-receptor family
US7247717B2 (en) 2000-11-14 2007-07-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
US7273610B2 (en) 2003-08-14 2007-09-25 Dyax Corp. Endotheliase-2 ligands
WO2007107774A2 (fr) * 2006-03-22 2007-09-27 Cartela R & D Ab Nouvelles méthodes de diagnostic et de traitement
US7276364B1 (en) 1999-11-18 2007-10-02 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
EP1366161B1 (fr) * 2001-02-28 2007-10-03 Genentech, Inc. Anticorps antagoniste contre le pro842
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
EP1873245A1 (fr) * 2001-02-28 2008-01-02 Genentech, Inc. Polypeptides homologue à l'interleukine-8 et utilisations thérapeutiques correspondantes
EP1897943A2 (fr) * 1999-12-23 2008-03-12 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
US7368250B2 (en) 1997-10-28 2008-05-06 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7368554B2 (en) 2000-06-06 2008-05-06 Bristol-Myers Squibb Company Polynucleotides encoding BSL2v1c2-Ig
US7402660B2 (en) 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
US7410772B2 (en) 2004-07-02 2008-08-12 Genentech, Inc. Compositions and methods for treatment of non-Hodgkin's lymphoma
US7414033B2 (en) 2003-03-21 2008-08-19 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US7473763B2 (en) 1999-12-23 2009-01-06 Genentech, Inc. Receptor for IL-17 homologous polypeptides and uses thereof
US7544482B2 (en) 2000-08-24 2009-06-09 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US7544659B2 (en) 2004-08-13 2009-06-09 Genentech, Inc. Promotion of axonal regeneration
EP2083018A2 (fr) 2003-04-16 2009-07-29 Genentech, Inc. Compositions et procédés associés à STOP-1
EP2082645A1 (fr) * 2006-04-19 2009-07-29 Genentech, Inc. Nouvelle dislocation de gènes, compositions et procédés correspondants
US7638603B2 (en) 1997-09-17 2009-12-29 Human Genome Sciences, Inc. Antibodies against interleukin 17 receptor-like protein
US7709611B2 (en) 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US7723478B2 (en) 1998-09-25 2010-05-25 Amgen Inc. DKR polypeptides
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7749500B2 (en) 1998-05-15 2010-07-06 Genentech, Inc. Antibodies to IL-17 polypeptides and therapeutic uses thereof
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7846737B2 (en) 2001-06-13 2010-12-07 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
EP2269628A2 (fr) 2002-05-29 2011-01-05 DeveloGen Aktiengesellschaft Proteines spécifiques du pancréas
EP2336321A1 (fr) * 1999-05-13 2011-06-22 Medical Research Council Recepteur homologue de OX2.
US20110159021A1 (en) * 2008-06-02 2011-06-30 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
EP2314612A3 (fr) * 2002-03-13 2011-08-03 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
US8003620B2 (en) 2006-08-04 2011-08-23 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
US8008450B2 (en) 2003-05-08 2011-08-30 Abbott Biotherapeutics Corp. Therapeutic use of anti-CS1 antibodies
US8058014B2 (en) 2006-09-29 2011-11-15 University Of Maryland, Baltimore Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2
US8133734B2 (en) 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
US8420084B2 (en) 2009-03-05 2013-04-16 Medarex, Inc. Fully human antibodies specific to CADM1
US8609816B2 (en) 2005-12-08 2013-12-17 Medarex, L.L.C. Human monoclonal antibodies to O8E
US9044382B2 (en) 2004-05-18 2015-06-02 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9433675B2 (en) 2012-05-23 2016-09-06 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis
US9650437B2 (en) 2008-05-05 2017-05-16 Novimmune S.A. Nucleic acid encoding and method of producing anti-IL-17A/IL-17F cross-reactive antibodies
US9770487B2 (en) 2013-02-20 2017-09-26 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma
US9903872B2 (en) 2006-08-29 2018-02-27 Oxford Biotherapeutics, Ltd. Identification of protein associated with hepatocellular carcinoma, gliobastoma and lung cancer
US9950047B2 (en) 2012-11-05 2018-04-24 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
US10011654B2 (en) 2003-07-08 2018-07-03 Genentech, Inc. Antibodies directed to IL-17A/IL-17F heterodimers
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US10137195B2 (en) 2013-03-18 2018-11-27 Ganymed Pharmaceuticals Gmbh Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US11312962B2 (en) 2015-07-10 2022-04-26 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (DGAT2)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008532516A (ja) * 2005-03-11 2008-08-21 ジェネンテック・インコーポレーテッド 遺伝子破壊、組成物、およびそれに関連する方法
MX2011011729A (es) 2009-05-05 2012-04-10 Novimmune Sa Anticuerpo anti il-17f y metodos de uso de los mismos.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054461A2 (fr) * 1998-04-17 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre
WO1999063088A2 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
WO2000058473A2 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx»
WO2000073454A1 (fr) * 1999-06-02 2000-12-07 Genentech, Inc. Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
WO2001057190A2 (fr) * 2000-02-03 2001-08-09 Hyseq, Inc. Acides nucleiques et polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040269A2 (fr) * 1999-11-30 2001-06-07 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
JP2004520806A (ja) * 2000-08-24 2004-07-15 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054461A2 (fr) * 1998-04-17 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre
WO1999063088A2 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
WO2000058473A2 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx»
WO2000073454A1 (fr) * 1999-06-02 2000-12-07 Genentech, Inc. Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
WO2001057190A2 (fr) * 2000-02-03 2001-08-09 Hyseq, Inc. Acides nucleiques et polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1259614A2 *

Cited By (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8202966B2 (en) 1997-04-16 2012-06-19 Millennium Pharmaceuticals, Inc. Human Dickkopf-related protein and nucleic acid molecules and uses therefor
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
US7645451B2 (en) 1997-04-16 2010-01-12 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
US7579168B2 (en) 1997-04-16 2009-08-25 Millennium Pharmaceuticals, Inc. Human Dickkopf-related nucleic acid molecules
US7217528B2 (en) 1997-08-19 2007-05-15 Human Genome Sciences, Inc. Antibodies to HFXJW48 polypeptide
US6881823B2 (en) 1997-08-19 2005-04-19 Human Genome Sciences, Inc. Human protein HFXJW48
US7838639B2 (en) 1997-09-12 2010-11-23 Biogen Idec Ma Inc. Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor
US7223852B2 (en) 1997-09-12 2007-05-29 Biogen Idec Ma Inc. Nucleic acids encoding TRAIN-R: a cysteine rich member of the TNF-receptor family
US7402658B2 (en) 1997-09-12 2008-07-22 Biogen Idec Ma Inc. TRAIN-R: a cysteine-rich member of the TNF-receptor family
EP1015488B1 (fr) * 1997-09-17 2009-09-09 Human Genome Sciences, Inc. Proteine de type recepteur d'interleukine 17
EP1015488A1 (fr) * 1997-09-17 2000-07-05 Human Genome Sciences, Inc. Proteine de type recepteur d'interleukine 17
US7638603B2 (en) 1997-09-17 2009-12-29 Human Genome Sciences, Inc. Antibodies against interleukin 17 receptor-like protein
US7514538B2 (en) 1997-10-28 2009-04-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7368250B2 (en) 1997-10-28 2008-05-06 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US8273703B2 (en) 1998-05-15 2012-09-25 Genentech, Inc. IL-17 receptor-like polypeptides and therapeutic uses thereof
US8075888B2 (en) 1998-05-15 2011-12-13 Genentech, Inc. Methods of treatment using antibodies to IL-17 homologous polypeptides
US7749500B2 (en) 1998-05-15 2010-07-06 Genentech, Inc. Antibodies to IL-17 polypeptides and therapeutic uses thereof
US7723478B2 (en) 1998-09-25 2010-05-25 Amgen Inc. DKR polypeptides
EP1157035A4 (fr) * 1999-03-03 2005-06-08 Univ Arkansas Serine protease transmembranaire surexprimee dans le carcinome ovarien et ses applications
EP1157035A1 (fr) * 1999-03-03 2001-11-28 The Board Of Trustees Of The University Of Arkansas Serine protease transmembranaire surexprimee dans le carcinome ovarien et ses applications
US7371814B2 (en) 1999-03-08 2008-05-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7232882B2 (en) 1999-03-08 2007-06-19 Genentech, Inc. Polypeptide uder-expressed in melanoma
US7193047B2 (en) 1999-03-08 2007-03-20 Genentech, Inc. Polypeptide encoded by a nucleic acid underexpressed in esophageal tumor
US7271247B2 (en) 1999-03-08 2007-09-18 Genentech, Inc. Antibodies to a polypeptide encoded by a nucleic acid differentially expressed in melanoma
US7378501B2 (en) 1999-03-08 2008-05-27 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7411037B2 (en) 1999-03-08 2008-08-12 Genentech, Inc. Polypeptides encoded by a nucleic acid underexpressed in melanoma
US8133734B2 (en) 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
EP2341143A1 (fr) * 1999-05-13 2011-07-06 Medical Research Council Récepteur homologue de l'OX2
EP2336321A1 (fr) * 1999-05-13 2011-06-22 Medical Research Council Recepteur homologue de OX2.
EP1623991A3 (fr) * 1999-09-01 2006-06-07 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP1637541A2 (fr) * 1999-09-01 2006-03-22 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP1621620A2 (fr) * 1999-09-01 2006-02-01 Genetech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP1623992A2 (fr) * 1999-09-01 2006-02-08 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP1623991A2 (fr) * 1999-09-01 2006-02-08 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP1621620A3 (fr) * 1999-09-01 2006-05-10 Genetech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP1623992A3 (fr) * 1999-09-01 2006-05-10 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP1623993A3 (fr) * 1999-09-01 2006-06-07 Genetech, Inc. Protéines sécrétées et transmembranaire et acides nucléiques les codant
EP1637541A3 (fr) * 1999-09-01 2006-06-07 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
US7276364B1 (en) 1999-11-18 2007-10-02 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
EP1897943A2 (fr) * 1999-12-23 2008-03-12 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP1897944A3 (fr) * 1999-12-23 2008-05-21 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP1897943A3 (fr) * 1999-12-23 2008-06-11 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP2290081A3 (fr) * 1999-12-23 2012-08-01 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
US7473763B2 (en) 1999-12-23 2009-01-06 Genentech, Inc. Receptor for IL-17 homologous polypeptides and uses thereof
US7491512B2 (en) 1999-12-23 2009-02-17 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
EP2258848A1 (fr) * 1999-12-23 2010-12-08 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
US8034342B2 (en) 2000-01-11 2011-10-11 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US7943738B2 (en) 2000-03-16 2011-05-17 Amgen Inc. IL-17 receptor like molecules and uses thereof
US8338132B2 (en) 2000-03-21 2012-12-25 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
WO2001083781A2 (fr) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, un nouveau membre dans la famille de la trypsine humaine et son utilisation
WO2001083781A3 (fr) * 2000-04-28 2002-07-11 Millennium Pharm Inc 14094, un nouveau membre dans la famille de la trypsine humaine et son utilisation
US7071004B1 (en) 2000-04-28 2006-07-04 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
US8664360B2 (en) 2000-06-06 2014-03-04 Bristols-Myers Squibb Company BSL3 polypeptides
US7807786B2 (en) 2000-06-06 2010-10-05 Bristol-Myers Squibb Company BSL2v1c2 polypeptides
US7279567B2 (en) 2000-06-06 2007-10-09 Bristol-Myers Squibb Company Polynucleotides-encoding B7-related polypeptide, BSL2-L165-35B
US10308702B2 (en) 2000-06-06 2019-06-04 Bristol-Myers Squibb Comapny BSL2v2c2-Ig polypeptides
US9399052B2 (en) 2000-06-06 2016-07-26 Bristol-Myers Squibb Company Polynucleotides encoding BSL2v2c2-Ig
US8354513B2 (en) 2000-06-06 2013-01-15 Bristol-Myers Squibb Company Polynucleotides encoding BSL2vcvc-lg
US7723479B2 (en) 2000-06-06 2010-05-25 Bristol-Myers Squibb Company BSL3 polypeptides
US8674076B2 (en) 2000-06-06 2014-03-18 Bristol-Myers Squibb Company BSL2vcvc-lg polypeptides
US8080636B2 (en) 2000-06-06 2011-12-20 Bristol-Myers Squibb Company BSL3 antibodies
US9409970B2 (en) 2000-06-06 2016-08-09 Bristol-Myers Squibb Company Polynucleotides encoding BSL2v2c2
US7358354B2 (en) 2000-06-06 2008-04-15 Bristol-Myers Squibb Company Polynucleotides encoding BSL3
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
US10400023B2 (en) 2000-06-06 2019-09-03 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides useful for immunomodulation
US7368554B2 (en) 2000-06-06 2008-05-06 Bristol-Myers Squibb Company Polynucleotides encoding BSL2v1c2-Ig
WO2002000857A3 (fr) * 2000-06-15 2002-07-25 Millennium Pharm Inc Acyltransférase humaine 53320 nouvellement découverte et ses utilisations
WO2002000857A2 (fr) * 2000-06-15 2002-01-03 Millennium Pharmaceuticals, Inc. Acyltransférase humaine 53320 nouvellement découverte et ses utilisations
WO2001098360A3 (fr) * 2000-06-22 2002-11-28 Biogen Inc Acides nucleiques et polypeptides de gp354
WO2001098360A2 (fr) * 2000-06-22 2001-12-27 Biogen, Inc. Acides nucleiques et polypeptides de gp354
WO2002002624A3 (fr) * 2000-06-30 2002-07-04 Amgen Inc Molecules de type b7 et utilisation de ces molecules
WO2002002624A2 (fr) * 2000-06-30 2002-01-10 Amgen, Inc. Molecules de type b7 et utilisation de ces molecules
US7402660B2 (en) 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
US7544482B2 (en) 2000-08-24 2009-06-09 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
EP1317472A1 (fr) * 2000-08-28 2003-06-11 Human Genome Sciences, Inc. 17 proteines humaines secretees
EP1317472A4 (fr) * 2000-08-28 2005-04-27 Human Genome Sciences Inc 17 proteines humaines secretees
WO2002020800A2 (fr) * 2000-09-01 2002-03-14 Millennium Pharmaceuticals, Inc. Kinases 16658, 14223, et 16002, et utilisations
WO2002020800A3 (fr) * 2000-09-01 2002-12-27 Millennium Pharm Inc Kinases 16658, 14223, et 16002, et utilisations
WO2002026834A3 (fr) * 2000-09-25 2003-01-23 Millennium Pharm Inc Element de la famille de udp-glucuronosyle et glycosyle transferase humaine, 32624, et utilisations correspondantes
WO2002026834A2 (fr) * 2000-09-25 2002-04-04 Millennium Pharmaceuticals Inc. Element de la famille de udp-glucuronosyle et glycosyle transferase humaine, 32624, et utilisations correspondantes
US8455217B2 (en) 2000-10-24 2013-06-04 Genentech, Inc. Nucleic acids encoding IL-17 homologous receptor-like polypeptides and therapeutic uses thereof
US7256267B2 (en) 2000-11-14 2007-08-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
US7247717B2 (en) 2000-11-14 2007-07-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
WO2002064776A3 (fr) * 2001-02-14 2003-08-21 Axaron Bioscience Ag Proteines de transduction de signal 15b3, 15b3-1 et 15b3-2 et sequences d'adn associees
WO2002064769A1 (fr) * 2001-02-15 2002-08-22 Shionogi & Co., Ltd. Nouveau marqueur de maladies
EP1873245A1 (fr) * 2001-02-28 2008-01-02 Genentech, Inc. Polypeptides homologue à l'interleukine-8 et utilisations thérapeutiques correspondantes
EP1366161B1 (fr) * 2001-02-28 2007-10-03 Genentech, Inc. Anticorps antagoniste contre le pro842
JP2010046065A (ja) * 2001-02-28 2010-03-04 Genentech Inc インターロイキン−８と相同なポリペプチドとその治療用途
EP1409655A2 (fr) * 2001-03-12 2004-04-21 Incyte Genomics, Inc. Proteines de la superfamille des immunoglobulines
EP1409655A4 (fr) * 2001-03-12 2005-04-06 Incyte Genomics Inc Proteines de la superfamille des immunoglobulines
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7345148B2 (en) 2001-04-11 2008-03-18 Bristol-Myers Squibb Company Human G-protein coupled receptor, HGPRBMY29sv1 polypeptides
US8124729B2 (en) 2001-04-11 2012-02-28 Bristol-Myers Squibb Company Splice variants of human G-protein coupled receptor HGPRBMY29 (HGPRMBY29SV2)
US7635758B2 (en) 2001-04-11 2009-12-22 Bristol-Myers Squibb Company Antibodies directed to G-protein coupled receptor HGPRBMY29sv1
US7049096B2 (en) 2001-04-11 2006-05-23 Bristol-Meyers Squibb Company Polynucleotides encoding a novel human G-protein coupled receptor splice variant HGPRBMY29sv1
US7276354B2 (en) 2001-04-11 2007-10-02 Bristol-Myers Squibb Company Polynucleotides encoding a novel human G-protein coupled receptor splice variant, HGPRBMY29SV2
US8062892B2 (en) 2001-06-13 2011-11-22 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
US7846737B2 (en) 2001-06-13 2010-12-07 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
EP1409523A4 (fr) * 2001-06-22 2005-06-15 Biogen Inc Acides nucleiques et polypeptides pancam
WO2003000021A3 (fr) * 2001-06-22 2003-11-20 Biogen Inc Acides nucleiques et polypeptides pancam
EP1409523A2 (fr) * 2001-06-22 2004-04-21 Biogen, Inc. Acides nucleiques et polypeptides pancam
WO2003000021A2 (fr) * 2001-06-22 2003-01-03 Biogen, Inc. Acides nucleiques et polypeptides pancam
WO2003004531A3 (fr) * 2001-07-06 2003-12-04 Bayer Healthcare Ag Regulation d'une proteine du type recepteur de la somatostatine humaine
WO2003004530A1 (fr) * 2001-07-06 2003-01-16 Bayer Aktiengesellschaft Régulation de la protéine semblable à un récepteur de la somatostatine humaine
WO2003004531A2 (fr) * 2001-07-06 2003-01-16 Bayer Healthcare Ag Regulation d'une proteine du type recepteur de la somatostatine humaine
WO2003010314A2 (fr) * 2001-07-26 2003-02-06 Genset S.A. Polynucleotides et polypeptides gmg-2 et leurs utilisations
WO2003010314A3 (fr) * 2001-07-26 2004-05-06 Genset Sa Polynucleotides et polypeptides gmg-2 et leurs utilisations
AU2002321768B2 (en) * 2001-07-26 2008-03-06 Serono Genetics Institute S.A. GMG-2 polynucleotides and polypeptides and uses thereof
WO2003012099A1 (fr) * 2001-08-01 2003-02-13 The New Industry Research Organization Synthase de chondroitine
US8334115B2 (en) 2001-08-01 2012-12-18 Glytech, Inc. Chondroitin synthase, method for producing the same and method for producing saccharide chain-extended chondroitin
US7947481B2 (en) 2001-08-01 2011-05-24 Otsuka Chemical Co., Ltd. Chondroitin synthase, method for producing the same and method for producing saccharide chain-extended chondroitin
US8685674B2 (en) 2001-08-01 2014-04-01 Glytech, Inc. Chondroitin synthase, method for producing the same and method for producing saccharide chain-extended chondroitin
US7354741B2 (en) 2001-08-01 2008-04-08 Otsuka Chemical Co., Ltd. Method for producing saccharide chain-extended chondroitin
WO2003018805A1 (fr) * 2001-08-23 2003-03-06 Japan Science And Technology Agency Regulateurs de la proliferation de cellules souches hematopoietiques et polynucleotides codant ces regulateurs
US7262026B2 (en) 2001-08-23 2007-08-28 Japan Science And Technology Agency Hematopoietic stem cell proliferation regulators and polynucleotides encoding the same
US7939268B2 (en) 2001-09-18 2011-05-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1487877A2 (fr) * 2001-09-18 2004-12-22 Genentech, Inc. Compositions et procedes pour le diagnostic et le traitement des tumeurs
EP1487877A4 (fr) * 2001-09-18 2005-08-24 Genentech Inc Compositions et procedes pour le diagnostic et le traitement des tumeurs
US7951546B2 (en) 2001-09-18 2011-05-31 Genetech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003025162A2 (fr) * 2001-09-20 2003-03-27 Bayer Healthcare Ag Regulation du precurseur de la sous-unite alpha de prolyl 4-hydroxylase humaine
WO2003025162A3 (fr) * 2001-09-20 2003-09-04 Bayer Ag Regulation du precurseur de la sous-unite alpha de prolyl 4-hydroxylase humaine
EP1469877A4 (fr) * 2001-11-02 2008-08-20 Tanox Inc Antigene specifique du lymphome des lymphocytes b destine a etre utilise dans le diagnostic et le traitement des malignites des lymphocytes b
EP1469877A2 (fr) * 2001-11-02 2004-10-27 Tanox, Inc. Antigene specifique du lymphome des lymphocytes b destine a etre utilise dans le diagnostic et le traitement des malignites des lymphocytes b
US7695937B2 (en) 2001-12-19 2010-04-13 Immunex Corporation Polynucleotides encoding C-type lectin polypeptides and methods of use thereof
WO2003054164A2 (fr) * 2001-12-19 2003-07-03 Immunex Corporation Polypeptide de lectine de type c, polynucleotide et procedes de fabrication et d'utilisation correspondant
US7396662B2 (en) 2001-12-19 2008-07-08 Immunex Corporation C-type lectin polypeptides
WO2003054164A3 (fr) * 2001-12-19 2003-09-18 Immunex Corp Polypeptide de lectine de type c, polynucleotide et procedes de fabrication et d'utilisation correspondant
US8048994B2 (en) 2001-12-19 2011-11-01 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
EP2314612A3 (fr) * 2002-03-13 2011-08-03 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
EP1494709A4 (fr) * 2002-04-17 2006-06-28 Genentech Inc Compositions et procedes pour le diagnostic et le traitement de tumeurs
EP1494709A2 (fr) * 2002-04-17 2005-01-12 Genentech, Inc. Compositions et procedes pour le diagnostic et le traitement de tumeurs
EP2269628A2 (fr) 2002-05-29 2011-01-05 DeveloGen Aktiengesellschaft Proteines spécifiques du pancréas
EP2275118A2 (fr) 2002-05-29 2011-01-19 DeveloGen Aktiengesellschaft Proteines spécifiques du pancreas
WO2003102182A1 (fr) * 2002-05-31 2003-12-11 Hidetoshi Inoko Gene slurp-2 associe a une maladie de peau inflammatoire et utilisation de ce gene
WO2003102193A1 (fr) * 2002-05-31 2003-12-11 Seikagaku Corporation Chondroitine synthetase et acide nucleique codant pour cette enzyme
JP2006518582A (ja) * 2002-09-11 2006-08-17 ジェネンテック・インコーポレーテッド 乾癬の治療のための新規組成物と方法
WO2004024077A2 (fr) * 2002-09-11 2004-03-25 Genentech, Inc. Nouvelle composition et nouveaux procedes pour le traitement du psoriasis
WO2004024077A3 (fr) * 2002-09-11 2009-06-18 Genentech Inc Nouvelle composition et nouveaux procedes pour le traitement du psoriasis
WO2004029631A3 (fr) * 2002-09-11 2006-03-02 Frankgen Biotechnologie Ag Procede pour identifier des proteines, specifiques de la barriere hemato-encephalique (bhe), et des fragments de ces dernieres
WO2004029631A2 (fr) * 2002-09-11 2004-04-08 Frankgen Biotechnologie Ag Procede pour identifier des proteines, specifiques de la barriere hemato-encephalique (bhe), et des fragments de ces dernieres
US8088588B2 (en) 2002-11-22 2012-01-03 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use of thereof
EP2400009A3 (fr) * 2002-11-22 2012-07-25 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
US7527933B2 (en) 2002-11-22 2009-05-05 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
JP2016104800A (ja) * 2002-11-22 2016-06-09 ガニュメート・ファーマシューティカルズ・アクチェンゲゼルシャフトＧａｎｙｍｅｄ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｇ 腫瘍において示差的に発現する遺伝子産物およびその利用
KR101604788B1 (ko) * 2002-11-22 2016-03-18 가니메드 파마슈티칼스 아게 종양에서 특이적으로 발현되는 유전 산물 및 그의 용도
US8586047B2 (en) 2002-11-22 2013-11-19 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US8637012B2 (en) 2002-11-22 2014-01-28 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
EP2399995A3 (fr) * 2002-11-22 2012-08-08 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
EP1563068A2 (fr) * 2002-11-22 2005-08-17 Ganymed Pharmaceuticals AG Produits geniques exprimes de maniere differentielle dans des tumeurs et leur utilisation
KR101507976B1 (ko) 2002-11-22 2015-04-07 가니메드 파마슈티칼스 아게 종양에서 특이적으로 발현되는 유전 산물 및 그의 용도
EP2400007A3 (fr) * 2002-11-22 2012-07-25 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
KR101483736B1 (ko) 2002-11-22 2015-01-16 가니메드 파마슈티칼스 아게 종양에서 특이적으로 발현되는 유전 산물 및 그의 용도
EP2400008A3 (fr) * 2002-11-22 2012-07-25 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
EP2400006A3 (fr) * 2002-11-22 2012-07-25 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
EP2399996A3 (fr) * 2002-11-22 2012-07-25 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
EP2400011A3 (fr) * 2002-11-22 2012-07-25 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
EP2400010A3 (fr) * 2002-11-22 2012-07-25 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
EP2400019A3 (fr) * 2002-11-22 2012-06-06 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
JP2010178740A (ja) * 2002-11-22 2010-08-19 Ganymed Pharmaceuticals Ag 腫瘍において示差的に発現する遺伝子産物およびその利用
EP2400016A3 (fr) * 2002-11-22 2012-05-02 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
EP2400013A3 (fr) * 2002-11-22 2012-04-11 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
EP2400012A3 (fr) * 2002-11-22 2012-04-11 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
EP2400017A3 (fr) * 2002-11-22 2012-05-02 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
EP2400015A3 (fr) * 2002-11-22 2012-04-18 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
EP2400014A3 (fr) * 2002-11-22 2012-05-02 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
EP2400018A3 (fr) * 2002-11-22 2012-05-02 Ganymed Pharmaceuticals AG Produits géniques d'expression différentielle dans les tumeurs et leur utilisation
WO2004058817A1 (fr) * 2002-12-26 2004-07-15 Takeda Pharmaceutical Company Limited Nouvelles proteines et leur utilisation
WO2004063226A2 (fr) * 2002-12-27 2004-07-29 Applied Research Systems Ars Holding N.V. Nouveaux polypeptides de type fibrilline
WO2004063226A3 (fr) * 2002-12-27 2004-09-30 Applied Research Systems Nouveaux polypeptides de type fibrilline
EP1588167A4 (fr) * 2003-01-16 2006-08-09 Univ Virginia Proteines lysozymoides specifiques du sperme
EP1588167A2 (fr) * 2003-01-16 2005-10-26 University Of Virginia Patent Foundation Proteines lysozymoides specifiques du sperme
US7550435B2 (en) 2003-02-24 2009-06-23 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
US7414033B2 (en) 2003-03-21 2008-08-19 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 1 expression
US8158597B2 (en) 2003-03-21 2012-04-17 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7799899B2 (en) 2003-04-16 2010-09-21 Genentech, Inc. Compositions and methods relating to STOP-1
EP2083018A2 (fr) 2003-04-16 2009-07-29 Genentech, Inc. Compositions et procédés associés à STOP-1
US10442859B2 (en) 2003-05-08 2019-10-15 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US9175081B2 (en) 2003-05-08 2015-11-03 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US8008450B2 (en) 2003-05-08 2011-08-30 Abbott Biotherapeutics Corp. Therapeutic use of anti-CS1 antibodies
US8133981B2 (en) 2003-05-08 2012-03-13 Abbott Biotherapeutics Corp. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US8349330B2 (en) 2003-05-08 2013-01-08 Abbott Biotherapeutics Corp. Therapeutic use of anti-CS1 antibodies
US8461306B2 (en) 2003-05-08 2013-06-11 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US8436146B2 (en) 2003-05-08 2013-05-07 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US8445646B2 (en) 2003-05-08 2013-05-21 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US8444980B2 (en) 2003-05-08 2013-05-21 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US8088898B2 (en) 2003-05-08 2012-01-03 Abbott Biotherapeutics Corp. Therapeutic use of anti-CS1 antibodies
US10011654B2 (en) 2003-07-08 2018-07-03 Genentech, Inc. Antibodies directed to IL-17A/IL-17F heterodimers
US7273610B2 (en) 2003-08-14 2007-09-25 Dyax Corp. Endotheliase-2 ligands
WO2005019418A2 (fr) 2003-08-18 2005-03-03 Isis Pharmaceuticals Inc. Modulation de l'expression de la diacylglycerol acyltransferase 2
EP2284267A2 (fr) 2003-08-18 2011-02-16 Isis Pharmaceuticals, Inc. Modulation de l'expression de la diacylglycérol acyltransférase 2
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US7732590B2 (en) 2003-08-18 2010-06-08 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US8258289B2 (en) 2003-08-18 2012-09-04 Isis Pharmaceuticals, Inc Modulation of diacylglycerol acyltransferase 2 expression
US8883997B2 (en) 2003-08-18 2014-11-11 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
WO2005061704A1 (fr) * 2003-12-24 2005-07-07 Takeda Pharmaceutical Company Limited Substance destinee a la prevention et au traitement du cancer
US9044382B2 (en) 2004-05-18 2015-06-02 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US7410772B2 (en) 2004-07-02 2008-08-12 Genentech, Inc. Compositions and methods for treatment of non-Hodgkin's lymphoma
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
US8101184B2 (en) 2004-08-04 2012-01-24 Amgen Inc. Treatment methods using Dkk-1 antibodies
US7709611B2 (en) 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
US7544659B2 (en) 2004-08-13 2009-06-09 Genentech, Inc. Promotion of axonal regeneration
US10174104B2 (en) 2005-11-24 2019-01-08 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US10738108B2 (en) 2005-11-24 2020-08-11 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
US11739139B2 (en) 2005-11-24 2023-08-29 Astellas Pharma Inc. Monoclonal antibodies against Claudin-18 for treatment of cancer
US10017564B2 (en) 2005-11-24 2018-07-10 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9499609B2 (en) 2005-11-24 2016-11-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9988453B2 (en) 2005-12-08 2018-06-05 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
US8609816B2 (en) 2005-12-08 2013-12-17 Medarex, L.L.C. Human monoclonal antibodies to O8E
US9296822B2 (en) 2005-12-08 2016-03-29 E.R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
WO2007107774A3 (fr) * 2006-03-22 2008-04-10 Cartela R & D Ab Nouvelles méthodes de diagnostic et de traitement
WO2007107774A2 (fr) * 2006-03-22 2007-09-27 Cartela R & D Ab Nouvelles méthodes de diagnostic et de traitement
EP2082645A1 (fr) * 2006-04-19 2009-07-29 Genentech, Inc. Nouvelle dislocation de gènes, compositions et procédés correspondants
US8455456B2 (en) 2006-08-04 2013-06-04 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
US8003620B2 (en) 2006-08-04 2011-08-23 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
US9903872B2 (en) 2006-08-29 2018-02-27 Oxford Biotherapeutics, Ltd. Identification of protein associated with hepatocellular carcinoma, gliobastoma and lung cancer
US8058014B2 (en) 2006-09-29 2011-11-15 University Of Maryland, Baltimore Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2
US9650437B2 (en) 2008-05-05 2017-05-16 Novimmune S.A. Nucleic acid encoding and method of producing anti-IL-17A/IL-17F cross-reactive antibodies
US9096681B2 (en) * 2008-06-02 2015-08-04 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides
US20110159021A1 (en) * 2008-06-02 2011-06-30 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
US11083783B2 (en) 2008-06-02 2021-08-10 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides
US8420084B2 (en) 2009-03-05 2013-04-16 Medarex, Inc. Fully human antibodies specific to CADM1
US11976130B2 (en) 2012-05-09 2024-05-07 Astellas Pharma Inc. Antibodies against claudin 18.2 useful in cancer diagnosis
US10053512B2 (en) 2012-05-09 2018-08-21 Ganymed Pharmaceuticals Ag Antibodies against claudin 18.2 useful in cancer diagnosis
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis
US10813996B2 (en) 2012-05-23 2020-10-27 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US9433675B2 (en) 2012-05-23 2016-09-06 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US10022444B2 (en) 2012-05-23 2018-07-17 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US12059464B2 (en) 2012-05-23 2024-08-13 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US9950047B2 (en) 2012-11-05 2018-04-24 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US10946069B2 (en) 2013-02-20 2021-03-16 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
US10314890B2 (en) 2013-02-20 2019-06-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
US11826402B2 (en) 2013-02-20 2023-11-28 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma
US9770487B2 (en) 2013-02-20 2017-09-26 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma
US11395852B2 (en) 2013-03-18 2022-07-26 Astellas Pharma Inc. Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10137195B2 (en) 2013-03-18 2018-11-27 Ganymed Pharmaceuticals Gmbh Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US11312962B2 (en) 2015-07-10 2022-04-26 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (DGAT2)

Also Published As

Publication number Publication date
WO2001068848A3 (fr) 2002-08-29
AU6802801A (en) 2001-09-24
CA2533991A1 (fr) 2001-09-20
AU2001268028A1 (en) 2001-09-24
CA2534391A1 (fr) 2001-09-20
JP2004508805A (ja) 2004-03-25
CA2533831A1 (fr) 2001-09-20
EP1259614A2 (fr) 2002-11-27
JP2006081548A (ja) 2006-03-30
CA2534186A1 (fr) 2001-09-20
CA2401448A1 (fr) 2001-09-20
CA2539214A1 (fr) 2001-09-20
CA2533903A1 (fr) 2001-09-20
CA2531917A1 (fr) 2001-09-20
CA2534018A1 (fr) 2001-09-20
CA2534030A1 (fr) 2001-09-20
JP2008301822A (ja) 2008-12-18

Similar Documents

Publication Publication Date Title
US7189838B2 (en) PRO9834 nucleic acids
US20030170801A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1259614A2 (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US20020127584A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040023321A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104552A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same

Legal Events

Date Code Title Description
ENP Entry into the national phase in:

Ref country code: US

Ref document number: 2001 816920

Date of ref document: 20010322

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase in:

Ref country code: US

Ref document number: 2001 874503

Date of ref document: 20010605

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase in:

Ref country code: US

Ref document number: 2001 964994

Date of ref document: 20010926

Kind code of ref document: A

Format of ref document f/p: F

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001945919

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2401448

Country of ref document: CA

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 567332

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001945919

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642